U.S. patent application number 15/596178 was filed with the patent office on 2018-04-05 for molecules with antigen binding and polyvalent fc gamma receptor binding activity.
The applicant listed for this patent is GLIKNIK INC.. Invention is credited to David BLOCK, Henrik OLSEN.
Application Number | 20180094061 15/596178 |
Document ID | / |
Family ID | 50150476 |
Filed Date | 2018-04-05 |
United States Patent
Application |
20180094061 |
Kind Code |
A1 |
BLOCK; David ; et
al. |
April 5, 2018 |
MOLECULES WITH ANTIGEN BINDING AND POLYVALENT FC GAMMA RECEPTOR
BINDING ACTIVITY
Abstract
The current invention involves biologically active proteins
termed stradobodies. The stradobodies have two or more domains that
create stradobody multimers. The stradobodies have both
antigen-binding capacity and the ability to bind Fc receptors
(FcR), and are useful in the treatment and prevention of
disease.
Inventors: |
BLOCK; David; (Baltimore,
MD) ; OLSEN; Henrik; (Baltimore, MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GLIKNIK INC. |
Baltimore |
MD |
US |
|
|
Family ID: |
50150476 |
Appl. No.: |
15/596178 |
Filed: |
May 16, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13971584 |
Aug 20, 2013 |
9683044 |
|
|
15596178 |
|
|
|
|
61785144 |
Mar 14, 2013 |
|
|
|
61691057 |
Aug 20, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 17/04 20180101;
C07K 2317/732 20130101; C07K 2317/73 20130101; A61P 9/10 20180101;
C07K 2317/55 20130101; A61P 21/00 20180101; A61P 31/00 20180101;
C07K 2317/30 20130101; C07K 2317/52 20130101; A61P 31/06 20180101;
Y02A 50/30 20180101; C07K 2317/53 20130101; A61P 29/00 20180101;
C07K 16/2887 20130101; A61P 1/04 20180101; C07K 16/2863 20130101;
A61P 7/04 20180101; A61P 37/06 20180101; C07K 16/32 20130101; A61P
35/00 20180101; Y02A 50/412 20180101; A61P 9/00 20180101; A61K
2039/505 20130101; A61P 31/12 20180101; C07K 16/241 20130101; A61P
3/10 20180101; C07K 2317/64 20130101; A61P 19/02 20180101; A61P
31/04 20180101; A61P 27/02 20180101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 16/24 20060101 C07K016/24; C07K 16/32 20060101
C07K016/32 |
Claims
1.-128. (canceled)
129. A method of modulating an immune response in a subject
comprising administering to the subject an effective amount of a
stradobody comprising an Fab domain; one or more Fc domains; and
one or more multimerization domains, wherein the one or more
multimerization domains separates two Fc domains or is located at
the carboxy terminus of the one or more Fc domains, and wherein the
one or more multimerization domains is capable of multimerizing
said stradobody.
130. The method of claim 129, wherein the one or more
multimerization domains are independently selected from the group
consisting of an isoleucine zipper, an IgG2 hinge, and a GPP
repeat.
131. The method of claim 129, wherein the stradobody comprises at
least one IgG2 hinge domain, wherein the amino acid sequence of the
IgG2 hinge domain is at least 80% homologous to SEQ ID NO: 3, and
wherein the IgG2 hinge is capable of multimerizing the
stradobody.
132. The method of claim 129, wherein the stradobody comprises at
least one isoleucine zipper, wherein the amino acid sequence of the
at least one isoleucine zipper is at least 80% homologous to SEQ ID
NO: 32, and wherein the isoleucine zipper is capable of
multimerizing the stradobody.
133. The method of claim 129, wherein the stradobody comprises two
multimerization domains.
134. The method of claim 133, wherein the two multimerization
domains are an isoleucine zipper and an IgG2 hinge.
135. The method of claim 134, wherein the two multimerization
domains separate two Fc domains.
136. The method of claim 134, wherein the two multimerization
domains are located at the carboxy end of the Fc region.
137. The method of claim 129, wherein the at least one Fc domain is
an IgG1 Fc domain, and wherein the IgG1 Fc domain comprises an IgG1
CH2 and IgG1 CH3.
138. The method of claim 137, wherein the IgG1 Fc domain further
comprises an IgG1 hinge.
139. The method of claim 137, wherein the amino acid sequence of at
least one IgG1 Fc domain is at least 80% homologous to SEQ ID NO:
2.
140. The method of claim 129, wherein the Fab domain is specific
for EGFR, Her2/neu, or CD20.
141. The method of claim 129, wherein the subject is a human.
142. The method of claim 129, wherein the stradobody is
administered to the subject intravenously, subcutaneously, orally,
nasally, intraperitoneally, sublingually, bucally, transdermally,
by subcutaneous or subdermal implantation, or intramuscularly.
143. A method of treating an inflammatory disease, autoimmune
disease, infectious disease, or cancer in a subject in need
thereof, comprising administering to the subject an effective
amount of a stradobody comprising an Fab domain; one or more Fc
domains; and one or more multimerization domains, wherein the one
or more multimerization domains separates two Fc domains or is
located at the carboxy terminus of the one or more Fc domains, and
wherein the one or more multimerization domains is capable of
multimerizing said stradobody.
144. The method of claim 143, wherein the subject is a human.
145. The method of claim 143, wherein the stradobody is
administered to the subject intravenously, subcutaneously, orally,
nasally, intraperitoneally, sublingually, bucally, transdermally,
by subcutaneous or subdermal implantation, or intramuscularly.
146. The method of claim 143, wherein the subject has cancer and
the cancer is selected from the group consisting of colorectal
cancer, head and neck cancer, fibrosarcoma, myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, basal cell carcinoma, adenocarcinoma,
sweat gland carcinoma, sebaceous gland carcinoma, papillary
carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary
carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,
oligodendroglioma, meningioma, melanoma, neuroblastoma,
retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's
macroglobulinemia, myelodysplastic disease, heavy chain disease,
neuroendocrine tumors, and Schwanoma.
147. The method of claim 143, wherein the subject has an autoimmune
or inflammatory disease, and wherein the autoimmune or inflammatory
disease is selected from the group consisting of idiopathic
thrombocytopenic purpura, Guillain-Barre syndrome, myasthenia
gravis, multiple sclerosis, optic neuritis, Kawasaki's disease,
rheumatoid arthritis, systemic lupus erythematosus, atopic
dermatitis, atherosclerosis, coronary artery disease,
cardiomyopathy, reactive arthritis, Crohn's disease, ulcerative
colitis, graft versus host disease, and type 1 diabetes
mellitus.
148. The method of claim 143, wherein the subject has an infectious
disease, and wherein the infectious disease is selected from the
group consisting of candidiasis, candidemia, aspergillosis,
streptococcal pneumonia, streptococcal skin and oropharyngeal
conditions, gram negative sepsis, tuberculosis, mononucleosis,
influenza, respiratory illness caused by respiratory syncytial
virus, human immunodeficiency virus, Hepatitis B, Hepatitis C,
malaria, schistosomiasis, methicillin-resistant Staph aureus,
vancomycin-resistant Enterococcus, carbapenem-resistant and
carbapenemase-producing Enterobacteriaceae, mycobacterial disease,
and trypanosomiasis.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 13/971,584, filed Aug. 20, 2013, now U.S. Pat. No. 9,683,044,
issued May 31, 2017, which claims priority to U.S. Provisional
Application No. 61/691,057, filed Aug. 20, 2012, and U.S.
Provisional Application No. 61/785,144, filed Mar. 14, 2013, the
contents of which are herein incorporated by reference in their
entireties.
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
[0002] The contents of the text file submitted electronically
herewith are incorporated herein by reference in their entirety: A
computer readable format copy of the Sequence Listing (filename:
GLIK_009_01US_310975_2048_SeqList_ST25.txt, date recorded: Mar. 12,
2013, file size 329 kilobytes).
FIELD OF THE INVENTION
[0003] This invention relates generally to the fields of
immunology, autoimmunity, inflammation, infectious diseases, and
tumor immunology. More specifically, the present invention relates
to biologically active biomimetic molecules comprising
immunoglobulin Fc domains and Fab domains, compositions comprising
such biomimetics, and methods of making and using such
biomimetics.
BACKGROUND OF THE INVENTION
[0004] Monoclonal antibody (mAb) therapy is an important and
growing part of medicine. Over 30 monoclonal antibodies have been
approved for various immunological diseases, infectious diseases,
and cancers either in the United States or Europe, and hundreds
more are under investigation. However, a common problem in
monoclonal antibody therapy development is lack of adequate
efficacy despite Fab and FcR binding. Because of the high doses
that are often necessary in order to achieve efficacy, adverse side
effects are commonly associated with therapeutic antibodies.
Further, low or altered expression of tumor and other target
antigens, as well as genetic mutations that affect antibody targets
or downstream effects of antibody binding, can render antibody
therapies ineffective. As an example, the monoclonal antibody
trastuzumab is a mAb directed specifically against the HER2/neu
breast cancer antigen and commercially available under the trade
name Herceptin.RTM., is approved by the United States Food and Drug
Administration for the treatment of breast cancer. Trastuzumab can
be effective in patients in which HER2/neu is highly expressed;
however, approximately 90% of breast cancer patients have tumors
that are not classified as HER2/neu high expressing. As another
example, cetuximab, a mAb directed specifically against the
epidermal growth factor receptor (EGFR) and commercially available
under the trade name Erbitux.RTM., is approved by the United States
Food and Drug Administration for the treatment of colon cancer.
Cetuximab blocks the EGFR and arrests a downstream KRAS
protein-dependent tumor proliferation pathway. From a clinical
perspective, cetuximab can improve overall response rates as well
as progression-free survival in patients whose tumors have wild
type (WT) KRAS. Unfortunately, 30-60% of colon cancer patients have
tumors with codon 12 or 13 KRAS mutations, and recent clinical
trials suggest that patients with mutated KRAS do not benefit from
treatment with cetuximab (summarized in Allegra et. al., Journal of
Clinical Oncology, 2009 Apr. 20; 27(12):2091-6). Thus, there is a
need for new antibody-like-based therapeutics in the treatment of
cancers, as well as in the treatment of autoimmune disorders and
inflammatory diseases.
[0005] Engagement and aggregation of Fc receptors, particularly low
affinity receptors such as Fc.gamma.RIIIa, on immune cells and
especially on natural killer (NK) cells by antibodies results in
activation, degranulation, and lysis of the target tumor or cell,
in a process known as antibody dependent cellular cytoxicity
(ADCC). Tumor cells and other cells targeted by the immune system
may also be killed through complement-dependent cytoxicity (CDC),
in which an antibody binds complement, leading to cell
cytotoxicity; or through direct cytotoxicity (DC) resulting from
direct antibody binding to antigen in the absence of NK cells or
complement; or by other mechanisms such as induction of apoptosis,
or interference with cellular growth or processes. There is
presently a need in the art to identify means of increasing ADCC,
CDC, DC, and other mechanisms of killing tumor cells or other
cells, thereby increasing the efficacy of mAb therapies. In
particular, when complement-dependent pathways for cell killing are
fully functional, CDC can be an effective method for killing cancer
cells and other target cells. However, many cells are resistant to
CDC due to cell membrane repair mechanisms and regulatory proteins
such as CD59, which inhibits the complement pathway. For example,
despite the high levels of expression of CD20 on B cell lymphoma
and leukemia cells, many patients with B cell malignancies are
unresponsive to, or become resistant to, treatment with the
anti-CD20 monoclonal antibody rituximab, at least in part due to
mechanisms of complement inhibition (Harjunpaa et al., Scand. J.
Immunol, 2000 51; 634-641). Therefore, there is a particular need
for molecules that are capable of increasing CDC.
SUMMARY OF THE INVENTION
[0006] The present invention relates to biologically active
biomimetic molecules comprising immunoglobulin Fc domains, Fab
domains, and multimerization domains; compositions comprising such
biomimetics; and methods of making and using such biomimetics.
These biomimetics have broad application for treating cancers,
inflammatory, autoimmune, and infectious disease conditions in
which a monoclonal antibody may be used or is already in clinical
use. The biomimetics of the present invention have the advantages
of more potent antibody-mediated cell cytoxicity,
complementmediated cell cytotoxicity, and complement clq binding
compared to a mAb whose Fab is identical to the Fab comprised in
the biomimetics of the present invention. The biomimetics of the
present invention also have the advantage of more potent
complement-dependent cell cytoxicity and direct cytotoxicity
compared to a mAb whose Fab is specific for the same antigen.
[0007] WO 2008/151088 discloses using biomimetic molecules
comprising two or more Fc domains, preferably in the context of a
stradomer, to which one or more Fab domains is attached, for the
treatment of pathological conditions including cancers, autoimmune
diseases and other inflammatory conditions, and infectious
diseases. WO 2008/151088 is incorporated herein by reference in its
entirety. The molecules comprising an Fab disclosed in WO
2008/151088 are termed "stradobodies" and possess the antigen
binding properties of the Fab portion of a monoclonal antibody and
the Fc receptor binding properties of stradomers. Thus, these
stradobodies bind, cross-link, and activate multiple Fc.gamma.
receptors on effector cells simultaneously, creating avidity that
cannot be accomplished by an individual mAb or immunoglobulin Fc
backbone binding to an individual Fc.gamma. receptor, even if
optimized via Fc mutagenesis, defucosylation, or other methods that
improve affinity between an individual mAb and an individual
Fc.gamma. receptor. Polyvalent binding of Fc.gamma. receptors on
effector cells is particularly important in the environment of low
epitope expression. Low epitope expression leads to mAb Fab binding
events too isolated to result in a sufficient density of
Fc-Fc.gamma. receptor binding events in close enough proximity on
the effector cell to cause downstream activation of low affinity
Fc.gamma. receptors on effector cells. However, as disclosed
herein, the inclusion of one or more multimerization domains in
addition to the Fab and Fc domains enhances the Fc.gamma.R binding
activity of the stradobodies, resulting in slow dissociation
characteristic of avidity, as well as antibody-dependent cell
cytoxicity (ADCC), complement-mediated cytoxicity (CDC), direct
cytotoxicity (DC), strong complement clq binding, and/or other
mechanisms of cellular toxicity. In particular, the multimerization
domains are located between two Fc domains or at the carboxy end of
the Fc region in the stradobodies disclosed herein. Surprisingly, a
stradobody comprising two particular multimerization domains, an
isoleucine zipper and an IgG2 hinge, resulted in particularly
strong multimerization, high cellular toxicity against target
cells, and high clq binding.
[0008] Nagashima et al. (Journal of Bioscience and Bioengineering
111(4): 391-6 (2011) and Molecular Immunology 45(10):2752-63
(2008)) described serial stradobodies with tandem repeats of Fc
domains, as anticipated by WO 2008/151088, which resulted in
enhanced ADCC relative to the parent monoclonal antibodies from
which they were derived, i.e. comprising the identical Fab region.
The stradobodies of the present invention, however, by virtue of
the multimerization domain(s), lead to multimerization of the
stradobody homodimers which in turn enhances the number of Fc
domains capable of simultaneously binding Fc.gamma.R and ultimately
leads to far superior binding and cytotoxicity when compared with
non-multimerizing compounds, such as those described in Nagashima
and elsewhere.
[0009] In one aspect, the current invention relates to a stradobody
comprising an Fab domain, one or more Fc domains, and one or more
multimerization domains. In a further embodiment, the one or more
multimerization domains is capable of multimerizing said
stradobody. In one embodiment, at least one of the one or more
multimerization domains separates two or more Fc domains. In
another embodiment, the at least one of the one or more
multimerization domains is located at the carboxy end of the Fc
region. In a preferred embodiment, one or more Fc domains is an
IgG1 Fc domain.
[0010] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody. In another embodiment, the multimerization domains are
independently selected from the group consisting of an isoleucine
zipper, an IgG2 hinge, and a GPP repeat. In another embodiment, the
stradobody comprises two multimerization domains. In a further
embodiment, the two multimerization domains are independently
selected from the group consisting of an isoleucine zipper, an IgG2
hinge, and a GPP repeat. In a still further embodiment, the two
multimerization domains are an isoleucine zipper and an IgG2 hinge.
In a still further embodiment, the two multimerization domains are
both an IgG2 hinge. In another embodiment, the two multimerization
domains are both an isoleucine zipper. In another embodiment, the
stradobody comprises three multimerization domains. In still
another embodiment, the stradobody comprises four or more
multimerization domains.
[0011] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein at least one of the one or more
multimerization domains is an isoleucine zipper. In a further
embodiment, the at least one isoleucine zipper is according to SEQ
ID NO: 32, and is capable of multimerizing the stradobody. In
another embodiment, at least one of the one or more multimerization
domains is an IgG2 hinge domain. In a further embodiment, the at
least one IgG2 hinge domain is according to SEQ ID NO: 3 and is
capable of multimerizing the stradobody. In another embodiment, at
least one of the one or more multimerization domains is a GPP
domain. In a further embodiment, the at least one GPP domain
comprises an amino acid sequence according to SEQ ID NO:26 and is
capable of multimerizing the stradobody.
[0012] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody. In a further embodiment, at least one Fc domain is an
IgG1 Fc domain, and the least one Fc domain comprises an IgG1 CH2,
and an IgG1 CH3. In a further embodiment, the Fc domain comprises
an IgG1 hinge, an IgG1 CH2, and an IgG1 CH3. In another embodiment,
the stradobody comprises more than one Fc domain. In a further
embodiment, each of the more than one Fc domains is an IgG1 Fc
domain. In a further embodiment, each of the more than one Fc
domains is an IgG3 Fc domain. In a further embodiment, each of the
more than one Fc domains is an IgG2 Fc domain. In a further
embodiment, each of the more than one Fc domains is an IgG4 Fc
domain. In a further embodiment, the more than one Fc domains is
comprised of an IgG1 Fc domain and an IgG2 Fc domain, IgG3 Fc
domain, or IgG4 Fc domain.
[0013] In one embodiment, the current invention relates to a
stradobody wherein the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, a first multimerization
domain, a second multimerization domain, and a second Fc domain. In
a further embodiment, at least one of the Fc domains is an IgG1 Fc
domain. In another embodiment, the stradobody comprises, from amino
to carboxy terminus, an Fab domain, a first Fc domain, an IgG2
hinge, an isoleucine zipper, and a second Fc domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, an isoleucine zipper,
an IgG2 hinge, and a second Fc domain. In one especially preferred
embodiment, the first Fc domain, isoleucine zipper, IgG2 hinge, and
second Fc domain together comprise an amino acid sequence according
to SEQ ID NO: 69. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, a first Fc domain,
an IgG2 hinge, a second IgG2 hinge, and a second Fc. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, an isoleucine zipper, a
second isoleucine zipper, and a second Fc domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, an isoleucine zipper,
and a second Fc domain. In another embodiment, the stradobody
comprises, from amino to carboxy terminus, an Fab domain, a first
Fc domain, an IgG2 hinge; and a second Fc domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, a G4S domain, an IgG2
hinge, and a second Fc domain. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, a first Fc domain, an IgG2 hinge, a G4S domain, a second Fc
domain. In another embodiment, the stradobody comprises, from amino
to carboxy terminus, an Fab domain, a first Fc domain, a G4S
domain, an isoleucine zipper, a second Fc domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, an isoleucine zipper, a
G4S domain, and a second Fc domain. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, a first Fc domain, a GPP domain, and a second Fc domain. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, a GPP domain, an IgG2
hinge, and a second Fc domain. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, a first Fc domain, an IgG2 hinge, a GPP domain, and a
second Fc domain. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, a first Fc domain, a
GPP domain, an isoleucine zipper, and a second Fc domain. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, an isoleucine zipper, a
GPP domain, and a second Fc domain. A skilled artisan will
recognize that other multimerization domains can be used in place
of the multimerization domains described here.
[0014] In a further embodiment, the first and the second Fc domains
are IgG1 Fc domains. In another embodiment, at least one IgG1 Fc
domain comprises an IgG1 CH2 and an IgG1 CH3. In a further
embodiment, the IgG1 Fc domain further comprises an IgG1 hinge.
[0015] In one embodiment, the current invention relates to a
composition comprising multimerized stradobodies, wherein the
stradobodies comprise, from amino to carboxy terminus, an Fab
domain, a first Fc domain, a first multimerization domain, a second
multimerization domain, and a second Fc domain.
[0016] In one embodiment, the current invention relates to a
stradobody wherein the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a single Fc domain, a first
multimerization domain, and a second multimerization domain. In a
further embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a single Fc domain, an isoleucine zipper,
and an IgG2 hinge. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, an Fc domain, an
IgG2 hinge, and an isoleucine zipper. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, and an IgG2 hinge. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, an IgG2 hinge, and a second IgG2 hinge. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, and an isoleucine zipper. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, an isoleucine zipper, and a
second isoleucine zipper. In another embodiment, the stradobody
comprises, from amino to carboxy terminus, an Fab domain, an Fc
domain, a G4S domain, and an IgG2 hinge. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, an IgG2 hinge, and a G4S domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, a G4S domain, and an
isoleucine zipper. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, an Fc domain, an
isoleucine zipper, and a G4S domain. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, a domain linkage, and an IgG2 hinge. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, a domain linkage, and an
isoleucine zipper. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, an Fc domain, an
IgG2 hinge, and a domain linkage. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, an isoleucine zipper and a domain linkage. In
another embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, and a GPP domain. In another
embodiment, the stradobody comprises, from amino to carboxy
terminus, an Fab domain, an Fc domain, a GPP domain, and an IgG2
hinge. In another embodiment, the stradobody comprises, from amino
to carboxy terminus, an Fab domain, an Fc domain, an IgG2 hinge,
and a GPP domain. In another embodiment, the stradobody comprises,
from amino to carboxy terminus, an Fab domain, an Fc domain, a GPP
domain, and an isoleucine zipper. In another embodiment, the
stradobody comprises, from amino to carboxy terminus, an Fab
domain, an Fc domain, an isoleucine zipper, and a GPP domain. A
skilled artisan will recognize that other multimerization domains
can be used in place of the multimerization domains described
here.
[0017] In a further embodiment, the Fc domain is an IgG1 Fc domain.
In a further embodiment, the IgG1 Fc domain comprises an IgG1 CH2
and an IgG1 CH3. In a still further embodiment, the IgG1 Fc domain
further comprises an IgG1 hinge.
[0018] In one embodiment, the current invention relates to a
composition comprising multimerized stradobodies, wherein the
stradobodies comprise, from amino to carboxy terminus, an Fab
domain, an Fc domain, a first multimerization domain, and a second
multimerization domain.
[0019] In another embodiment, the stradobody comprises, from amino
to carboxy terminus, an Fab domain, two or more Fc domains, and one
or more multimerization domains. In a further embodiment, the Fc
domain is an IgG1 Fc domain.
[0020] In one embodiment, the current invention relates to a
stradobody wherein the stradobody comprises, from amino to carboxy
terminus, an Fab domain, a first Fc domain, one or more
multimerization domains, and a second Fc domain. In another
embodiment, the current invention relates to a stradobody wherein
the stradobody comprises, from amino to carboxy terminus, an Fab
domain, a first Fc domain, and one or more multimerization domains.
In a further embodiment, the stradobody further comprises one or
more multimerization domains at the C-terminal end of the Fc
region. In a further embodiment, one or more of the Fc domains is
an IgG1 Fc domain.
[0021] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the Fab domain is specific for EGFR. In one
embodiment, the amino acid sequence of the Fab domain is at least
80% homologous to SEQ ID NO: 31. In a further embodiment, the amino
acid sequence of the Fab domain is at least 90% homologous to SEQ
ID NO: 31. In still a further embodiment, the amino acid sequence
of the Fab domain is at least 95% homologous to SEQ ID NO: 31. In
yet a further embodiment, the amino acid sequence of the Fab domain
is at least 99% homologous to SEQ ID NO: 31. In a yet further
embodiment, the amino acid sequence of the Fab domain is SEQ ID NO:
31. In some embodiments, the one or more Fc domain is an IgG1 Fc
domain.
[0022] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 33. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 33. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
33. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 33. In a yet
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 33. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 33.
[0023] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 70. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 70. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
70. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 70. In a yet
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 70. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 70.
[0024] In another embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the Fab domain is specific for HER2/neu
antigen. In one embodiment, the amino acid sequence of the Fab
domain is at least 80% homologous to SEQ ID NO: 34. In a further
embodiment, the amino acid sequence of the Fab domain is at least
90% homologous to SEQ ID NO: 34. In still a further embodiment, the
amino acid sequence of the Fab domain is at least 95% homologous to
SEQ ID NO: 34. In yet a further embodiment, the amino acid sequence
of the Fab domain is at least 99% homologous to SEQ ID NO: 34. In a
yet further embodiment, the amino acid sequence of the Fab domain
is SEQ ID NO: 34. In some embodiments, the one or more Fc domain is
an IgG1 Fc domain.
[0025] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 35. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 35. In a still further embodiment, the amino acid
sequence of the stradobody is t least 90% homologous to SEQ ID NO:
35. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 35. In yet a
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 35. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 35. The skilled artisan would
understand that stradobodies and in particular multimerizing
stradobodies can be readily produced with an Fab directed against
any tumor antigen.
[0026] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 91. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 91. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
91. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 91. In a yet
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 91. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 91.
[0027] In another embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the Fab domain is specific for CD20. In one
embodiment, the amino acid sequence of the Fab domain is at least
80% homologous to SEQ ID NO: 36. In a further embodiment, the amino
acid sequence of the Fab domain is at least 90% homologous to SEQ
ID NO: 36. In still a further embodiment, the amino acid sequence
of the Fab domain is at least 95% homologous to SEQ ID NO: 36. In
yet a further embodiment, the amino acid sequence of the Fab domain
is at least 99% homologous to SEQ ID NO: 36. In a yet further
embodiment, the amino acid sequence of the Fab domain is SEQ ID NO:
36. In some embodiments, the one or more Fc domain is an IgG1 Fc
domain.
[0028] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 37. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 37. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
37. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 37. In yet a
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 37. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 37.
[0029] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 76. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 76. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
76. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 76. In a yet
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 76. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 76.
[0030] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the Fab domain is specific for a TNF
superfamily member. Members of the TNF superfamily include, without
limitation, TNF, TNF-.alpha., TNF-.beta., Lymphotoxin (LT),
Lymphotoxin.beta. (LT.beta.), OX40 Ligand, CD40 Ligand, CD95/Fas
Ligand, CD27 Ligand (CD70), CD30 Ligand, CD137/4-1BB Ligand, TRAIL,
TRANCE/RANKL, TWEAK/Apo-3, APRIL, BAFF/Blys, LIGHT, TL1A/VEGI, GITR
Ligand, EDA-A1, and EDA-A2. In one embodiment, the stradobody
comprises an Fab domain that is specific for TNF (i.e., an anti-TNF
stradobody; for example, the stradobody GB7542). In another
embodiment, the stradobody comprises an Fab domain that is specific
for Blys (i.e., an anti-Blys stradobody). In another embodiment,
the stradobody comprises an Fab domain that is specific for TRAIL
(i.e., an anti-TRAIL stradobody). In another embodiment, the
stradobody comprises an Fab domain that is specific for OX40L
(i.e., an anti-OX40L stradobody). In another embodiment, the
stradobody comprises an Fab domain that is specific for 4-1BB
(i.e., an anti-4-1BB stradobody). In another embodiment, the
stradobody comprises a Fab domain that is specific for APRIL,
(i.e., an anti-APRIL stradobody). In another embodiment, the
stradobody comprises a Fab domain that is specific for TRANCE
(i.e., an anti-TRANCE stradobody). In another embodiment, the
stradobody comprises a Fab domain that is specific for LT.beta.
(i.e., an anti-LT.beta. stradobody), In another embodiment, the
stradobody comprises a Fab domain that is specific for CD40L (i.e.,
an anti-CD40L stradobody). The skilled artisan would understand
that stradobodies and in particular multimerizing stradobodies can
be readily produced with an Fab directed against any immune cell
surface receptor.
[0031] In another embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the Fab domain is specific for TNF. In one
embodiment, the amino acid sequence of the Fab domain is at least
80% homologous to SEQ ID NO: 67. In a further embodiment, the amino
acid sequence of the Fab domain is at least 90% homologous to SEQ
ID NO: 67. In still a further embodiment, the amino acid sequence
of the Fab domain is at least 95% homologous to SEQ ID NO: 67. In
yet a further embodiment, the amino acid sequence of the Fab domain
is at least 99% homologous to SEQ ID NO: 67. In a yet further
embodiment, the amino acid sequence of the Fab domain is SEQ ID NO:
67. In some embodiments, the one or more Fc domain is an IgG1 Fc
domain.
[0032] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 66. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 66. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
66. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 66. In yet a
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 66. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 66. The skilled artisan would
understand that stradobodies and in particular multimerizing
stradobodies can be readily produced with an Fab directed against
any cytokine or soluble receptor.
[0033] In one embodiment, the current invention relates to a
stradobody wherein the amino acid sequence of the stradobody is at
least 80% homologous to SEQ ID NO: 87. In a further embodiment, the
amino acid sequence of the stradobody is at least 85% homologous to
SEQ ID NO: 87. In a still further embodiment, the amino acid
sequence of the stradobody is at least 90% homologous to SEQ ID NO:
87. In a yet further embodiment, the amino acid sequence of the
stradobody is at least 95% homologous to SEQ ID NO: 87. In a yet
further embodiment, the amino acid sequence is at least 99%
homologous to SEQ ID NO: 87. In a yet further embodiment, the amino
acid sequence is SEQ ID NO: 87.
[0034] In one embodiment, the stradobody of the current invention
comprises an Fab domain that is specific for IFN.gamma.,
IFN.alpha., IFN.beta., IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12, IL-13, IL-15, IL-17, or IL-23. In one embodiment, the
stradobody of the current invention comprises an Fab domain that is
specific for a cytokine, wherein the stradobody is useful for
treatment or prevention of an inflammatory or autoimmune disease.
For example, in one embodiment, the stradobody is an anti-IL-2,
anti-IL-8, or anti-IL-17 stradobody. The skilled artisan would
understand that stradobodies and in particular multimerizing
stradobodies can be readily produced with an Fab directed against
any interleukin or interferon.
[0035] In one embodiment, the current invention relates to a
stradobody wherein the stradobody comprises an Fab directed against
one or more infectious disease antigens. The skilled artisan would
understand that stradobodies and in particular multimerizing
stradobodies can be readily produced with an Fab directed against
any infectious disease antigen. The skilled artisan would further
understand that stradobodies and in particular multimerizing
stradobodies can be readily produced with an Fab derived from a
monoclonal antibody that may be used or is already in clinical use
for treatment or prevention of infectious disease.
[0036] For Example, multimerizing stradobodies can be produced with
an Fab derived from a monoclonal antibody that may be used or is
already in clinical use for neutralization of viruses,
neutralization of bacteria or bacterial toxins, blocking of viral
entry into host cells, blocking immune inhibitory mechanisms
triggered by pathogens, blocking of immunopathogenic responses
triggered by pathogens, or other means of treating or preventing
infectious disease. Exemplary monoclonal antibodies in clinical use
or in development for clinical use for treatment or prevention of
infectious disease include, but are not limited to, palivizumab and
motavizumab, both of which are specific for respiratory syncitial
virus (RSV) glycoprotein F; ibalizumab, an anti-CD4 antibody for
blocking human immunodeficiency virus (HIV) entry into host cells;
Pro-140 and CCR5mAb004, anti-CCR5 antibodies for blocking HIV entry
into host cells; F105, an anti-gp120 antibody for neutralizing
envelope glycoprotein gp120 of HIV, which is also used in viral
entry; sevirumab, which is specific for cytomegalovirus (CMV)
envelope glycoprotein H; bavituximab, an anti-phosphatidyl serine
antibody used to neutralize Hepatitis C virus (HCV); nivolumab
(also known as MDX1106/BMS936558/ONO-4538) and pidilizumab (also
known as CT-011), both of which are specific for the immune
inhibitory molecule PD-1 on immune cells and are used as
immunomodulation antibodies in HCV infection; MBL-HCV1, an HCV
neutralizing antibody specific for the HCV structural protein E2;
foravirumab, a rabies virus neutralizing antibody specific for
glycoprotein G; ETI-204 (anthim), raxibacumab, and AVP 21D9, each
of which is a Bacillus anthracis toxin neutralization antibody
specific for B. anthracis protective antigen; SAR279356 and other
anti-poly-N-acetyl glucosamine (PNAG) antibodies, which are useful
in Staphylococcus and other bacterial infections, particularly
multi drug-resistant infections; pagibaximab, which is specific for
anti-lipoteichoic acid and used for prevention of Staphylococcus
infection; tefibazumab, which is specific for clumping factor A and
is also useful for Staphylococcus infection; urtoxazumab, an
anti-Shiga-like toxin 2B antibody for E. coli infection; shigamabs,
which is a cocktail of two mAbs, caStx1 and caStx2, for
neutralization of E. coli STEC toxins Stx1 and Stx2; actoxumab
(anti-Clostridum difficile enterotoxin A) and bezlotoxumab (anti-C.
difficile enterotoxin B), which may be administered together as a
cocktail of two antibodies known as MK3415A; panobacumab, an
anti-LPS antibody used in Pseudomonas aeruginosa infection; KB 001,
an anti-type 3 secretion system antibody used in P. aeruginosa
infection); and 18B7, anti-capsular polysaccharide antibody for
Cyptococcus neoformans infection.
[0037] In one embodiment, the current invention relates to a
stradobody comprising an Fab domain, one or more Fc domains, and
one or more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody, and wherein the two or more Fc domains are capable of
binding Fc.gamma.R. In a further embodiment, the Fc.gamma.R is
Fc.gamma.RIIIa. In a further embodiment, the Fc.gamma.RIIIa are on
effector cells. In a yet further embodiment, the Fc.gamma.RIIIa are
on NK cells. In another embodiment, the Fc.gamma.RIIIa are on
macrophages. In another embodiment, the Fc.gamma.R is
Fc.gamma.RIIb. In a further embodiment, the Fc.gamma.RIIb are on B
cells. In another embodiment, the Fc.gamma.RIIb are on dendritic
cells.
[0038] In a further embodiment, the amino acid sequence of the two
or more Fc domains is at least 80% homologous to SEQ ID NO: 2. In a
further embodiment, the amino acid sequence of the two or more Fc
domains is at least 90% homologous to SEQ ID NO: 2. In still a
further embodiment, the amino acid sequence of the two or more Fc
domains is at least 95% homologous to SEQ ID NO: 2. In yet a
further embodiment, the amino acid sequence of the two or more Fc
domains is at least 99% homologous to SEQ ID NO: 2. In a yet
further embodiment, the amino acid sequence of the two or more Fc
domains is SEQ ID NO: 2.
[0039] In one aspect, the current invention relates to a method of
modulating an immune response in a subject comprising administering
to the subject an effective amount of the stradobody comprising an
Fab domain, one or more Fc domains, and one or more multimerization
domains, wherein the one or more multimerization domains is capable
of multimerizing said stradobody.
[0040] In one embodiment, the current invention relates to a method
of treating an inflammatory or autoimmune disease, an infectious
disease, or a cancer in a subject in need thereof comprising
administering to the subject an effective amount of a stradobody
that comprises an Fab domain, one or more Fc domains, and one or
more multimerization domains, wherein the one or more
multimerization domains is capable of multimerizing said
stradobody. In a further embodiment, the subject has cancer. In a
still further embodiment, the cancer is selected from the group
consisting of colorectal cancer, head and neck cancer,
fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic
sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer,
prostate cancer, squamous cell carcinoma, basal cell carcinoma,
adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,
papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,
oligodendroglioma, meningioma, melanoma, neuroblastoma,
retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's
macroglobulinemia, myelodysplastic disease, heavy chain disease,
neuroendocrine tumors, and Schwanoma.
[0041] In another embodiment, the subject has an autoimmune or
inflammatory disease. In a further embodiment, the autoimmune or
inflammatory disease is selected from the group consisting of
Idiopathic Thrombocytopenic Purpura, alloimmune/autoimmune
thrombocytopenia, Acquired immune thrombocytopenia, Autoimmune
neutropenia, Autoimmune hemolytic anemia, Parvovirus B19-associated
red cell aplasia, Acquired antifactor VIII autoimmunity, acquired
von Willebrand disease, Multiple Myeloma and Monoclonal Gammopathy
of Unknown Significance, Alzheimer's Disease, Sepsis, Aplastic
anemia, pure red cell aplasia, Diamond-Blackfan anemia, hemolytic
disease of the newborn, Immune-mediated neutropenia, refractoriness
to platelet transfusion, neonatal, post-transfusion purpura,
hemolytic uremic syndrome, systemic Vasculitis, Thrombotic
thrombocytopenic purpura, Evan's syndrome, Guillain-Barre syndrome,
Chronic Inflammatory Demyelinating Polyradiculoneuropathy,
Paraproteinemic IgM demyelinating Polyneuropathy, Lambert-Eaton
myasthenic syndrome, Myasthenia gravis, Multifocal Motor
Neuropathy, Lower Motor Neuron Syndrome associated with anti-/GM1,
Demyelination, Multiple Sclerosis, optic neuritis, Stiff Man
Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo
antibodies, paraneoplastic encephalomyelitis, sensory neuropathy
with anti-Hu antibodies, epilepsy, Encephalitis, Myelitis,
Myelopathy especially associated with Human T-cell lymphotropic
virus-1, Autoimmune Diabetic Neuropathy, Acute Idiopathic
Dysautonomic Neuropathy, Kawasaki's disease, Rheumatoid arthritis,
Felty's syndrome, ANCA-positive Vasculitis, Spontaneous
Polymyositis, Dermatomyositis, Antiphospholipid syndromes,
Recurrent spontaneous abortions, Systemic Lupus Erythematosus,
Juvenile idiopathic arthritis, Raynaud's, CREST syndrome, Uveitis,
Toxic Epidermal Necrolysis, Gangrene, Granuloma, Autoimmune skin
blistering diseases including Pemphigus vulgaris, Bullous
Pemphigoid, and Pemphigus foliaceus, Vitiligo, Streptococcal toxic
shock syndrome, Scleroderma, systemic sclerosis including diffuse
and limited cutaneous systemic sclerosis, Atopic dermatitis
(especially steroid dependent), Inclusion Body Myositis,
Necrotizing fasciitis, Inflammatory Myopathies, Myositis,
Anti-Decorin (BJ antigen) Myopathy, Paraneoplastic Necrotic
Myopathy, X-linked Vacuolated Myopathy, Penacillamine-induced
Polymyositis, Atherosclerosis, Coronary Artery Disease,
Cardiomyopathy, pernicious anemia, autoimmune chronic active
hepatitis, primary biliary cirrhosis, Celiac disease, dermatitis
herpetiformis, cryptogenic cirrhosis, Reactive arthritis, Crohn's
disease, Whipple's disease, ulcerative colitis, sclerosing
cholangitis, Graft Versus Host Disease, Antibody-mediated rejection
of the graft, Post-bone marrow transplant rejection,
Post-infectious disease inflammation, Lymphoma, Leukemia,
Neoplasia, Asthma, Type 1 Diabetes mellitus with anti-beta cell
antibodies, Sjogren's syndrome, Mixed Connective Tissue Disease,
Addison's disease, Vogt-Koyanagi-Harada Syndrome,
Membranoproliferative glomerulonephritis, Goodpasture's syndrome,
Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis,
micropolyarterits, Churg-Strauss syndrome, Polyarteritis nodosa,
and Multisystem organ failure.
[0042] The present invention further comprises methods and
compositions effective for the treatment of infectious disease,
including but not limited to those caused by bacterial,
mycological, parasitic, and viral agents. Examples of such
infectious agents include the following: staphylococcus,
streptococcaceae, neisseriaaceae, cocci, enterobacteriaceae,
pseudomonadaceae, vibrionaceae, campylobacter, pasteurellaceae,
bordetella, francisella, brucella, legionellaceae, bacteroidaceae,
clostridium, corynebacterium, propionibacterium, gram-positive
bacilli, anthrax, actinomyces, nocardia, mycobacterium, treponema,
borrelia, leptospira, mycoplasma, ureaplasma, rickettsia,
chlamydiae, other gram-positive bacilli, other gram-negative
bacilli, systemic mycoses, other opportunistic mycoses, protozoa,
nematodes, trematodes, cestodes, adenoviruses, herpesviruses
(including, for example, herpes simplex virus and Epstein Barr
virus, and herpes zoster virus), poxviruses, papovaviruses,
hepatitis viruses, papilloma viruses, orthomyxoviruses (including,
for example, influenza A, influenza B, and influenza C),
paramyxoviruses, coronaviruses, picornaviruses, reoviruses,
togaviruses, flaviviruses, bunyaviridae, rhabdoviruses, respiratory
syncitial virus, human immunodeficiency virus and retroviruses.
Exemplary infectious diseases include but are not limited to
candidiasis, candidemia, aspergillosis, streptococcal pneumonia,
streptococcal skin and oropharyngeal conditions, gram negative
sepsis, tuberculosis, mononucleosis, influenza, respiratory illness
caused by Respiratory Syncytial Virus, malaria, schistosomiasis,
and trypanosomiasis.
[0043] In a further embodiment the stradobody is administered
intravenously, subcutaneously, orally, nasally, intraperitoneally,
sublingually, bucally, transdermally, by subcutaneous or subdermal
implantation, intraduodenally, or intramuscularly. In one
embodiment, the stradobody is administered intravenously. Because
of the enhanced efficacy of the stradobodies of the current
invention, in some embodiments the stradobodies may be administered
at a lower dose intravenously compared with monoclonal antibodies
specific for the same antigen. In one embodiment, the stradobody is
administered intravenously at a dose of about 0.01 mg/Kg to about
1000 mg/Kg IV. In a further embodiment, the stradobody is
administered at about 0.1 mg/Kg to about 100 mg/Kg IV. In yet a
further embodiment, the stradobody is administered at about 0.5
mg/Kg to about 50 mg/Kg IV. In still a further embodiment, the
stradobody is administered at about 1 mg/Kg to about 25 mg/Kg IV.
In still a further embodiment, the stradobody is administered at
about 5 mg/Kg to about 15 mg/Kg IV. In one embodiment, the
stradobody is administered subcutaneously. Because of the enhanced
efficacy of the stradobodies of the current invention, in some
embodiments the stradobody may be administered at a lower dose
subcutaneously compared with monoclonal antibodies specific for the
same antigen. In one embodiment, the stradobody is administered
subcutaneously at a dose of about 0.01 mg/Kg to about 1000 mg/Kg
SQ. In a further embodiment, the stradobody is administered at
about 0.2 mg/Kg to about 150 mg/Kg SQ. In yet a further embodiment,
the stradobody is administered at about 0.5 mg/Kg to about 80 mg/Kg
SQ. In still a further embodiment, the stradobody is administered
at about 2 mg/Kg to about 50 mg/Kg SQ. In still a further
embodiment, the stradobody is administered at about 5 mg/Kg to
about 30 mg/Kg SQ. In still a further embodiment, the stradobody is
administered before, concurrently, or after a monoclonal antibody.
In still a further embodiment, the stradobody administered before,
concurrently, or after a monoclonal antibody has an Fab directed
against the same antigen as the monoclonal antibody. In still a
further embodiment, the stradobody administered before,
concurrently, or after a monoclonal antibody has an Fab directed
against a different antigen from the monoclonal antibody.
[0044] In a further embodiment, the stradobody is administered
before, during or after administration of one or more additional
pharmaceutical and/or therapeutic agents. In a further embodiment
the additional pharmaceutically active agent comprises a steroid; a
biologic anti-autoimmune drug such as a monoclonal antibody, a
fusion protein, or an anti-cytokine; a non-biologic anti-autoimmune
drug; an immunosuppressant; an antibiotic; and anti-viral agent; a
cytokine; or an agent otherwise capable of acting as an
immune-modulator. In still a further embodiment, the steroid is
prednisone, prednisolone, cortisone, dexamethasone, mometesone
testosterone, estrogen, oxandrolone, fluticasone, budesonide,
beclamethasone, albuterol, or levalbuterol. In still a further
embodiment, the stradobody is administered before, during or after
administration of a chemotherapeutic agent. In still a further
embodiment, the stradobody and the additional therapeutic agent
display therapeutic synergy when administered together. In one
embodiment, the stradobody is administered prior to the
administration of the additional therapeutic agent. In another
embodiment, the stradobody is administered at the same time as the
administration of the additional therapeutic agent. In still
another embodiment, the stradobody is administered after the
administration with the additional therapeutic agent. In one
embodiment, the stradobody is administered prior to the
administration of a danger signal. In another embodiment, the
stradobody is administered at the same time as the administration
of a danger signal. In still another embodiment, the stradobody is
administered after the administration of a danger signal.
[0045] In another embodiment, the stradobody is administered to
treat humans, non-human primates (e.g., monkeys, baboons, and
chimpanzees), mice, rats, bovines, horses, cats, dogs, pigs,
rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs,
hamsters, bats, birds (e.g., chickens, turkeys, and ducks), fish
and reptiles with species-specific or chimeric stradobody
molecules. In yet another embodiment, the human is an adult or a
child. In still another embodiment, the stradobody is administered
to prevent autoimmune disease. In a further embodiment the
stradobody is administered to prevent vaccine-associated autoimmune
conditions in companion animals and livestock.
[0046] In one embodiment, the current invention relates to a
stradobody wherein the stradobody displays enhanced cell killing
compared to a monoclonal antibody specific for the same antigen. In
one embodiment, the enhanced cell killing is mediated by ADCC. In a
further embodiment, the stradobody displays ADCC that is at least 2
times higher compared to a monoclonal antibody specific for the
same antigen. In another embodiment, the stradobody displays ADCC
that is at least 5 times higher compared to a monoclonal antibody
specific for the same antigen. In another embodiment, the
stradobody displays ADCC that is at least 10 times higher compared
to a monoclonal antibody specific for the same antigen. In another
embodiment, the stradobody displays ADCC that is at least 20 times
higher compared to a monoclonal antibody specific for the same
antigen. In another embodiment, the enhanced cell killing is
mediated by CDC. In a further embodiment, the stradobody displays
CDC that is at least 2 times higher compared to a monoclonal
antibody specific for the same antigen. In another embodiment, the
stradobody displays CDC that is at least 5 times higher compared to
a monoclonal antibody specific for the same antigen. In another
embodiment, the stradobody displays CDC that is at least 10 times
higher compared to a monoclonal antibody specific for the same
antigen. In another embodiment, the stradobody displays CDC that is
at least 20 times higher compared to a monoclonal antibody specific
for the same antigen. In another embodiment, the enhanced cell
killing is mediated by DC. In a further embodiment, the stradobody
displays DC that is at least 2 times higher compared to a
monoclonal antibody specific for the same antigen. In another
embodiment, the stradobody displays DC that is at least 5 times
higher compared to a monoclonal antibody specific for the same
antigen. In another embodiment, the stradobody displays DC that is
at least 10 times higher compared to a monoclonal antibody specific
for the same antigen. In another embodiment, the stradobody
displays DC that is at least 20 times higher compared to a
monoclonal antibody specific for the same antigen.
[0047] In one embodiment, the stradobody contains two or more
multimerization domains, and displays enhanced cell killing
compared to a stradobody containing one multimerization domain. In
one embodiment, the cell killing is mediated by ADCC. In a further
embodiment, stradobody with two or more multimerization domains
displays ADCC that is at least 2 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays ADCC that is at least 5 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays ADCC that is at least 10 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays ADCC that is at least 20 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, the enhanced cell killing is mediated by CDC. In a
further embodiment, stradobody with two or more multimerization
domains displays CDC that is at least 2 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays CDC that is at least 5 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays CDC that is at least 10 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays CDC that is at least 20 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, the enhanced cell killing is mediated by DC. In a
further embodiment, stradobody with two or more multimerization
domains displays DC that is at least 2 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays DC that is at least 5 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays DC that is at least 10 times higher compared to a
stradobody containing one multimerization domain. In another
embodiment, stradobody with two or more multimerization domains
displays DC that is at least 20 times higher compared to a
stradobody containing one multimerization domain.
[0048] In another embodiment, the current invention relates to a
stradobody wherein the stradobody displays enhanced inhibition of
cellular proliferation compared to a monoclonal antibody specific
for the same antigen. In one embodiment, the stradobody inhibits
cellular proliferation by at least 10% more compared to a
monoclonal antibody specific for the same antigen. In another
embodiment, the stradobody inhibits cellular proliferation by at
least 20% more compared to a monoclonal antibody specific for the
same antigen. In another embodiment, the stradobody inhibits
cellular proliferation by at least 50% more compared to a
monoclonal antibody specific for the same antigen. In another
embodiment, the current invention relates to a stradobody that
contains two or more multimerization domains, and displays enhanced
inhibition of cellular proliferation compared to a stradobody
containing one multimerization domain. In one embodiment, the
stradobody inhibits cellular proliferation by at least 10% more
compared to a stradobody containing one multimerization domain. In
another embodiment, the stradobody inhibits cellular proliferation
by at least 20% more compared to a stradobody containing one
multimerization domain. In another embodiment, the stradobody
inhibits cellular proliferation by at least 50% more compared to a
stradobody containing one multimerization domain.
[0049] In one embodiment, the current invention relates to a
stradobody wherein the stradobody displays enhanced complement
binding compared to a monoclonal antibody specific for the same
antigen. In a further embodiment, the stradobody displays enhanced
complement binding compared to a monoclonal antibody specific for
the same antigen. In one embodiment, the enhanced complement
binding is binding to C1q. In one embodiment, the stradobody
displays enhanced complement binding that is at least 2 times
higher compared to a monoclonal antibody specific for the same
antigen. In another embodiment, the stradobody displays enhanced
complement binding that is at least 5 times higher compared to a
monoclonal antibody specific for the same antigen. In another
embodiment, the stradobody displays enhanced complement binding
that is at least 10 times higher compared to a monoclonal antibody
specific for the same antigen. In another embodiment, the
stradobody displays enhanced complement binding that is at least 20
times higher compared to a monoclonal antibody specific for the
same antigen. In one embodiment, the enhanced complement binding is
measured by the EC50 value. In one embodiment, the EC50 value for
complement binding is at least 5 times lower for the stradobody
compared to the monoclonal antibody specific for the same antigen.
In another embodiment, the EC50 value for complement binding is at
least 10 times lower for the stradobody compared to the monoclonal
antibody specific for the same antigen. In a further embodiment,
the EC50 value for complement binding is at least 20 times lower
for the stradobody compared to the monoclonal antibody specific for
the same antigen. In one embodiment, a multimerizing stradobody
demonstrates increased complement binding relative to a
non-multimerizing stradobody specific for the same antigen. In
another embodiment, a multimerizing stradobody demonstrates a lower
EC50 value for complement binding relative to a non-multimerizing
stradobody specific for the same antigen. In a further embodiment,
the EC50 value for the multimerizing stradobody is at least 2 times
lower for the multimerizing stradobody compared to the
non-multimerizing stradobody. In a further embodiment, the EC50
value for the multimerizing stradobody is at least 5 times lower
for the multimerizing stradobody compared to the non-multimerizing
stradobody.
[0050] In one embodiment, the level of complement binding exhibited
by a stradobody varies depending on the Fab. Thus, in one
embodiment, two stradobodies having the identical multimerizing
domains and identical Fc regions but different Fab exhibit a
different level of complement binding. In one embodiment, a
multimerizing stradobody having an anti-CD20 Fab exhibits
dramatically higher complement binding compared to a multimerizing
stradobody having the identical multimerizing domains and identical
Fc regions as the anti-CD20 Fab, but having an anti-TNF or an
anti-HER2/neu Fab.
[0051] In one embodiment, the current invention relates to
compositions comprising multimerized stradobodies. In a further
embodiment, the composition comprises at least 2, at least 3, at
least 4, at least 5, at least 6, at least 7, at least 8, at least
9, at least 10, or more stradobodies.
BRIEF DESCRIPTION OF THE FIGURES
[0052] FIG. 1 is a schematic depiction of multimerized serial and
multimerized C-terminal stradobodies and the building blocks that
make up stradobodies.
[0053] FIG. 2 is a schematic depiction of general structures of
serial stradobodies.
[0054] FIG. 3 is a schematic depiction of the structures of several
serial stradobodies illustrating constructs with one or more of the
indicated multimerization or linkage domains.
[0055] FIG. 4 is an illustration of serial stradobody
constructs.
[0056] FIG. 5 is a schematic depiction of the structures of several
multimerized C-terminal stradobodies illustrating constructs with
one or more of the indicated multimerization domains.
[0057] FIG. 6 is an illustration of multimerized C-terminal
stradobody constructs.
[0058] FIG. 7 is a schematic depiction of the structure of a
preferred stradobody of the current invention, comprising two IgG1
Fc domains separated by an isoleucine zipper and an IgG2 hinge.
[0059] FIG. 8 is a non-reducing SDS-PAGE gel showing the formation
of multimers of the indicated C-terminal multimerized stradobodies,
in comparison to the unaltered antibody GB2500.
[0060] FIG. 9 is a non-reducing SDS-PAGE gel showing the formation
of multimers of the indicated serial stradobodies, in comparison to
the unaltered antibody GB2500.
[0061] FIG. 10 shows the ADCC of the indicated stradobodies in
comparison to the unaltered HER2/neu antibody GB2500, as measured
by percent killing of target cells at a range of effector to target
cell ratios.
[0062] FIG. 11 shows the ADCC dose response of the indicated
stradobodies in comparison to the unaltered HER2/neu antibody
GB2500, as measured by percent killing of target cells at a range
of stradobody concentrations.
[0063] FIG. 12 shows representative plasmon resonance (Biacore)
data indicating binding to and dissociation from Fc.gamma.RIIIa for
each indicated stradobody or unaltered antibody GB2500.
[0064] FIG. 13 shows the Fc.gamma.RIIIa binding data for all of the
tested stradobodies or unaltered antibody GB2500.
[0065] FIG. 14 depicts the correlation between Biacore binding (RU)
and ADCC activity of the indicated stradobodies. ADCC activity is
presented as mean of fold difference relative to GB2500 for each
stradobody.
[0066] FIG. 15 shows the results of the purification of a
stradobody construct by ion exchange chromatography on a Mono Q
column. Lane SB is the unfractionated stradobody; peaks 1, 2, and 3
on the elution chromatogram (right panel) were analyzed by
non-denaturing gel (left panel).
[0067] FIG. 16 shows a non-reducing (top panel) and a reducing
(bottom panel) SDS-PAGE gel showing the formation of multimers of
the indicated serial stradobodies, in comparison to the unaltered
antibody GB2500.
[0068] FIG. 17A-FIG. 17D show the binding of the parent antibody
GB2500 or the indicated serial stradobody to Fc.gamma.RIIIa. GB2500
(grown in HEK or CHO cells; FIG. 17A) was tested at concentrations
ranging from 3333-208 nM. Serial stradobodies GB2524 (FIG. 17A,
GB2538 (FIG. 17B), GB2540 (FIG. 17B, GB2542 (FIG. 17C), GB2554
(FIG. 17C), and GB2555 (FIG. 17D) were tested at concentrations
ranging from 200-12.5 nM.
[0069] FIG. 18 is a schematic diagram of the experimental flow
chart for studies involving human PBMC-SCID (hu-PBMC SCID) mice
treated with tradobodies or their corresponding monoclonal
antibodies.
[0070] FIG. 19 shows the serum levels of human IgM over time in
hu-PMBC SCID mice treated with PBS, GB4500, GB4563, or GB4542.
[0071] FIG. 20 shows the number of human B cells in the peripheral
blood over time in hu-PBMC SCID mice treated with PBS, GB4500,
GB4563, or GB4542.
[0072] FIG. 21 shows the number of human B cells in the spleens of
hu-PBMC SCID mice treated with PBS, GB4500, GB4563, or GB4542.
[0073] FIG. 22 shows the percent inhibition of cell proliferation
mediated by GB4500 or GB4542 at the indicated concentrations of
antibody or stradobody, in .mu.g/mL. Statistical significance of
GB4500 versus GB4542 was calculated using T-test; * p<0.05,
**P<0.005.
[0074] FIG. 23 shows the percent inhibition of cell proliferation
mediated by GB4500 or GB4542 at the indicated pmol/mL of antibody
or stradobody.
[0075] FIG. 24 shows the percent complement-dependent cytoxicity
mediated by GB4500, GB4596, or GB4542 at the indicated
concentration of antibody or stradobody, in g/mL.
[0076] FIG. 25 shows the percent complement-dependent cytoxicity
mediated by GB4500 or GB4542 at the indicated pmol/mL of antibody
or stradobody.
[0077] FIG. 26 shows the mean tumor volume over time following
intratumoral injection of PBS, GB4500, or GB4542, with or without
CpG, in a mouse Raji-SCID lymphoma model.
[0078] FIG. 27 shows the median tumor volume over time following
intratumoral injection of PBS, GB4500, or GB4542, with or without
CpG, in a mouse Raji-SCID lymphoma model.
[0079] FIG. 28 shows complement C1q binding with antibody GB2500,
stradobody GB2542, antibody GB7500, stradobody GB7542, antibody
GB4500, and stradobody GB4542, as measured by absorbance (450 nm)
at the indicated stradobody or antibody concentration.
[0080] FIG. 29 shows the EC50 values for binding to complement C1q
for antibody GB2500, stradobody GB2542, antibody GB7500, stradobody
GB7542, antibody GB4500, and stradobody GB4542.
[0081] FIG. 30 shows complement C1q binding with antibody GB2500,
and stradobodies GB2542, GB2554, and GB2555. GB2542 is a
multimerizing stradobody, and GB2554 and GB2555 are linear
stradobodies that do not contain any multimerization domains.
[0082] FIG. 31 shows the EC50 values for binding to complement C1q
for antibody GB2500, multimerizing stradobody GB2542, and
non-multimerizing stradobodies GB2554 and GB2555.
[0083] FIG. 32 shows the compiled ADCC data on all 12 anti-HER2/neu
stradobodies and GB2500. Each row in the table of FIG. 32
represents a purified and tested stradobody batch. Data are
presented as percent killing by NK cells isolated from the
indicated donor, at the indicated ratio of effector to target
cell.
DETAILED DESCRIPTION OF THE INVENTION
[0084] The approach to rational molecular design for
antigen-binding compounds with FcR binding capacity described
herein includes recombinant and/or biochemical creation of
immunologically active biomimetic(s) which are surprisingly more
efficient at inducing cytotoxicity including antibody-mediated cell
cytoxicity, complement-dependent cell cytoxicity, direct cell
cytoxicity, and other mechanisms of cellular toxicity compared to
mAbs with specificity for the same antigen. The compounds have
utility for treating, for example, cancer, autoimmune and
inflammatory diseases, and infectious diseases. Each embodiment is
described in detail below along with specific exemplary
embodiments.
[0085] As used herein, the use of the word "a" or "an" when used in
conjunction with the term "comprising" in the claims and/or the
specification may mean "one," but it is also consistent with the
meaning of "one or more," "at least one," and "one or more than
one."
[0086] As used herein, the terms "biomimetic", "biomimetic
molecule", "biomimetic compound", and related terms, refer to a
human made compound that imitates the function of another compound,
such as pooled human Intravenous Immunoglobulin ("hIVIG"), a
monoclonal antibody or the Fc or Fab fragment of an antibody.
"Biologically active" biomimetics are compounds which possess
biological activities that are the same as or similar to their
naturally occurring counterparts. By "naturally occurring" is meant
a molecule or portion thereof that is normally found in an
organism. By naturally occurring is also meant substantially
naturally occurring. "Immunologically active" biomimetics are
biomimetics which exhibit immunological activity the same as or
similar to naturally occurring immunologically active molecules,
such as antibodies, cytokines, interleukins and other immunological
molecules known in the art. In preferred embodiments, the
biomimetics of the present invention are stradobodies, as defined
herein.
[0087] By "homologous" is meant identity over the entire sequence
of a given nucleic acid or amino acid sequence. For example, by
"80% homologous" is meant that a given sequence shares about 80%
identity with the claimed sequence and can include insertions,
deletions, substitutions, and frame shifts. One of ordinary skill
in the art will understand that sequence alignments can be done to
take into account insertions and deletions to determine identity
over the entire length of a sequence.
[0088] The immunologically active biomimetics of the present
invention are capable of binding to one or more antigens. In some
embodiments, the immunologically active biomimetics of the present
invention are capable of binding to two different antigens, similar
to bispecific antibodies. In other embodiments, the immunologically
active biomimetics of the present invention are capable of binding
to more than two different antigens. The biomimetics of the present
invention also possess one or more immune modulating activities of
the IgG Fc domain and have at least a first Fc domain capable of
binding FcRn, DC-SIGN, SIGN-RI and/or an Fc.gamma.R including
Fc.gamma.RI, Fc.gamma.RII, Fc.gamma.RIII and Fc.gamma.RIV. In some
embodiments, the biomimetics of the present invention possess a
second Fc domain capable of binding FcRn, DC-SIGN, SIGN-RI and/or
an Fc.gamma.R including Fc.gamma.RI, Fc.gamma.RII, Fc.gamma.RIII
and Fc.gamma.RIV. Thus, when multimerized, the immunologically
active biomimetics contain at least two dimeric structures, each
possessing the ability to bind to one or more antigens, and the
ability to bind to one or more of FcRn, DC-SIGN, SIGN-RI and/or and
FC.gamma.R.
[0089] The following paragraphs define the building blocks of the
biomimetics of the present invention, both structurally and
functionally, and then define the biomimetics themselves. However,
it is first helpful to note that, as indicated above, each of the
biomimetics of the present invention has at least two Fc domains,
and at least one Fab domain. At a minimum, an Fc domain is a
dimeric polypeptide (or a dimeric region of a larger polypeptide)
that comprises two peptide chains or arms (monomers) that associate
to form a functional Fc.gamma. receptor binding site. Therefore,
the functional form of the individual Fc fragments and Fc domains
discussed herein generally exist in a dimeric (or multimeric) form.
The monomers of the individual fragments and domains discussed
herein are the single chains or arms that must associate with a
second chain or arm to form a functional dimeric structure.
Fc Regions and Fab Regions
[0090] "Fc fragment" is a term of art that is used to describe the
protein region or protein folded structure that is routinely found
at the carboxy terminus of immunoglobulins. The Fc fragment
consists of the carboxy terminal portions of the antibody heavy
chains. Each of the chains in an Fc fragment is between about
220-265 amino acids in length and the chains are often linked via a
disulfide bond. The Fc fragment often contains one or more
independent structural folds or functional subdomains. In
particular, the Fc fragment encompasses an Fc domain, defined
herein as the minimum structure that binds an Fc.gamma. receptor.
An isolated Fc fragment is comprised of two Fc fragment monomers
(e.g., the two carboxy terminal portions of the antibody heavy
chains; further defined herein) that are dimerized. When two Fc
fragment monomers associate, the resulting Fc fragment has
Fc.gamma. receptor binding activity.
[0091] "Fab fragment" is a term of art that is used to describe the
protein region or protein folded structure that contains the
antigen binding domain of an antibody. Fab fragments are comprised
of both a heavy chain and a light chain, and are between about
200-250 amino acids in length. In some embodiments, the Fab
fragment is comprised of the variable region and the CH1 region of
the parent antibody. The Fab fragment can be isolated from the Fc
fragment of a monoclonal antibody through the use of enzymatic
digestion, for example papain digestion, which is an incomplete and
imperfect process (see Mihaesco C and Seligmann M. Papain Digestion
Fragments Of Human IgM Globulins. Journal of Experimental Medicine,
Vol 127, 431-453 (1968)). The Fab fragment and the Fc fragment
together constitutes the holo-antibody, meaning here the complete
antibody.
[0092] An "Fc partial fragment" is a domain comprising less than
the entire Fc fragment of an antibody, yet which retains sufficient
structure to have the same activity as the Fc fragment, including
Fc.gamma. receptor binding activity. An Fc partial fragment may
therefore lack part or all of a hinge region, part or all of a CH2
domain, part or all of a CH3 domain, and/or part or all of a CH4
domain, depending on the isotype of the antibody from which the Fc
partial domain is derived. An example of a Fc partial fragment
includes a molecule comprising the upper, core and lower hinge
regions plus the CH2 domain of IgG3 (Tan, L K, Shopes, R J, Oi, V T
and Morrison, S L, Influence of the hinge region on complement
activation, CIq binding, and segmental flexibility in chimeric
human immunoglobulins, Proc Natl Acad Sci USA. 1990 January; 87(1):
162-166). Thus, in this example the Fc partial fragment lacks the
CH3 domain present in the Fc fragment of IgG3. Another example of
an Fc partial fragment includes a molecule comprising the CH2 and
CH3 domains of IgG1. In this example, the Fc partial fragment lacks
the hinge domain present in IgG1. Fc partial fragments are
comprised of two Fc partial fragment monomers. As further defined
herein, when two such Fc partial fragment monomers associate, the
resulting Fc partial fragment has Fc.gamma. receptor binding
activity.
[0093] The term "Fab domain" describes the minimum region (in the
context of a larger polypeptide) or smallest protein folded
structure (in the context of an isolated protein) that can bind to
an antigen. The Fab domain is the minimum binding region of an Fab
fragment that allows binding of the molecule to an antigen. "Fab
domain" is used interchangeably herein with "Fab".
[0094] As used herein, "Fc domain" describes the minimum region (in
the context of a larger polypeptide) or smallest protein folded
structure (in the context of an isolated protein) that can bind to
or be bound by an Fc receptor (FcR). In both an Fc fragment and an
Fc partial fragment, the Fc domain is the minimum binding region
that allows binding of the molecule to an Fc receptor. While an Fc
domain can be limited to a discrete homodimeric polypeptide that is
bound by an Fc receptor, it will also be clear that an Fc domain
can be a part or all of an Fc fragment, as well as part or all of
an Fc partial fragment. When the term "Fc domains" is used in this
invention it will be recognized by a skilled artisan as meaning
more than one Fc domain. An Fc domain is comprised of two Fc domain
monomers. As further defined herein, when two such Fc domain
monomers associate, the resulting Fc domain has Fc receptor binding
activity. Thus an Fc domain is a dimeric structure that can bind an
Fc receptor.
[0095] As used herein, "Fc partial domain" describes a portion of
an Fc domain. Fc partial domains include the individual heavy chain
constant region domains (e.g., CH1, CH2, CH3 and CH4 domains) and
hinge regions of the different immunoglobulin classes and
subclasses. Thus, human Fc partial domains of the present invention
include the CH1 domains of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2,
IgD and IgE, the CH2 domains of IgG1, IgG2, IgG3, IgG4, IgM, IgA1,
IgA2, IgD and IgE, the CH3 domains of IgG1, IgG2, IgG3, IgG4, IgM,
IgA1, IgA2, IgD and IgE, the CH4 domains of IgM and IgE, and the
hinge regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and
IgE. The corresponding Fc partial domains in other species will
depend on the immunoglobulins present in that species and the
naming thereof. In one preferred embodiment, the Fc partial domains
of the current invention comprise CH1, CH2, and hinge domains of
IgG. In another preferred embodiment, the Fc partial domains of the
current invention comprise CH1, CH2 and hinge domains of IgG and
the hinge domain of IgG2. The Fc partial domain of the present
invention may further comprise a combination of more than one of
these domains and hinges. However, the individual Fc partial
domains of the present invention and combinations thereof lack the
ability to bind an Fc.gamma.R. Therefore, the Fc partial domains
and combinations thereof comprise less than an Fc domain. Fc
partial domains may be linked together to form a peptide that has
Fc.gamma. receptor binding activity, thus forming an Fc domain. In
the present invention, Fc partial domains are used with Fc domains
as the building blocks to create the biomimetics of the present
invention, as defined herein. Each Fc partial domain is comprised
of two Fc partial domain monomers. When two such Fc partial domain
monomers associate, an Fc partial domain is formed.
[0096] As indicated above, each of Fc fragments, Fc partial
fragments, Fc domains and Fc partial domains are dimeric proteins
or domains. Thus, each of these molecules is comprised of two
monomers that associate to form the dimeric protein or domain.
While the characteristics and activity of the homodimeric forms was
discussed above the monomeric peptides are discussed as
follows.
[0097] As used herein, an "Fc fragment monomer" is a single chain
protein that, when associated with another Fc fragment monomer,
comprises an Fc fragment. The Fc fragment monomer is thus the
carboxy terminal portion of one of the antibody heavy chains that
make up the Fc fragment of a holo-antibody (e.g., the contiguous
portion of the heavy chain that includes the hinge region, CH2
domain and CH3 domain of IgG). In one embodiment, the Fc fragment
monomer comprises, at a minimum, one chain of a hinge region (a
hinge monomer), one chain of a CH2 domain (a CH2 domain monomer)
and one chain of a CH3 domain (a CH3 domain monomer), contiguously
linked to form a peptide. In another embodiment, the Fc fragment
monomer comprises at least one chain of a hinge region, one chain
of a CH2 domain, one chain of a CH3 domain, and one chain of a CH4
domain (a CH4 domain monomer) contiguously linked to form a
peptide. In one embodiment, the CH2, CH3 and hinge domains are from
different isotypes. In a particular embodiment, the Fc fragment
monomer contains an IgG2 hinge domain and IgG CH2 and CH3
domains.
[0098] As used herein, "Fc domain monomer" describes the single
chain protein that, when associated with another Fc domain monomer,
comprises an Fc domain that can bind to an Fc.gamma. receptor. The
association of two Fc domain monomers creates one Fc domain. An Fc
domain monomer alone, comprising only one side of an Fc domain,
cannot bind an Fc.gamma. receptor.
[0099] As used herein, "Fc partial domain monomer" describes the
single chain protein that, when associated with another Fc partial
domain monomer, comprises an Fc partial domain. The association of
two Fc partial domain monomers creates one Fc partial domain.
Stradomers
[0100] The stradobodies of the present invention are comprised of
stradomers, and an Fab domain. In one embodiment, the stradobodies
of the present invention are comprised of multimerizing stradomers
and an Fab domain. Stradomers are biomimetic compounds capable of
binding two or more Fc receptors, preferably two or more Fc.gamma.
receptors, and more preferably demonstrating significantly improved
binding relative to an Fc domain and most preferably demonstrating
slow dissociation characteristic of avidity. In one embodiment, the
stradobodies of the present invention are used to bind FcRn,
DC-SIGN, SIGN-RI and/or Fc.gamma. receptors on effector cells such
as NK cells and monocyte-derived cells such as immature dendritic
cells and macrophages. In another embodiment, the stradobodies of
the present invention are used to bind Fc.gamma.RIIb receptors on B
cells. In one embodiment, the Fc.gamma. receptors are low affinity
Fc.gamma. receptors such as Fc.gamma.IIIa. The physical stradomer
conformations have been previously described in U.S. Patent
Application Publication No. 2010/0239633, and PCT Publication No.
WO 2012/016073, both of which are incorporated by reference herein
in their entireties.
[0101] A "serial stradomer" is a dimeric polypeptide comprised of
two linear stradomer monomers that, when associated, form two or
more Fc domains capable of binding two or more Fc.gamma. receptors.
Serial stradomers preferably have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, or more Fc domains, as well as Fc partial domains. The
Fc domains and/or Fc partial domains may be linked by domain
linkages, as further defined herein.
[0102] As will be evident, the Fc fragments, Fc partial fragments,
Fc domains and Fc partial domains discussed above are used in the
construction of the various stradomer conformations. It is the
individual Fc domain monomers and Fc partial domain monomers, also
discussed above, that self-associate to form the dimeric structures
that are the stradomers that comprise the stradobodies described
herein. Further, the stradomers are associated with an Fab domain
to form the stradobodies of the present invention.
[0103] As used herein, the term "stradomer monomer" or "stradomer
unit" refers to a single, contiguous peptide molecule that, when
associated with at least a second stradomer monomer, forms a
polypeptide comprising at least two Fc domains. Stradomer monomers
may be associated to form stradomers by inter-stradomer monomer
linkages or they may form stradomers through self-assembly via
covalent and non-covalent bonds.
[0104] A stradomer monomer may have an amino acid sequence that
will form one, two, three, four, five, six, seven, eight, nine,
ten, eleven, twelve, thirteen, fourteen or more Fc domains when
associated with another stradomer monomer to form a stradomer. A
stradomer monomer may further have an amino acid sequence that will
form one, two, three, four, five, six, seven, eight, nine, ten,
eleven, twelve, thirteen, fourteen or more Fc partial domains when
associated with another stradomer monomer to form a stradomer.
[0105] The regions of stradomer monomers that will form Fc domains
and Fc partial domains in the context of a stradomer may simply be
arranged from carboxy terminal to amino terminal of successive
regions of the stradomer monomer molecule. The arrangement of the
particular Fc domain monomers and Fc partial domain monomers
permits formation of two functional Fc domains upon association of
two stradomer monomers.
[0106] An Fc domain can be functionally defined by its ability to
bind FcRn, DC-SIGN, SIGN-RI and/or an Fc.gamma. receptor. The
compounds of the current invention bind to cognate canonical Fc
receptors including Fc.gamma.RIIIa, Fc.gamma.RIIb and/or SIGN-RI
with higher affinity and/or much higher avidity than human IgG1 Fc
control. Alternatively, the compounds of the current invention bind
preferentially to the neonatal receptor FcRn over the Fc canonical
receptors as a result of a point mutation at position 297 of the
IgG1 Fc. As a result, the particular amino acid sequence of an Fc
domain will vary based on the Fc partial domains that comprise the
Fc domain. However, in one embodiment of the present invention the
Fc domain comprises the hinge region and a CH2 domain of an
immunoglobulin molecule. In a further preferred embodiment the Fc
domain comprises the hinge region, a CH2 domain and CH3 domain of
an immunoglobulin molecule. In a further embodiment, the Fc domain
comprises the hinge region, a CH2 domain, CH3 domain and CH4 domain
of an immunoglobulin molecule. In yet another embodiment, the Fc
domain comprises the hinge region, a CH2 domain and CH4 domain of
an immunoglobulin molecule. In a further preferred embodiment, the
Fc domain comprises a CH2 domain and CH3 domain. In a preferred
embodiment, the Fc domain contains the hinge, CH2 and CH3 domain of
IgG1 (SEQ ID NO:2). In another preferred embodiment, the Fc domain
contains the CH2 and CH3 domains of IgG1 (SEQ ID NO: 19).
Domain Linkage
[0107] As indicated above, a "domain linkage" is a peptide linkage
between Fc domain monomers and/or Fc partial domain monomers that
comprise each of the individual stradomer monomers of the
stradobodies of the present invention. The domain linkage may be 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
or more amino acids. A domain linkage does not occur between Fc
partial domain monomers that are in their natural sequence. That
is, where linked naturally contiguous portions of Fc domain
monomers are used, such as the hinge region, CH2 domain and CH3
domain of IgG, these Fc partial domain monomers comprise a
contiguous sequence and no domain linkage between these elements is
required. In contrast, for example, when two or more Fc domain
monomers or partial Fc domain monomers are linked in a manner that
is not naturally occurring to form an individual stradomer monomer,
domain linkages may be used. An example would be the linkage
between two hinge/CH2/CH3 peptides, creating an individual
stradomer monomer of a stradomer comprising:
hinge/CH2/CH3/L/hinge/CH2/CH3, where "L" is the domain linkage. In
the various cases described, the domain linkage may be one of the
naturally occurring portions of the heavy chain that joins the
hinge and CH domains in the Fc domain monomer of an antibody.
Alternatively, the domain linkage may be any other amino acid
sequence that provides needed spacing and flexibility between the
Fc domain monomers and partial Fc domain monomers of an individual
stradomer monomer and that allows the individual stradomer monomers
to pair with each other to form the stradomers making up the
stradobodies of the present invention. An exemplary domain linkage
is a GS linker sequence. The GS linker sequence may comprise 1, 2,
3, 4, or more repeats of GGGGS. Preferably, a GS linker sequence
comprises 3 (G3S) or 4 (G4S) repeats of GGGGS.
[0108] In some embodiments, each immunologically active biomimetic
compound will preferably contain at least one domain linkage in
each stradomer monomer of the stradobody which will function to
maintain the Fc domains of the immunologically active biomimetic
within a restricted spatial region and which will facilitate
Fc.gamma.R activation activity, for example, by aggregating
Fc.gamma.Rs through co-binding to the Fc domains within the
immunologically active biomimetic. Preferably, the domain linkages
will allow the same or a greater degree of conformational
variability as is provided by the hinge domain of IgG molecules.
All of the above linkages are well-known in the art.
Inter-Stradomer Monomer Linkage
[0109] A separate linkage found in the biomimetic compounds of the
present invention is the "inter-stradomer monomer linkage" that
occurs between two or more individual stradomer monomers that
comprise the stradobodies of the present invention. While the
domain linkages are short amino acid sequences that serve to link
the Fc domain monomers and partial Fc domain monomers that comprise
individual stradomer monomers of the biomimetic compounds to each
other, the inter-stradomer monomer linkages serve to join two or
more individual stradomer monomers that comprise the biomimetic
compounds. The inter-stradomer monomer linkage may be any linkage
capable of stably associating the individual stradomer monomers. In
some embodiments, the inter-stradomer monomer linkage may be a
covalent link between the stradomer monomers. Alternatively, the
inter-stradomer monomer linkage between stradomer monomers may be
by direct chemical cross-linking. In preferred embodiments, the
stradomer monomer structures take advantage of the natural
self-assembly properties between Fc domain monomers to create
self-assembling stradomers comprising the stradobodies of the
present invention. The skilled artisan will understand that the
inter-stradomer monomer linkages permits two or more individual
stradobody monomers to form the biomimetic compounds of the
stradobody comprising the present multimerizing stradobody
invention and that the resulting compounds have the ability to
cross-link more than one Fc.gamma.R.
[0110] As discussed above, in a preferred embodiment, the
inter-stradomer monomer linkage that forms a stradomer is a linkage
that results from self-assembly of stradomer monomers. In one
embodiment, the two stradomer monomers that comprise the stradomer
are identical peptides, such that the two individual stradomer
monomers that comprise the stradomer are identical in sequence.
However, the skilled artisan will understand that other embodiments
include stradomers where the stradomer monomers differ from each
other in amino acid sequence.
[0111] Two stradomer monomers can form a stradomer by, for example,
aligning in parallel such that pairing takes place between
identical Fc partial domain monomers in the stradomer monomers.
However, the present invention also includes embodiments where
pairing occurs between non-identical Fc partial domain monomers,
and embodiments where pairing occurs between identical Fc partial
domain monomers in the stradomer monomers but where the alignment
of the two stradomer monomers is offset.
Multimerization Domains
[0112] The multimerization domain may comprise a peptide sequence
that causes dimeric proteins to further multimerize.
"Multimerization," as used herein, refers to the linking or binding
together of multiple (i.e., two or more) individual stradobody
homodimers. For example, stradobodies are multimerized when at
least one stradobody homodimer (i.e., at least one homodimeric
polypeptide comprising one or more Fc domains and one or more Fab
domains) is attached to at least one other stradobody homodimer via
a multimerization domain. Examples of peptide multimerization
domains include IgG2 hinge, isoleucine zipper, collagen
Glycine-Proline-Proline repeat ("GPP") and zinc fingers. The
influence of glycosylation on peptide multimerization is well
described in the art (e.g., Role of Carbohydrate in Multimeric
Structure of Factor VIII/V on Willebrand Factor Protein. Harvey R.
Gralnick, Sybil B. Williams and Margaret E. Rick. Proceedings of
the National Academy of Sciences of the United States of America,
Vol. 80, No. 9, [Part 1: Biological Sciences] (May 1, 1983), pp.
2771-2774; Multimerization and collagen binding of vitronectin is
modulated by its glycosylation. Kimie Asanuma, Fumio Arisaka and
Haruko Ogawa. International Congress Series Volume 1223, December
2001, Pages 97-101).
[0113] In one preferred embodiment, the multimerization domain is
an IgG2 hinge. As is known in the art, the hinge region of human
IgG2 can form covalent dimers (Yoo, E. M. et al. J. Immunol. 170,
3134-3138 (2003); Salfeld Nature Biotech. 25, 1369-1372 (2007)).
The dimer formation of IgG2 is potentially mediated through the
IgG2 hinge structure by C--C bonds (Yoo et al 2003), suggesting
that the hinge structure alone can mediate dimer formation. The
amount of IgG2 dimers found in human serum, however, is limited.
There is no quantitative evidence of the multimerization of IgG2
beyond the dimer of the homodimer. (Yoo et al. 2003). That is,
native IgG2 has not been found to form higher order multimers in
human serum.
[0114] The amino acid sequence of the human IgG2 hinge monomer is
as follows: ERKCCVECPPCP (SEQ ID NO: 3). Mutation of any one of the
4 cysteines in SEQ ID NO: 3 may be associated with greatly
diminished multimerization of the stradobody. There are two C-X-X-C
portions of the IgG2 hinge monomer. Thus, stradobodies of the
present invention may comprise either the complete 12 amino acid
sequence of the IgG2 hinge monomer, or either or both of the four
amino acid cores, along with Fc domain monomers. While the X-X of
the core structures can be any amino acid, in a preferred
embodiment the X-X sequence is V-E or P-P. The skilled artisan will
understand that the IgG2 hinge monomer may be comprised of any
portion of the hinge sequence in addition to the core four amino
acid structure, including all of the IgG2 hinge sequence and some
or all of the IgG2 CH2 and CH3 domain monomer sequences. Without
being bound by theory, the IgG2 hinge multimerization domain of one
stradobody homodimer may form multimers by interacting with any
portion of another stradobody homodimer. That is, the IgG2 hinge of
one stradobody homodimer may multimerize by binding the IgG2 hinge
of another stradobody homodimer, thereby forming a dimer of the
homodimer, or higher order multimers while retaining increased
functional binding to Fc receptors relative to natural IgG1 Fc.
Alternatively, the IgG2 hinge domain of one stradobody homodimer
may bind the IgG1 hinge of another stradobody homodimer, thereby
forming a dimer of the homodimer, or higher order multimers while
retaining increased functional binding to Fc receptors relative to
natural IgG1 Fc. It is also possible that the IgG2 hinge domain of
one stradobody homodimer binds to another portion of the IgG1 Fc
domain, i.e. the CH2 or CH3 domain of another stradobody homodimer
to form the dimer of the homodimer, or higher order multimers while
retaining increased functional binding to Fc receptors relative to
natural IgG1 Fc.
[0115] In another preferred embodiment, leucine zippers may be used
as multimerization domains. In another preferred embodiment,
isoleucine zippers may be used as multimerization domains. Leucine
and isoleucine zippers (coiled-coil domains) are known to
facilitate formation of protein dimers, trimers and tetramers
(Harbury et al. Science 262:1401-1407 (1993); O'Shea et al. Science
243:538 (1989)).
[0116] While the skilled artisan will understand that different
types of leucine and isoleucine zippers may be used, in one
embodiment the isoleucine zipper from the GCN4 transcriptional
regulator modified as described (Morris et al., MoI. Immunol.
44:3112-3121 (2007); Harbury et al. Science 262:1401-1407 (1993))
is used: GGGSIKOIEDKIEEILSKIYHIENEIARIKKLIGERGHGGG (SEQ ID NO: 5).
In another embodiment, the sequence of the isoleucine zipper used
is: GGGSIKOIEDKIEEILSKIYHIENEIARIKKLIGERGHDI (SEQ ID NOs: 32).
These isoleucine zipper sequences are only two of several possible
sequences that can be used for multimerization of Fc domain
monomers. While the entire sequence shown in SEQ ID NOs: 5 or 32
may be used, the underlined portion of the sequence represents the
core sequence of the isoleucine zipper that may be used in the
stradobodies of the present invention. Thus, stradomer monomers
comprising the stradobodies of the present invention may comprise
either the complete amino acid sequence of the isoleucine zipper,
or the 28 amino acid core, along with one or more Fc domain
monomers. The skilled artisan will also understand that the
isoleucine zipper may be comprised of any portion of the zipper in
addition to the core 28 amino acid structure, and thus may be
comprised of more than 28 amino acids but less than the entire
sequence of SEQ ID NOs: 5 or 32.
[0117] In another preferred embodiment, GPP repeats may be used as
multimerization domains. GPP is an amino acid sequence found in
human collagen that causes collagen protein: protein binding. While
the skilled artisan will understand that different types of GPP
repeats may be used as a Multimerization Domain, in a preferred
embodiment the Glycine-Proline-Proline repeats as described (Fan et
al FASEB Journal 3796 vol 22 2008) is used: (SEQ ID NO:26) This
Glycine-Proline-Proline repeat sequence is only one of several
possible sequences that can be used for multimerization of
stradobodies. While the entire sequence shown in SEQ ID NO:26 may
be used, repeats of different length may also possible be used to
multimerize Fc domain monomers. Likewise, repeats containing
different amino acids within the GPP repeats may also be
substituted.
Stradobody
[0118] The present invention is directed to stradobodies and
methods of making and using stradobodies. As used herein,
"stradobody" refers to a molecule comprising two or more Fc
domains, to which one or more Fab domains is attached. Thus, by
virtue of such Fab domains and Fc domains, stradobodies have both
antigen binding capacity and Fc.gamma. receptor binding activity.
In some embodiments, the Fc.gamma. receptor activity may be due to
an ability to bind and cross-link Fc.gamma.R equal to or greater
than the Fc portion of a native structure holo-antibody. The Fab
portion of the stradobody may comprise both a heavy and a light
chain. The variable heavy chain and the light chain may be
independently from any compatible immunoglobulin such as IgA1,
IgA2, IgM, IgD, IgE, IgG, IgG2, IgG3, or IgG4, and may be from the
same or different Ig isotype, but preferably are from the same Ig
isotype. The light chains kappa or lambda may also be from
different Ig isotypes. In some embodiments, stradobodies, like
stradomers, can bind two or more Fc.gamma.Rs and modulate immune
function. In one embodiment, the stradobodies of the current
invention comprise a Fab domain, one or more Fc domains, and one or
more multimerization domains, wherein at least one of the one or
more multimerization domains separates two or more Fc domains, or
is located at the carboxy end of the Fc region. The term "Fc
region" is used herein to refer to the region of the stradobody
that comprises Fc domains, domain linkages, and multimerization
domains. Thus, the Fc region is the region of the stradobody that
does not comprise the Fab domain. Multimerization domains are
described above and are amino acid sequences known to cause protein
multimerization in the proteins where they naturally occur. In one
embodiment, the multimerization domains may be IgG hinges,
isoleucine zippers, or a combination thereof. In a particular
embodiment, the stradobody is comprised of an Fab, a first Fc
domain, an isoleucine zipper, an IgG2 hinge, and a second Fc
domain. The Fab comprises both a heavy chain and a light chain as
found in native immunoglobulin structures.
[0119] The stradobodies of the current invention may be classified
as either serial stradobodies or C-terminal stradobodies. The
general structures of these stradobodies are shown in FIG. 1. The
serial and C-terminal stradobodies of the current invention
preferably comprise an Fab domain; one or more Fc domains; and one
or more multimerization domains. For example, the serial and
C-terminal stradobodies of the invention preferably comprise an Fab
domain; 1, 2, 3, 4, or 5 Fc domains; and 1, 2, 3, 4, or 5
multimerization domains. In some embodiments, the serial and
C-terminal stradobodies of the current invention further comprise
one or more spacers or flexible linkers. Serial stradobodies
preferably comprise 2 or more Fc domains. For example, serial
stradobodies preferably comprise 2, 3, 4, 5, or 6 Fc domains.
[0120] Serial stradobodies were designed to simultaneously bind and
cross-link multiple low-affinity Fc.gamma.Rs by incorporating two
or more Fc domains in a chimeric heavy chain. The Fc domains are
separated by one or more different or the same multimerization
domains, spacers, and/or flexible linkers. Serial stradobodies may
be either multimerizing serial stradobodies or non-multimerizing
serial stradobodies. Multimerizing serial stradobodies comprise at
least one multimerization domain are associated with the formation
of multimers. Multimerization domains are described above and
include IgG2 hinges, isoleucine zippers, collagen GPP, and zinc
fingers. Non-multimerizing serial stradobodies may not comprise a
multimerization domain, but may comprise one or more domain
linkage, such as a G4S linker. In some embodiments, a multimerizing
serial stradobody comprises both one or more multimerization
domains and one or more domain linkages. General structures of
serial stradobodies are shown in FIG. 2. More specific structures
of exemplary serial stradobody constructs comprising one or more of
the indicated multimerization domains and/or linker domains (ILZ
refers to isoleucine zipper; 2H refers to IgG2 hinge; and G4S
refers to an amino acid sequence Gly.sub.4Ser) are shown in FIG. 3.
Serial stradobody constructs that comprise an Fab region specific
for EGFR are shown below in Table 1. Serial stradobody constructs
that comprise an Fab region specific for HER2/neu or an Fab region
specific for CD20 are shown in FIG. 4 and below in Table 1.
[0121] C-terminal multimerized stradobodies were designed to
simultaneously bind and cross-link multiple low-affinity
Fc.gamma.Rs by incorporating one or more multimerization domains at
the C-terminal end of the Fc region and thereby promote formation
of stradobody complexes able to interact with multiple Fc receptors
simultaneously. Exemplary structures of C-terminal stradobodies are
shown in FIG. 5. C-terminal multimerized stradobodies that comprise
an anti-EGFR Fab are shown in FIG. 6 and below in Table 1.
C-terminal multimerized stradobody constructs that comprise an
anti-CD20 Fab are also shown in FIG. 6 and below in Table 1. In the
C-terminal stradobodies, the Fc region of the heavy chain has one
or more different or the same multimerization domains, spacers, or
flexible linkers on the C-terminal side. The C-terminal
stradobodies shown also include a construct that contains a
multimerization domain and a purification tag.
TABLE-US-00001 TABLE 1 Unaltered monoclonal antibody and stradobody
constructs Construct Specificity Monoclonal antibodies GB2500
(Trastuzumab) HER2/neu GB3500 (Cetuximab) EGFR GB4500 (Rituximab)
CD20 GB7500 (Adalimumab) TNF Multimerizing serial stradobodies
GB2524 HER2/neu GB2538 HER2/neu GB2540 HER2/neu GB2542 HER2/neu
GB3524 EGFR GB3538 EGFR GB3540 EGFR GB3542 EGFR GB4524 CD20 GB4538
CD20 GB4540 CD20 GB4542 CD20 GB7524 TNF GB7538 TNF GB7540 TNF
GB7542 TNF Non-multimerizing serial stradobodies GB2554 HER2/neu
GB2555 HER2/neu GB3554 EGFR GB3555 EGFR GB4554 CD20 GB4555 CD20
GB7554 TNF GB7555 TNF C-terminal multimerized stradobodies GB2534
HER2/neu GB2545 HER2/neu GB2546 HER2/neu GB2547 HER2/neu GB2549
HER2/neu GB2550 HER2/neu GB2560 HER2/neu GB2561 HER2/neu GB2562
HER2/neu GB2563 HER2/neu GB2589 HER2/neu GB2590 HER2/neu GB3534
EGFR GB3545 EGFR GB3546 EGFR GB3547 EGFR GB3549 EGFR GB3550 EGFR
GB3560 EGFR GB3561 EGFR GB3562 EGFR GB3563 EGFR GB3589 EGFR GB3590
EGFR GB4534 CD20 GB4545 CD20 GB4546 CD20 GB4547 CD20 GB4549 CD20
GB4550 CD20 GB4560 CD20 GB4561 CD20 GB4562 CD20 GB4563 CD20 GB4589
CD20 GB4590 CD20 GB7534 TNF GB7545 TNF GB7546 TNF GB7547 TNF GB7549
TNF GB7550 TNF GB7560 TNF GB7561 TNF GB7562 TNF GB7563 TNF GB7589
TNF GB7590 TNF
[0122] The skilled artisan will recognize that the specific
stradobodies described above are exemplary, and that serial
stradobodies with various structures and combinations of stradomers
and stradomer building blocks are possible, for example, serial
multimerized C-terminal stradobodies comprising one or more
multimerization domain and two or more Fc domains. Serial
multimerized C-terminal stradobodies may comprise one or more
multimerization domains between two Fc domains and one or more
multimerization domains at the C-terminal end of the Fc region.
[0123] Stradobodies will possess the antigen binding properties of
the Fab portion and the above described stradomer properties. Such
a combination will serve to bind, cross-link, and activate
Fc.gamma. receptors on effector cells at a higher rate than can be
accomplished by an Fc backbone of a holo-antibody, particularly in
the environment of low epitope expression (e.g. the 90% of breast
cancer patients whose tumors are not classified as HER2/neu high
expressors), inducing ADCC, CDC, and/or DC in a higher percentage
of patients. As indicated above, one or more antigen-binding Fab
domains can be added to the stradomers to form stradobodies.
[0124] We surprisingly found that stradobodies with one or more
multimerization domains between two Fc domains (e.g. GB2542,
GB3542, GB4542, and GB7542 corresponding to SEQ ID Nos 35, 33, 37
and 66, respectively), or located at the carboxy end of the Fc
region (e.g. GB2547, GB3547, GB4547, and GB7547, corresponding to
SEQ ID Nos 91, 70, 76 and 87, respectively), exhibited not only
superior multimerization, but also superior binding and superior
cytoxicity in comparison both to the parent mAb and to stradobodies
without multimerization domains or with one or more multimerization
domain located at the N-terminal end of the Fc region, including in
ADCC, CDC, DC, and other mechanisms of cytoxicity. In particular, a
stradobody comprising both an isoleucine zipper and an IgG2 hinge
yielded particularly strong ADCC, CDC, and DC and particularly
strong clq binding. Unexpectedly, when these two multimerization
domains were located between two Fc domains, multimerization,
binding to Fc.gamma.R, and ADCC, CDC, and DC results as well as clq
binding were particularly robust.
[0125] We surprisingly found that the presence of an Fab can
dramatically alter the ability of the resulting stradobody to
multimerize relative to the isolated stradomer that comprises the
stradobody. More specifically, stradomers with N-terminal
multimerization domains can multimerize well and function well but
a stradobody comprised of the same stradomer, as disclosed in WO
2008/151088, may multimerize poorly or not at all. Conversely, it
is possible for serial stradobodies with one or more
multimerization domains or stradobodies with one or more C-terminal
multimerization domains to multimerize better than the stradomer
that comprises such stradobody.
[0126] In some embodiments, the stradobody of the invention further
comprises a danger signal or damage signal. In some embodiments,
the stradobody of the invention is administered to patients
concurrently with, or in the same treatment cycle as, a danger
signal or damage signal. Pradeu and Cooper (Front Immunol. 3:
Article 287, 1-9 (2012) have recently reviewed such danger signals
or damage signals. In one embodiment, danger signals or damage
signals that may be comprised within or administered with the
stradobody of the invention include endogenous signals including
CD40-L, TNF-.alpha., IL-1.beta., IFN.alpha., Intracellular
nucleotides ATP or UTP, Long unmethylated CpG sequences, Heat Shock
Proteins, reactive oxygen intermediates, Vasoactive Intestinal
Peptide, metalloproteinase-9, degradation products of heparan
sulfate, small breakdown products of hyaluronan, LDL-derived
phospholipids, or LOX-1. In another embodiment, danger signals or
damage signals that may be comprised within or administered with
the stradobody of the invention include uric acid,
high-mobility-group box 1, an inflammasome (a multiprotein complex
that contains a pattern recognition receptor), IL-1 .alpha.; S100
proteins; hepatoma-derived growth factor, IL-1 .alpha.; high
concentrations of adenosine 5'-triphosphatase,
.beta.-D-glucopyranosylceramide, IL-33, nanoparticles such as gold
nanoparticles, or F-actin. In an especially preferred embodiment,
the stradobody of the invention comprises a peptide danger signal
or damage signal at the carboxy end of the stradobody, including
Vasoactive Intestinal Peptide, metalloproteinase-9, Heat Shock
Protein, High Mobility group 1, S-100, IL-1a, hepatoma derived
growth factor, peptides that share amino acid sequence similarity
of at least 70% with these peptides, and peptides that are
fragments of these peptides.
[0127] In some embodiments, the stradobody of the invention
comprises an Fab that is specific for EGFR. In some embodiments,
the EGFR-specific Fab is derived from the monoclonal antibody
cetuximab. In some embodiments, the Fab is at least 80%, at least
85%, at least 90%, at least 95%, at least 96%, at least 97%, at
least 98%, at least 99%, or 100% homologous to SEQ ID NO: 31.
[0128] In some embodiments, the stradobody of the invention
comprises an Fab that is specific for HER2/neu. In other
embodiments, the stradobody comprises an Fab that is derived from
the anti-HER2/neu monoclonal antibody trastuzumab. In some
embodiments, the Fab is at least 80%, at least 85%, at least 90%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100% homologous to SEQ ID NO 34.
[0129] In some embodiments, the stradobody of the invention
comprises an Fab that is specific for CD20. In other embodiments,
the stradobody comprises an Fab that is derived from the anti-CD20
monoclonal antibody rituximab. In some embodiments, the Fab is at
least 80%, at least 85%, at least 90%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99%, or 100% homologous to SEQ
ID NO 36.
[0130] In some embodiments, the stradobody of the invention
comprises an Fab that is specific for TNF. In other embodiments,
the stradobody comprises an Fab that is derived from the anti-TNF
monoclonal antibody adalimumab. In some embodiments, the Fab is at
least 80%, at least 85%, at least 90%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99%, or 100% homologous to SEQ
ID NO 67.
[0131] In some embodiments, the stradobody of the invention
comprises more than one Fab. In further embodiments, each of the
more than one Fab is specific for a different antigen. For example,
a stradobody may comprise Fabs specific for EGFR and HER2/neu; CD3
and CD19; CD3 and CD20; CD3 and carcinoembryonic antigen; CD3 and
EGFR; and combinations thereof.
[0132] In certain embodiments, stradobodies comprise, from amino to
carboxy terminus, an Fab domain, a first IgG1 CH2, a first IgG1
CH3, an isoleucine zipper, an IgG2 hinge, a second IgG1 CH2, and a
second IgG1 CH3 (FIG. 7).
[0133] In a particular embodiment, the stradobody of the invention
comprises a leader amino acid sequence according to SEQ ID NO: 1,
an EGFR-specific variable region and CH2 region amino acid sequence
according to SEQ ID NO: 31, an IgG1 Fc domain according to SEQ ID
NO: 2, an isoleucine zipper according to SEQ ID NO: 32, and an IgG2
hinge according to SEQ ID NO: 3.
[0134] In another embodiment, the amino acid sequence of the whole
stradobody is according to SEQ ID NO: 33 (construct GB3542 in Table
2). In one embodiment, the stradobody is at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99%, or 100%
homologous to SEQ ID NO: 33.
[0135] In another embodiment, the amino acid sequence of the whole
stradobody is according to SEQ ID NO: 35 (construct GB2542 in Table
2). In one embodiment, the stradobody is at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99%, or 100%
homologous to SEQ ID NO: 35.
[0136] In another embodiment, the amino acid sequence of the whole
stradobody is according to SEQ ID NO: 37 (construct GB4542 in Table
2). In one embodiment, the stradobody is at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99%, or 100%
homologous to SEQ ID NO: 37.
[0137] In another embodiment, the amino acid sequence of the whole
stradobody is according to SEQ ID NO: 66 (construct GB7542 in Table
2). In one embodiment, the stradobody is at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99%, or 100%
homologous to SEQ ID NO: 66.
TABLE-US-00002 TABLE 2 Amino acid sequences of stradobody
constructs GB2542, GB3542, GB4542, and GB7542, and components of
constructs GB2542, GB3542 GB4542, and GB7542. Sequence Leader
sequence METDTLLLWVLLLWVPGSTG (SEQ ID NO: 1) GB2542 Variable and
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQA CH1 regions (identical
PGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY to variable and CH1
LQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVT regions of
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT trastuzumab/GB2500)
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ (SEQ ID NO: 34)
TYICNVNHKPSNTKVDKKV GB3542 Variable and
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQS CH1 regions (identical
PGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFF to variable and CH1
KMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA regions of
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS cetuximab/GB3500)
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT (SEQ ID NO: 31)
YICNVNHKPSNTKVDKRV GB4542 Variable and
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVK CH1 regions (identical
QTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSST to variable and CH1
AYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTT regions of
VTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP rituximab/GB4500)
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVVPSSSLG (SEQ ID NO: 36)
TQTYICNVNHKPSNTKVDKKV GB 7542 Variable and
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQ CH1 regions (identical
APGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSL to variable and CH1
YLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVT regions of
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT adalimumab/GB7500)
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ (SEQ ID NO: 67)
TYICNVNHKPSNTKVDKKV IgG1 Fc
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP (SEQ ID NO: 2)
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Isoleucine Zipper
GGGSIKQIEDKIEEILSKIYHIENEIARIKKLIGERGHDI (SEQ ID NO: 32 ) IgG2
Hinge ERKCCVECPPCP (SEQ ID NO: 3) GB2542 Construct
METDTLLLWVLLLWVPGSTGEVQLVESGGGLVQPGGSLR (SEQ ID NO: 35)
LSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTR
YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSR
WGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK
VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSLEGG
GSIKQIEDKIEEILSKIYHIENEIARIKKLIGERGHDIERKCCV
ECPPCPRLEGPRFEEPKSCDKTHTCPPCPAPELLGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK GB3542 Construct
METDTLLLWVLLLWVPGSTGQVQLKQSGPGLVQPSQSLSI (SEQ ID NO: 33)
TCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDY
NTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALT
YYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGKSLEGGGSIKQI
EDKIEEILSKIYHIENEIARIKKLIGERGHDIERKCCVECPPCP
RLEGPRFEEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K GB4542 Construct
METDTLLLWVLLLWVPGSTGQVQLQQPGAELVKPGASVK (SEQ ID NO: 37)
MSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDT
SYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCA
RSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
KVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSLEG
GGSIKQIEDKIEEILSKIYHIENEIARIKKLIGERGHDIERKCC
VECPPCPRLEGPRFEEPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK GB7542 Construct
METDTLLLWVLLLWVPGSTGEVQLVESGGGLVQPGRSLR (SEQ ID NO: 66)
LSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHI
DYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA
KVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK
VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSLEGG
GSIKQIEDKIEEILSKIYHIENEIARIKKLIGERGHDIERKCCV
ECPPCPRLEGPRFEEPKSCDKTHTCPPCPAPELLGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK
[0138] It is understood that the stradobodies disclosed herein can
be derived from any of a variety of species. Indeed, Fc domains, or
Fc partial domains, in any one biomimetic molecule of the present
invention can be derived from immunoglobulin from more than one
(e.g., from two, three, four, five, or more) species. However, they
will more commonly be derived from a single species. In addition,
it will be appreciated that any of the methods disclosed herein
(e.g., methods of treatment) can be applied to any species.
Generally, the components of a biomimetic applied to a species of
interest will all be derived from that species. However,
biomimetics in which all the components are of a different species
or are from more than one species (including or not including the
species to which the relevant method is applied) can also be
used.
[0139] The specific CH1, CH2, CH3 and CH4 domains and hinge regions
that comprise the Fc domains and Fc partial domains of the
stradobodies of the present invention may be independently
selected, both in terms of the immunoglobulin subclass, as well as
in the organism, from which they are derived. Accordingly, the
stradobodies disclosed herein may comprise Fc domains and partial
Fc domains that independently come from various immunoglobulin
types such as human IgG1, IgG2, IgG3, IgG4, IgA1, IgA1, IgD, IgE,
and IgM, mouse IgG2a, or dog IgGa or IgGb. Preferably, for human
therapeutics the Fc domains of the current invention are of the
human IgG1 isotype. Similarly each Fc domain and partial Fc domain
may be derived from various species, preferably a mammalian
species, including non-human primates (e.g., monkeys, baboons, and
chimpanzees), humans, murine, rattus, bovine, equine, feline,
canine, porcine, rabbits, goats, deer, sheep, ferrets, gerbils,
guinea pigs, hamsters, bats, birds (e.g., chickens, turkeys, and
ducks), fish and reptiles to produce species-specific or chimeric
stradobody molecules.
[0140] The Fab may be a chimeric structure comprised of human
constant regions and non-human variable regions such as the
variable region from a mouse, rat, rabbit, monkey, or goat
antibody. One of ordinary skill in the art would be able to make a
variety of Fab chimeric structures for incorporation into
stradobodies using methodologies currently available and described
in the scientific literature for such constructions. Individual Fab
domains, Fc domains and partial Fc domains may also be humanized.
Thus, "humanized" stradobodies may be designed analogous to
"humanized" monoclonal antibodies.
[0141] One of skill in the art will realize that different Fc
domains and partial Fc domains will provide different types of
functionalities. For example, Fc.gamma.Rs bind specifically to IgG
immunoglobulins and not well other classes of immunoglobulins.
Thus, one of skill in the art, intending to design a stradobody
with multiple Fc.gamma. receptor binding capacity, would design
stradomer Fc domains that at least incorporate the well
characterized Fc.gamma. receptor binding sequences of IgG,
including those in the lower IgG hinge region and/or the IgG CH2
& CH3 domains. One of ordinary skill in the art will also
understand various deleterious consequences can be associated with
the use of particular Ig domains, such as the anaphylaxis
associated with IgA infusions. The biomimetics disclosed herein
should generally be designed to avoid such effects, although in
particular circumstances such effects may be desirable.
[0142] The present invention also encompasses stradobodies
comprising Fc domains and Fc partial domains having amino acids
that differ from the naturally-occurring amino acid sequences of
the Fc domain or Fc partial domain. Preferred Fc domains for
inclusion in the biomimetic compounds of the present invention have
a measurable specific binding affinity to either a holo-Fc.gamma.
receptor or a soluble extracellular domain portion of an
Fc.gamma.R. Primary amino acid sequences and X-ray crystallography
structures of numerous Fc domains and Fc domain monomers are
available in the art. See, e.g., Woof J M, Burton D R. Human
antibody-Fc receptor interactions illuminated by crystal
structures. Nat Rev Immunol. 2004 February; 4(2):89-99.
Representative Fc domains with Fc.gamma. receptor binding capacity
include the Fc domains from human IgG (SEQ ID NO: 2). These native
sequences have been subjected to extensive structure-function
analysis including site directed mutagenesis mapping of functional
sequences. Based on these prior structure-function studies and the
available crystallography data, one of skill in the art may design
functional Fc domain sequence variants while preserving the Fc
domain's Fc.gamma.R receptor binding capacity. For example,
cysteine residues may be added to enhance sulfide bonding between
monomers or deleted to alter the interaction between stradomer
homodimers that comprise the stradobody homodimer.
[0143] In addition, the present invention encompasses stradobodies
comprising Fab domains having amino acids that differ from the
amino acid sequence of the antibody from which the Fab domain is
derived. Fab domains for inclusion in the biomimetic compounds of
the present invention have a measurable specific binding affinity
to a particular antigen. Preferably, the biomimetic compounds have
a binding affinity that is greater than the binding affinity of
corresponding unaltered antibodies.
[0144] The amino acid changes may decrease, increase, or leave
unaltered the binding affinity of the stradobody to the Fc.gamma.
receptor or the antigen. Preferably such amino acid changes will be
conservative amino acid substitutions, however, such changes
include deletions, additions and other substitutions. Conservative
amino acid substitutions typically include changes within the
following groups: glycine and alanine; valine, isoleucine, and
leucine; aspartic acid and glutamic acid; asparagine, glutamine,
serine and threonine; lysine, histidine and arginine; and
phenylalanine and tyrosine. Additionally, the amino acid change may
enhance multimerization strength, for example by the addition of
cysteine residues.
[0145] The amino acid changes may be naturally occurring or may be
introduced, for example by site directed mutagenesis. The amino
acid changes can occur anywhere within the Fc domain or Fab domain
so long as the Fc domain retains its receptor binding function and
biological activity, and the Fab domain retains its antigen binding
function and biological activity. In a preferred embodiment, the
polymorphism or mutation leads to enhanced receptor/antigen binding
and/or enhanced multimerization or biological function. For Fc
domains, the polymorphism/mutation preferably occurs at one or more
of amino acid positions 233-435 according to the EU index as in
Kabat et al., Sequences of Proteins of Immunological Interest,
5.sup.th Ed. Public Health Service, National Institutes of Health,
Bethesda, Md. (1991). Specific polymorphisms/mutations in these
amino acid positions are well known in the art and can be found,
for example in Shields, et al. (2001) "High Resolution Mapping of
the Binding Site on Human IgG1 for Fc.gamma.RI, Fc.gamma.RII,
Fc.gamma.RIII and FcRn and Design of IgG Variants with Improved
Binding to the Fc.gamma.R," J. Biol. Chem., 276(9):6591-6601, which
is herein incorporated by reference in its entirety.
[0146] From the above, it will be appreciated that stradobodies of
the present invention include stradobodies having: (a) only
naturally occurring Fab and Fc domains; (b) a mixture of naturally
occurring Fab and Fc domains and Fab and Fc domains with altered
amino acid sequences; and (c) only Fab and Fc domains with altered
amino acid sequences. All that is required is that stradobodies
containing altered amino acid sequences have at least 25%; 30%;
40%; 50%; 60%; 70%; 80%; 90%; 95%; 96%; 97%; 98%; 99%; 99.5%; or
100% or even more of the ability of a corresponding stradobody
comprising Fab and Fc domains with naturally-occurring sequences to
bind to antigen and to Fc.gamma.R receptors.
[0147] The aforementioned Fc.gamma. receptor and antigen binding
sites occurring in the stradobodies of the present invention may be
altered in sequence through genetic engineering to predictably
derive binding sites with altered binding capabilities and
affinities relative to a native sequence. For example, specific
residues may be altered that reduce Fc domain binding of the
biomimetic compounds to Fc.gamma.RIIb while increasing binding to
Fc.gamma.RIIIa or vice versa or that reduce Fc domain binding of
the biomimetic compounds to Fc.gamma.RIIb while increasing binding
to FcRn or vice versa. An example of an extensive mutagenesis based
structure-function analysis for human IgG Fc.gamma. receptor
binding sequences is Robert L. Shields, et al. High Resolution
Mapping of the Binding Site on Human IgG1 for Fc.gamma.RI,
Fc.gamma.RII, Fc.gamma.RIII, and FcRn and Design of IgG1 Variants
with Improved Binding to the Fc.gamma.R. J. Biol. Chem., February
2001; 276: 6591-6604. Similar studies have been performed on murine
IgG Fc (mIgG Fc). Based on the structural and primary sequence
homologies of native IgG Fc domains across species, one of skill in
the art may translate the extensive structure-function knowledge of
human IgG Fc and mouse IgG Fc to rational mutagenesis of all native
Fc.gamma. receptor binding site sequences in the biomimetic
compounds of the present invention to design binding sites with
particular Fc.gamma. receptor specificities and binding
affinities.
[0148] In addition to the amino acid sequence composition, the
carbohydrate content of the Fc domain is known to play an important
role on Fc domain structure and binding interactions with
Fc.gamma.R. See, e.g., Robert L. Shields, et al. Lack of Fucose on
Human IgG1 N-Linked Oligosaccharide Improves Binding to Human
Fc.gamma.RIII and Antibody-dependent Cellular Toxicity. J. Biol.
Chem., July 2002; 277: 26733-26740 (doi:10.1074/jbc.M202069200);
Ann Wright and Sherie L. Morrison. Effect of C2-Associated
Carbohydrate Structure on Ig Effector Function: Studies with
Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of
Chinese Hamster Ovary Cells. J. Immunol, April 1998; 160:
3393-3402. Similarly, the extent of fucosylation of antibodies is
known to play a role in antigen binding and ADCC. See, e.g.,
Yamane-Ohnuki and Satoh, Production of therapeutic antibodies with
controlled fucosylation. Mabs. 2009 May-June; 1(3):230-236.
Carbohydrate content may be controlled using, for example,
particular protein expression systems including particular cell
lines or in vitro enzymatic modification. In some embodiments, the
stradobodies are defucosylated. Defucosylation is known to improve
the affinity of IgG1 Fc for Fc.gamma.RIIIa. Thus, the present
invention includes stradobodies with the native carbohydrate
content of holo-antibody from which the domains were obtained, as
well as those stradobody compounds with an altered carbohydrate
content. In another embodiment, a modified cell line is used to
generate a preferred glycosylation pattern. In another embodiment,
chemoenzymatic glycosylation is used to generate a preferred
glycosylation pattern including with non-natural sugars. In another
embodiment, multimer components of the stradobody are characterized
by a different glycosylation pattern compared with the homodimer
component of the same stradobody. In a preferred embodiment, the
stradobody is enriched for multimers comprising a glycosylation
pattern that enhances Fc receptor binding.
[0149] The addition to the polypeptide chain of an Fc partial
domain, a multimerization region, or glycosylation changes may
create a conformational change in the Fc domain permitting enhanced
binding of the Fc domain to an Fc.gamma. receptor. Thus, seemingly
very minor changes to the polypeptide may also create a stradobody
capable of enhanced binding of multiple Fc.gamma. receptors or FcRn
receptors or a stradobody with decreased ability to bind multiple
Fc.gamma. receptors or FcRn receptors.
[0150] The skilled artisan will further recognize that the Fc
domains, and Fc partial domains used in the embodiments of the
present invention need not be full-length versions. That is, the
present invention encompasses the use of Fc domain monomers and Fc
partial domain monomers lacking amino acids from the amino
terminus, carboxy terminus or middle of the particular Fc domain
monomers and Fc partial domain monomers that comprise the
stradobodies of the present invention.
[0151] For example, the binding site on human IgG immunoglobulins
for Fc.gamma. receptors has been described (e.g. Radaev, S., Sun,
P., 2001. Recognition of Immunoglobulins by Fc.gamma. Receptors.
Molecular Immunology 38, 1073-1083; Shields, R. L. et. al., 2001.
High Resolution Mapping of the Binding Site on Human IgG1 for
Fc.gamma.RI, Fc.gamma.RII, Fc.gamma.RIII, and FcRn and Design of
IgG1 Variants with Improved Binding to the Fc.gamma.R. J. Biol.
Chem. 276 (9), 6591-6604). Based on that knowledge, one may remove
amino acids from the Fc domain of these immunoglobulins and
determine the effects on the binding interaction between the Fc
domain and the receptor. Thus, the present invention encompasses
IgG Fc domains having at least about 90% of the amino acids
encompassing positions 233 through 338 of the lower hinge and CH2
as defined in Radaev, S., Sun, P., 2001.
[0152] Fc partial domains of IgG immunoglobulins of the present
invention may include all or part of the hinge region, all or part
of the CH2 domain, and all or part of the CH3 domain.
[0153] The IgG Fc partial domains having only a part of the hinge
region, part of the CH2 domain or part of the CH3 domain are
constructed from Fc partial domain monomers. Thus, the present
invention includes IgG hinge region monomers derived from the
N-terminus of the hinge region or the C-terminus of the hinge
region. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or
62 (up to 15 for IgG1, up to 12 for IgG2, up to 62 for IgG3, up to
12 for IgG4) amino acids of the hinge region.
[0154] The present invention also includes IgG CH2 domain monomers
derived from the N-terminus of the CH2 domain or the C-terminus of
the CH2 domain. They can thus contain, for example, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,
109, or 110 (up to 110 for IgG1 and IgG3, up to 109 for IgG2 and
IgG4) amino acids of the CH2 domain.
[0155] The present invention further includes IgG CH3 domain
monomers derived from the N-terminus of the CH3 domain or the
C-terminus of the CH3 domain. They can thus contain, for example,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,
57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105,
106, or 107 (up to 106 for IgG1 and IgG3, up to 107 for IgG2 and
IgG4) amino acids of the CH3 domain.
[0156] The term "isolated" polypeptide or peptide as used herein
refers to a polypeptide or a peptide which either has no
naturally-occurring counterpart or has been separated or purified
from components which naturally accompany it, e.g., in tissues such
as pancreas, liver, spleen, ovary, testis, muscle, joint tissue,
neural tissue, gastrointestinal tissue, or breast tissue or tumor
tissue (e.g., breast cancer tissue), or body fluids such as blood,
serum, or urine. Typically, the polypeptide or peptide is
considered "isolated" when it is at least 70%, by dry weight, free
from the proteins and other naturally-occurring organic molecules
with which it is naturally associated. Preferably, a preparation of
a polypeptide (or peptide) of the invention is at least 80%, more
preferably at least 90%, and most preferably at least 99%, by dry
weight, the polypeptide (peptide), respectively, of the invention.
Since a polypeptide or peptide that is chemically synthesized is,
by its nature, separated from the components that naturally
accompany it, the synthetic polypeptide or peptide is
"isolated."
[0157] An isolated polypeptide (or peptide) of the invention can be
obtained, for example, by extraction from a natural source (e.g.,
from tissues or bodily fluids); by expression of a recombinant
nucleic acid encoding the polypeptide or peptide; or by chemical
synthesis. A polypeptide or peptide that is produced in a cellular
system different from the source from which it naturally originates
is "isolated," because it will necessarily be free of components
which naturally accompany it. The degree of isolation or purity can
be measured by any appropriate method, e.g., column chromatography,
polyacrylamide gel electrophoresis, or HPLC analysis.
Pharmaceutical Compositions
[0158] Administration of the stradobody compositions described
herein will be via any common route, orally, parenterally, or
topically. Exemplary routes include, but are not limited to oral,
nasal, buccal, rectal, vaginal, ophthalmic, subcutaneous,
intramuscular, intraperitoneal, intravenous, intraarterial,
intratumoral, spinal, intrathecal, intra-articular, intra-arterial,
sub-arachnoid, sublingual, oral mucosal, bronchial, lymphatic,
intra-uterine, subcutaneous, intratumor, integrated on an
implantable device such as a suture or in an implantable device
such as an implantable polymer, intradural, intracortical, or
dermal. Such compositions would normally be administered as
pharmaceutically acceptable compositions as described herein. In a
preferred embodiment the isolated stradobody is administered
intravenously or subcutaneously.
[0159] The term "pharmaceutically acceptable carrier" as used
herein includes any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents and the like. The use of such media and agents for
pharmaceutically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible with the
vectors or cells of the present invention, its use in therapeutic
compositions is contemplated. Supplementary active ingredients also
can be incorporated into the compositions.
[0160] The stradobody compositions of the present invention may be
formulated in a neutral or salt form. Pharmaceutically-acceptable
salts include the acid addition salts (formed with the free amino
groups of the protein) and which are formed with inorganic acids
such as, for example, hydrochloric or phosphoric acids, or such
organic acids as acetic, oxalic, tartaric, mandelic, and the like.
Salts formed with the free carboxyl groups can also be derived from
inorganic bases such as, for example, sodium, potassium, ammonium,
calcium, or ferric hydroxides, and such organic bases as
isopropylamine, trimethylamine, histidine, procaine and the
like.
[0161] Sterile injectable solutions are prepared by incorporating
the stradobody in the required amount in the appropriate solvent
with various of the other ingredients enumerated above, as
required, followed by filtered sterilization. Generally,
dispersions are prepared by incorporating the various sterilized
active ingredients into a sterile vehicle which contains the basic
dispersion medium and the required other ingredients from those
enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred methods
of preparation are vacuum-drying and freeze-drying techniques which
yield a powder of the active ingredient plus any additional desired
ingredient from a previously sterile-filtered solution thereof.
[0162] Further, one embodiment is a stradobody composition suitable
for oral administration and is provided in a pharmaceutically
acceptable carrier with or without an inert diluent. The carrier
should be assimilable or edible and includes liquid, semi-solid,
i.e., pastes, or solid carriers. Except insofar as any conventional
media, agent, diluent or carrier is detrimental to the recipient or
to the therapeutic effectiveness of a stradobody preparation
contained therein, its use in an orally administrable a stradobody
composition for use in practicing the methods of the present
invention is appropriate. Examples of carriers or diluents include
fats, oils, water, saline solutions, lipids, liposomes, resins,
binders, fillers and the like, or combinations thereof. The term
"oral administration" as used herein includes oral, buccal, enteral
or intragastric administration.
[0163] In one embodiment, the stradobody composition is combined
with the carrier in any convenient and practical manner, i.e., by
solution, suspension, emulsification, admixture, encapsulation,
microencapsulation, absorption and the like. Such procedures are
routine for those skilled in the art.
[0164] In a specific embodiment, the stradobody composition in
powder form is combined or mixed thoroughly with a semi-solid or
solid carrier. The mixing can be carried out in any convenient
manner such as grinding. Stabilizing agents can be also added in
the mixing process in order to protect the composition from loss of
therapeutic activity through, i.e., denaturation in the stomach.
Examples of stabilizers for use in an orally administrable
composition include buffers, antagonists to the secretion of
stomach acids, amino acids such as glycine and lysine,
carbohydrates such as dextrose, mannose, galactose, fructose,
lactose, sucrose, maltose, sorbitol, mannitol, etc., proteolytic
enzyme inhibitors, and the like. More preferably, for an orally
administered composition, the stabilizer can also include
antagonists to the secretion of stomach acids.
[0165] Further, the stradobody composition for oral administration
which is combined with a semi-solid or solid carrier can be further
formulated into hard or soft shell gelatin capsules, tablets, or
pills. More preferably, gelatin capsules, tablets, or pills are
enterically coated. Enteric coatings prevent denaturation of the
composition in the stomach or upper bowel where the pH is acidic.
See, i.e., U.S. Pat. No. 5,629,001. Upon reaching the small
intestines, the basic pH therein dissolves the coating and permits
the composition to be released to interact with intestinal cells,
e.g., Peyer's patch M cells.
[0166] In another embodiment, the stradobody composition in powder
form is combined or mixed thoroughly with materials that create a
nanoparticle encapsulating the immunologically active biomimetic or
to which the immunologically active biomimetic is attached. Each
nanoparticle will have a size of less than or equal to 100 microns.
The nanoparticle may have mucoadhesive properties that allow for
gastrointestinal absorption of an immunologically active biomimetic
that would otherwise not be orally bioavailable.
[0167] In another embodiment, a powdered composition is combined
with a liquid carrier such as, i.e., water or a saline solution,
with or without a stabilizing agent.
[0168] A specific stradobody formulation that may be used is a
solution of immunologically active biomimetic protein in a
hypotonic phosphate based buffer that is free of potassium where
the composition of the buffer is as follows: 6 mM sodium phosphate
monobasic monohydrate, 9 mM sodium phosphate dibasic heptahydrate,
50 mM sodium chloride, pH 7.0.+/-0.1. The concentration of
immunologically active biomimetic protein in a hypotonic buffer may
range from 10 microgram/ml to 100 milligram/ml. This formulation
may be administered via any route of administration, for example,
but not limited to, intravenous administration.
[0169] Further, a stradobody composition for topical administration
which is combined with a semi-solid carrier can be further
formulated into a cream or gel ointment. A preferred carrier for
the formation of a gel ointment is a gel polymer. Preferred
polymers that are used to manufacture a gel composition of the
present invention include, but are not limited to carbopol,
carboxymethyl-cellulose, and pluronic polymers. Specifically, a
powdered stradobody composition is combined with an aqueous gel
containing an polymerization agent such as Carbopol 980 at
strengths between 0.5% and 5% wt/volume for application to the skin
for treatment of disease on or beneath the skin. The term "topical
administration" as used herein includes application to a dermal,
epidermal, subcutaneous or mucosal surface.
[0170] Further, a stradobody composition can be formulated into a
polymer for subcutaneous or subdermal implantation. A preferred
formulation for the implantable drug-infused polymer is an agent
Generally Regarded as Safe and may include, for example,
cross-linked dextran (Samantha Hart, Master of Science Thesis,
"Elution of Antibiotics from a Novel Cross-Linked Dextran Gel:
Quantification" Virginia Polytechnic Institute and State
University, Jun. 8, 2009) dextran-tyramine (Jin, et al. (2010)
Tissue Eng. Part A. 16(8):2429-40), dextran-polyethylene glycol
(Jukes, et al. (2010) Tissue Eng. Part A., 16(2):565-73), or
dextran-gluteraldehyde (Brondsted, et al. (1998) J. Controlled
Release, 53:7-13). One skilled in the art will know that many
similar polymers and hydrogels can be formed incorporating the
stradobody fixed within the polymer or hydrogel and controlling the
pore size to the desired diameter.
[0171] Upon formulation, solutions are administered in a manner
compatible with the dosage formulation and in such amount as is
therapeutically effective to result in an improvement or
remediation of the symptoms. The formulations are easily
administered in a variety of dosage forms such as ingestible
solutions, drug release capsules and the like. Some variation in
dosage can occur depending on the condition of the subject being
treated. The person responsible for administration can, in any
event, determine the appropriate dose for the individual subject.
Moreover, for human administration, preparations meet sterility,
general safety and purity standards as required by FDA Center for
Biologics Evaluation and Research standards.
[0172] The route of administration will vary, naturally, with the
location and nature of the disease being treated, and may include,
for example intradermal, transdermal, subdermal, parenteral, nasal,
intravenous, intramuscular, subcutaneous, percutaneous,
intratracheal, intraperitoneal, intratumoral, perfusion, lavage,
direct injection, and oral administration.
[0173] The term "parenteral administration" as used herein includes
any form of administration in which the compound is absorbed into
the subject without involving absorption via the intestines.
Exemplary parenteral administrations that are used in the present
invention include, but are not limited to intramuscular,
intravenous, intraperitoneal, intratumoral, intraocular, nasal or
intraarticular administration.
[0174] In addition, the stradobody of the current invention may
optionally be administered before, during or after another
pharmaceutical agent.
[0175] Below are specific examples of various pharmaceutical
formulation categories and preferred routes of administration, as
indicated, for specific exemplary diseases:
[0176] Buccal or sub-lingual dissolvable tablet: angina,
polyarteritis nodosa.
[0177] Intravenous: Idiopathic Thrombocytopenic Purpura, Inclusion
Body Myositis, Paraproteinemic IgM demyelinating Polyneuropathy,
Necrotizing fasciitis, Pemphigus, Gangrene, Dermatomyositis,
Granuloma, Lymphoma, Sepsis, Aplastic anemia, Multisystem organ
failure, Multiple Myeloma and Monoclonal Gammopathy of Unknown
Significance, Chronic Inflammatory Demyelinating
Polyradiculoneuropathy, Inflammatory Myopathies, Thrombotic
thrombocytopenic purpura, Myositis, Anemia, Neoplasia, Hemolytic
anemia, Encephalitis, Myelitis, Myelopathy especially associated
with Human T-cell lymphotropic virus-1, Leukemia, Multiple
sclerosis and optic neuritis, Asthma, Epidermal necrolysis,
Lambert-Eaton myasthenic syndrome, Myasthenia gravis, Neuropathy,
Uveitis, Guillain-Barre syndrome, Graft Versus Host Disease, Stiff
Man Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo
antibodies, paraneoplastic encephalomyelitis and sensory neuropathy
with anti-Hu antibodies, systemic vasculitis, Systemic Lupus
Erythematosus, autoimmune diabetic neuropathy, acute idiopathic
dysautonomic neuropathy, Vogt-Koyanagi-Harada Syndrome, Multifocal
Motor Neuropathy, Lower Motor Neuron Syndrome associated with
anti-/GM1, Demyelination, Membranoproliferative glomerulonephritis,
Cardiomyopathy, Kawasaki's disease, Rheumatoid arthritis, and
Evan's syndrome IM-ITP, CIDP, MS, Dermatomyositis, Myasthenia
Gravis, muscular dystrophy. The term "intravenous administration"
as used herein includes all techniques to deliver a compound or
composition of the present invention to the systemic circulation
via an intravenous injection or infusion.
[0178] Dermal gel, lotion, cream or patch: vitiligo, Herpes zoster,
acne, chelitis psoriasis.
[0179] Rectal suppository, gel, or infusion: ulcerative colitis,
Crohn's disease, hemorrhoidal inflammation.
[0180] Oral as pill, troche, encapsulated, or with enteric coating:
Crohn's disease, celiac sprue, irritable bowel syndrome,
inflammatory liver disease, Barrett's esophagus.
[0181] Intra-cortical: epilepsy, Alzheimer's Disease, Multiple
sclerosis, Parkinson's Disease, Huntingdon's Disease.
[0182] Intra-abdominal infusion or implant: endometriosis.
[0183] Intra-vaginal gel or suppository: bacterial, trichomonal, or
fungal vaginitis.
[0184] Medical devices: coated on coronary artery stent, prosthetic
joints.
[0185] The stradobodies described herein may be administered at
least once daily, weekly, biweekly or monthly or potentially less
frequently. A biphasic dosage regimen may be used wherein the first
dosage phase comprises about 0.1% to about 300% of the second
dosage phase. Because of the enhanced efficacy of the stradobodies
of the current invention, in some embodiments the stradobodies may
be administered at a lower dose intravenously compared with
monoclonal antibodies specific for the same antigen. The effective
stradobody dose is generally from about 1% to about 500% of the
effective monoclonal antibody whose Fab is the same as the
stradobody, more preferably, about 50% to about 100% of the
effective monoclonal antibody dose. The effective monoclonal
antibody dose in clinical cancer treatment varies. For the
Her-2/neu monoclonal antibody, the dose is generally in the range
of about 2 mg/Kg to about 4 mg/Kg administered every 7-21 days. For
the EGFR monoclonal antibody the dose is generally in the range of
about 250-400 mg/square meter which is about 5 mg/Kg-25 mg/Kg
administered every 7-21 days.
[0186] In one embodiment, the stradobody is administered
intravenously at a dose of about 0.01 mg/Kg to about 1000 mg/Kg IV.
In a further embodiment, the stradobody is administered at about
0.1 mg/Kg to about 100 mg/Kg IV. In yet a further embodiment, the
stradobody is administered at about 0.5 mg/Kg to about 50 mg/Kg IV.
In still a further embodiment, the stradobody is administered at
about 1 mg/Kg to about 25 mg/Kg IV. In still a further embodiment,
the stradobody is administered at about 5 mg/Kg to about 15 mg/Kg
IV. In one embodiment, the stradobody is administered
subcutaneously. Because of the enhanced efficacy of the
stradobodies of the current invention, in some embodiments the
stradobody may be administered at a lower dose subcutaneously
compared with monoclonal antibodies specific for the same antigen.
In one embodiment, the stradobody is administered subcutaneously at
a dose of about 0.01 mg/Kg to about 1000 mg/Kg SQ. In a further
embodiment, the stradobody is administered at about 0.2 mg/Kg to
about 150 mg/Kg SQ. In yet a further embodiment, the stradobody is
administered at about 0.5 mg/Kg to about 80 mg/Kg SQ. In still a
further embodiment, the stradobody is administered at about 2 mg/Kg
to about 50 mg/Kg SQ. In still a further embodiment, the stradobody
is administered at about 5 mg/Kg to about 30 mg/Kg SQ.
Therapeutic Applications of Stradobodies
[0187] Based on rational design and in vitro and in vivo
validations, the stradobodies of the present invention will serve
as important biopharmaceuticals for treating cancer and for
modulating immune function in a variety of other contexts such as
bioimmunotherapy for autoimmune diseases and inflammatory diseases
and infections. Medical conditions suitable for treatment with the
immunologically active biomimetics described herein include those
cancers or inflammatory disease conditions in which a monoclonal
antibody may be used or is already in clinical use.
[0188] In addition, exemplary medical conditions having an
inflammatory component that will benefit from treatment with
stradobodies include Amyotrophic Lateral Sclerosis, Huntington's
Disease, Alzheimer's Disease, Parkinson's Disease, Atherogenesis,
Myocardial Infarction, Stroke, Hepatitis B, Hepatitis C, Human
Immunodeficiency Virus associated inflammation,
adrenoleukodystrophy, and epileptic disorders especially those
believed to be associated with postviral encephalitis including
Rasmussen Syndrome, West Syndrome, and Lennox-Gastaut Syndrome.
[0189] The general approach to therapy using the isolated
stradobodies described herein is to administer to a subject having
a disease or condition, a therapeutically effective amount of the
isolated immunologically active biomimetic to effect a treatment.
In some embodiments, diseases or conditions may be broadly
categorized as inflammatory diseases with an imbalance in cytokine
networks, an autoimmune disorder mediated by pathogenic
autoantibodies or autoaggressive T cells, or an acute or chronic
phase of a chronic relapsing disease or process.
[0190] "Immune modulating activities," "modulating immune
response," "modulating the immune system," and "immune modulation"
mean altering immune systems by changing the activities,
capacities, and relative numbers of one or more immune cells,
including maturation of a cell type within its cell type or into
other cell types. For example, immune modulation of immature
monocytes may lead to greater populations of more mature monocytes,
dendritic cells, macrophages, or osteoclasts, all of which are
derived from immature monocytes. As another example, immune
modulation of memory B cells may lead to selective apoptosis of
certain memory B cells with concomitant decreases in production of
particular antibodies. As another example, immune modulation of NK
cells may lead to enhanced Antibody Dependent Cell Cytotoxicity. As
another example, immune modulating activities may lead to increased
populations of cells with phenotypes that may otherwise not be
expressed at high levels, such as CD8 beta+/CD11c+cells. As another
example, immune modulating activities may lead to decreases of
proinflammatory cytokines or cytokines that are commonly elevated
in autoimmune diseases such as IL-6 and IL-8. As another example,
immune modulating activities may lead to activation of NKT cells
with subsequent secretion and cleavage of TGF-beta. For example,
immune cell receptors may be bound by immunologically active
biomimetics and activate intracellular signaling to induce various
immune cell changes, referred to separately as "activating immune
modulation." Blockading immune cell receptors to prevent receptor
activation is also encompassed within "immune modulation" and may
be separately referred to as "inhibitory immune modulation."
[0191] The terms "treating" and "treatment" as used herein refer to
administering to a subject a therapeutically effective amount of a
stradobody of the present invention so that the subject has an
improvement in a disease or condition, or a symptom of the disease
or condition. The improvement is any improvement or remediation of
the disease or condition, or symptom of the disease or condition.
The improvement is an observable or measurable improvement, or may
be an improvement in the general feeling of well-being of the
subject. Thus, one of skill in the art realizes that a treatment
may improve the disease condition, but may not be a complete cure
for the disease. Specifically, improvements in subjects may include
one or more of: decreased inflammation; decreased inflammatory
laboratory markers such as C-reactive protein; decreased
autoimmunity as evidenced by one or more of: improvements in
autoimmune markers such as autoantibodies or in platelet count,
white cell count, or red cell count, decreased rash or purpura,
decrease in weakness, numbness, or tingling, increased glucose
levels in patients with hyperglycemia, decreased joint pain,
inflammation, swelling, or degradation, decrease in cramping and
diarrhea frequency and volume, decreased angina, decreased tissue
inflammation, or decrease in seizure frequency; decreases in cancer
tumor burden, increased time to tumor progression, decreased cancer
pain, increased survival or improvements in the quality of life; or
delay of progression or improvement of osteoporosis.
[0192] The term "therapeutically effective amount" or "effective
amount" as used herein refers to an amount that results in an
improvement or remediation of the symptoms of the disease or
condition.
[0193] As used herein, "prophylaxis" can mean complete prevention
of the symptoms of a disease, a delay in onset of the symptoms of a
disease, or a lessening in the severity of subsequently developed
disease symptoms.
[0194] The term "subject" is used interchangeably with the term
"patient" herein, and is taken to mean any mammalian subject to
which stradobodies of the present invention are administered
according to the methods described herein. In a specific
embodiment, the methods of the present disclosure are employed to
treat a human subject. The methods of the present disclosure may
also be employed to treat non-human primates (e.g., monkeys,
baboons, and chimpanzees), mice, rats, bovines, horses, cats, dogs,
pigs, rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs,
hamsters, bats, birds (e.g., chickens, turkeys, and ducks), fish
and reptiles.
[0195] In particular, the stradobodies of the present invention may
be used to treat conditions including but not limited to congestive
heart failure (CHF), vasculitis, rosacea, acne, eczema, myocarditis
and other conditions of the myocardium, systemic lupus
erythematosus, diabetes, spondylopathies, synovial fibroblasts, and
bone marrow stroma; bone loss; Paget's disease, osteoclastoma;
multiple myeloma; breast cancer; disuse osteopenia; malnutrition,
periodontal disease, Gaucher's disease, Langerhans' cell
histiocytosis, spinal cord injury, acute septic arthritis,
osteomalacia, Cushing's syndrome, monoostotic fibrous dysplasia,
polyostotic fibrous dysplasia, periodontal reconstruction, and bone
fractures; sarcoidosis; osteolytic bone cancers, lung cancer,
kidney cancer and rectal cancer; bone metastasis, bone pain
management, and humoral malignant hypercalcemia, ankylosing
spondylitis and other spondyloarthropathies; transplantation
rejection, viral infections, hematologic neoplasias and
neoplastic-like conditions for example, Hodgkin's lymphoma;
non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic
lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle
cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma,
marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic
leukemia), tumors of lymphocyte precursor cells, including B-cell
acute lymphoblastic leukemia/lymphoma, and T-cell acute
lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T
and NK cells, including peripheral T-cell leukemias, adult T-cell
leukemia/T-cell lymphomas and large granular lymphocytic leukemia,
Langerhans cell histiocytosis, myeloid neoplasias such as acute
myelogenous leukemias, including AML with maturation, AML without
differentiation, acute promyelocytic leukemia, acute myelomonocytic
leukemia, and acute monocytic leukemias, myelodysplastic syndromes,
and chronic myeloproliferative disorders, including chronic
myelogenous leukemia, tumors of the central nervous system, e.g.,
brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma,
ependymoma, and retinoblastoma), solid tumors (nasopharyngeal
cancer, basal cell carcinoma, pancreatic cancer, cancer of the bile
duct, Kaposi's sarcoma, testicular cancer, uterine, vaginal or
cervical cancers, ovarian cancer, primary liver cancer or
endometrial cancer, tumors of the vascular system (angiosarcoma and
hemangiopericytoma)) or other cancer.
[0196] The stradobodies of the present invention may be used to
treat autoimmune diseases. The term "autoimmune disease" as used
herein refers to a varied group of more than 80 diseases and
conditions. In all of these diseases and conditions, the underlying
problem is that the body's immune system attacks the body itself.
Autoimmune diseases affect all major body systems including
connective tissue, nerves, muscles, the endocrine system, skin,
blood, and the respiratory and gastrointestinal systems. Autoimmune
diseases include, for example, systemic lupus erythematosus,
rheumatoid arthritis, multiple sclerosis, myasthenia gravis, and
type 1 diabetes.
[0197] The disease or condition treatable using the compositions
and methods of the present invention may be a hematoimmunological
process, including but not limited to Idiopathic Thrombocytopenic
Purpura, alloimmune/autoimmune thrombocytopenia, Acquired immune
thrombocytopenia, Autoimmune neutropenia, Autoimmune hemolytic
anemia, Parvovirus B19-associated red cell aplasia, Acquired
antifactor VIII autoimmunity, acquired von Willebrand disease,
Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance,
Sepsis, Aplastic anemia, pure red cell aplasia, Diamond-Blackfan
anemia, hemolytic disease of the newborn, Immune-mediated
neutropenia, refractoriness to platelet transfusion, neonatal,
post-transfusion purpura, hemolytic uremic syndrome, systemic
Vasculitis, Thrombotic thrombocytopenic purpura, or Evan's
syndrome.
[0198] The disease or condition may also be a neuroimmunological
process, including but not limited to Guillain-Barre syndrome,
Chronic Inflammatory Demyelinating Polyradiculoneuropathy,
Paraproteinemic IgM demyelinating Polyneuropathy, Lambert-Eaton
myasthenic syndrome, Myasthenia gravis, Multifocal Motor
Neuropathy, Lower Motor Neuron Syndrome associated with anti-/GM1,
Demyelination, Multiple Sclerosis and optic neuritis, Stiff Man
Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo
antibodies, paraneoplastic encephalomyelitis, sensory neuropathy
with anti-Hu antibodies, epilepsy, Encephalitis, Myelitis,
Myelopathy especially associated with Human T-cell lymphotropic
virus-1, Autoimmune Diabetic Neuropathy, Alzheimer's disease,
Parkinson's disease, Huntingdon's disease, or Acute Idiopathic
Dysautonomic Neuropathy.
[0199] The disease or condition may also be a Rheumatic disease
process, including but not limited to Kawasaki's disease,
Rheumatoid arthritis, Felty's syndrome, ANCA-positive Vasculitis,
Spontaneous Polymyositis, Dermatomyositis, Antiphospholipid
syndromes, Recurrent spontaneous abortions, Systemic Lupus
Erythematosus, Juvenile idiopathic arthritis, Raynaud's, CREST
syndrome, or Uveitis.
[0200] The disease or condition may also be a dermatoimmunological
disease process, including but not limited to Toxic Epidermal
Necrolysis, Gangrene, Granuloma, Autoimmune skin blistering
diseases including Pemphigus vulgaris, Bullous Pemphigoid,
Pemphigus foliaceus, Vitiligo, Streptococcal toxic shock syndrome,
Scleroderma, systemic sclerosis including diffuse and limited
cutaneous systemic sclerosis, or Atopic dermatitis (especially
steroid dependent).
[0201] The disease or condition may also be a musculoskeletal
immunological disease process, including but not limited to
Inclusion Body Myositis, Necrotizing fasciitis, Inflammatory
Myopathies, Myositis, Anti-Decorin (BJ antigen) Myopathy,
Paraneoplastic Necrotic Myopathy, X-linked Vacuolated Myopathy,
Penacillamine-induced Polymyositis, Atherosclerosis, Coronary
Artery Disease, or Cardiomyopathy.
[0202] The disease or condition may also be a gastrointestinal
immunological disease process, including but not limited to
pernicious anemia, autoimmune chronic active hepatitis, primary
biliary cirrhosis, Celiac disease, dermatitis herpetiformis,
cryptogenic cirrhosis, Reactive arthritis, Crohn's disease,
Whipple's disease, ulcerative colitis, or sclerosing
cholangitis.
[0203] The disease or condition may also be Graft Versus Host
Disease, Antibody-mediated rejection of the graft, Post-bone marrow
transplant rejection, Postinfectious disease inflammation,
Lymphoma, Leukemia, Neoplasia, Asthma, Type 1 Diabetes mellitus
with anti-beta cell antibodies, Sjogren's syndrome, Mixed
Connective Tissue Disease, Addison's disease, Vogt-Koyanagi-Harada
Syndrome, Membranoproliferative glomerulonephritis, Goodpasture's
syndrome, Graves' disease, Hashimoto's thyroiditis, Wegener's
granulomatosis, micropolyarterits, Churg-Strauss syndrome,
Polyarteritis nodosa or Multisystem organ failure.
[0204] In addition to having clinical utility for treating
immunological disorders, stradobodies have therapeutic use in
infectious disease, cancer, and inflammatory disease treatment. The
stradobodies may be used essentially following known protocols for
any corresponding therapeutic antibody. The stradobodies will
generally be designed to enhance the effect demonstrated on an
effector cell by a monoclonal antibody, such as ADCC in cancer or
decreased monocyte and DC maturation with decreased cytokine
release in autoimmune disease, and thereby potentiate the immune
response against the cancer relative to that which would occur
using, for example, a source monoclonal antibody for the Fab
portion of the stradobody.
[0205] Infectious diseases, include, but are not limited to, those
caused by bacterial, mycological, parasitic, and viral agents.
Examples of such infectious agents include the following:
staphylococcus, streptococcaceae, neisseriaaceae, cocci,
enterobacteriaceae, pseudomonadaceae, vibrionaceae, campylobacter,
pasteurellaceae, bordetella, francisella, brucella, legionellaceae,
bacteroidaceae, clostridium, corynebacterium, propionibacterium,
gram-positive bacilli, anthrax, actinomyces, nocardia,
mycobacterium, treponema, borrelia, leptospira, mycoplasma,
ureaplasma, rickettsia, chlamydiae, other gram-positive bacilli,
other gram-negative bacilli, systemic mycoses, other opportunistic
mycoses, protozoa, nematodes, trematodes, cestodes, adenoviruses,
herpesviruses (including, for example, herpes simplex virus and
Epstein Barr virus, and herpes zoster virus), poxviruses,
papovaviruses, hepatitis viruses, papilloma viruses,
orthomyxoviruses (including, for example, influenza A, influenza B,
and influenza C), paramyxoviruses, coronaviruses, picornaviruses,
reoviruses, togaviruses, flaviviruses, bunyaviridae, rhabdoviruses,
respiratory syncitial virus, human immunodeficiency virus and
retroviruses. Exemplary infectious diseases include but are not
limited to candidiasis, candidemia, aspergillosis, streptococcal
pneumonia, streptococcal skin and oropharyngeal conditions, gram
negative sepsis, tuberculosis, mononucleosis, influenza,
respiratory illness caused by Respiratory Syncytial Virus, malaria,
schistosomiasis, and trypanosomiasis.
[0206] "Cancer" herein refers to or describes the physiological
condition in mammals that is typically characterized by unregulated
cell growth. Examples of cancer include but are not limited to
carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma,
osteogenic sarcoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, leiomyosarcoma,
rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma),
osteoclastoma, neuroendocrine tumors, mesothelioma, chordoma,
synovioma, schwanoma, meningioma, adenocarcinoma, melanoma, and
leukemia or lymphoid malignancies. More particular examples of such
cancers include squamous cell cancer (e.g. epithelial squamous cell
cancer), lung cancer including small-cell lung cancer, non-small
cell lung cancer, adenocarcinoma of the lung and squamous carcinoma
of the lung, small cell lung carcinoma, cancer of the peritoneum,
hepatocellular cancer, gastric or stomach cancer including
gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical
cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,
breast cancer, colon cancer, rectal cancer, colorectal cancer,
endometrial or uterine carcinoma, salivary gland carcinoma, kidney
or renal cancer, prostate cancer, vulval cancer, thyroid cancer,
hepatic carcinoma, anal carcinoma, penile carcinoma, testicular
cancer, esophageal cancer, tumors of the biliary tract, Ewing's
tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, papillary
adenocarcinomas, cystadenocarcinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms'
tumor, testicular tumor, lung carcinoma, bladder carcinoma,
epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
craniopharyngioma, ependymoma, pinealoma, hemangioblastoma,
acoustic neuroma, oligodendroglioma, meningioma, melanoma,
neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple
myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease,
heavy chain disease, neuroendocrine tumors, Schwanoma, and other
carcinomas, head and neck cancer, myeloid neoplasias such as acute
myelogenous leukemias, including AML with maturation, AML without
differentiation, acute promyelocytic leukemia, acute myelomonocytic
leukemia, and acute monocytic leukemias, myelodysplastic syndromes,
and chronic myeloproliferative disorders, including chronic
myelogenous leukemia, tumors of the central nervous system, e.g.,
brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma,
ependymoma, and retinoblastoma), solid tumors (nasopharyngeal
cancer, basal cell carcinoma, pancreatic cancer, cancer of the bile
duct, Kaposi's sarcoma, testicular cancer, uterine, vaginal or
cervical cancers, ovarian cancer, primary liver cancer or
endometrial cancer, tumors of the vascular system (angiosarcoma and
hemangiopericytoma), hematologic neoplasias and neoplastic-like
conditions for example, Hodgkin's lymphoma; non-Hodgkin's lymphomas
(Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic
leukemia, mycosis fungoides, mantle cell lymphoma, follicular
lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma,
hairy cell leukemia and lymphoplasmacytic leukemia), tumors of
lymphocyte precursor cells, including B-cell acute lymphoblastic
leukemia/lymphoma, and T-cell acute lymphoblastic
leukemia/lymphoma, thymoma, tumors of the mature T and NK cells,
including peripheral T-cell leukemias, adult T-cell leukemia/T-cell
lymphomas and large granular lymphocytic leukemia, osteolytic bone
cancers, and bone metastasis.
[0207] Antibodies comprise Fab domains from which a stradobody may
be designed. Exemplary monoclonal antibodies include but are not
limited to 3F8, 8H9, abagovomab, abciximab, adalimumab,
adecatumumab, afelimomab, afutuzumab, alacizumab pegol, ALD518,
alemtuzumab, altumomab pentetate, amatuximab, anatumomab mafenatox,
anrukinzumab (IMA-638), apolizumab, arcitumomab, aselizumab,
atinumab, atlizumab (tocilizumab), atorolimumab, bapineuzumab,
basiliximab, bavituximab, bectumomab, belimumab, benralizumab,
bertilimumab, besilesomab, bevacizumab, biciromab, bivatuzumab
mertansine, blinatumomab, blosozumab, brentuximab vedotin,
briakinumab, brodalumab, canakinumab, cantuzumab mertansine,
cantuzumab ravtansine, capromab pendetide, carlumab, catumaxomab,
CC49, cedelizumab, certolizumab pegol, cetuximab, Ch.14.18,
citatuzumab bogatox, cixutumumab, clenoliximab, clivatuzumab
tetraxetan, conatumumab, crenezumab, CR6261, dacetuzumab,
daclizumab, dalotuzumab, daratumumab, denosumab, detumomab,
dorlimomab aritox, drozitumab, ecromeximab, eculizumab, edobacomab,
edrecolomab, efalizumab, efungumab, elotuzumab, elsilimomab,
enavatuzumab, enlimomab pegol, enokizumab, ensituximab, epitumomab
cituxetan, epratuzumab, erlizumab, ertumaxomab, etaracizumab,
etrolizumab, exbivirumab, fanolesomab, faralimomab, farletuzumab,
FBTA05, felvizumab, fezakinumab, ficlatuzumab, figitumumab,
flanvotumab, fontolizumab, foralumab, foravirumab, fresolimumab,
fulranumab, galiximab, ganitumab, gantenerumab, gavilimomab,
gemtuzumab ozogamicin, gevokizumab, girentuximab, glembatumumab
vedotin, golimumab, gomiliximab, GS6624, ibalizumab, ibritumomab
tiuxetan, icrucumab, igovomab, imciromab, indatuximab ravtansine,
infliximab, intetumumab, inolimomab, inotuzumab ozogamicin,
ipilimumab, iratumumab, itolizumab, ixekizumab, keliximab,
labetuzumab, lebrikizumab, lemalesomab, lerdelimumab, lexatumumab,
libivirumab, lintuzumab, lorvotuzumab mertansine, lucatumumab,
lumiliximab, mapatumumab, maslimomab, mavrilimumab, matuzumab,
mepolizumab, metelimumab, milatuzumab, minretumomab, mitumomab,
mogamulizumab, morolimumab, motavizumab, moxetumomab pasudotox,
muromonab-CD3, nacolomab tafenatox, namilumab, naptumomab
estafenatox, narnatumab, natalizumab, nebacumab, necitumumab,
nerelimomab, nimotuzumab, nofetumomab merpentan, ocrelizumab,
odulimomab, ofatumumab, olaratumab, olokizumab, omalizumab,
onartuzumab, oportuzumab monatox, oregovomab, otelixizumab,
oxelumab, ozoralizumab, pagibaximab, palivizumab, panitumumab,
panobacumab, pascolizumab, pateclizumab, pemtumomab, pertuzumab,
pexelizumab, pintumomab, ponezumab, priliximab, pritumumab, PRO
140, racotumomab, radretumab, rafivirumab, ramucirumab,
ranibizumab, raxibacumab, regavirumab, reslizumab, rilotumumab,
rituximab, robatumumab, roledumab, romosozumab, rontalizumab,
rovelizumab, ruplizumab, samalizumab, sarilumab, satumomab
pendetide, secukinumab, sevirumab, sibrotuzumab, sifalimumab,
siltuximab, siplizumab, sirukumab, solanezumab, sonepcizumab,
sontuzumab, stamulumab, sulesomab, suvizumab, tabalumab,
tacatuzumab tetraxetan, tadocizumab, talizumab, tanezumab,
taplitumomab paptox, tefibazumab, telimomab aritox, tenatumomab,
teneliximab, teplizumab, teprotumumab, TGN1412, ticilimumab
(tremelimumab), tigatuzumab, TNX-650, tocilizumab (=atlizumab),
toralizumab, tositumomab, tralokinumab, trastuzumab, TRBS07,
tregalizumab, tremelimumab, tucotuzumab celmoleukin, tuvirumab,
ublituximab, urelumab, urtoxazumab, ustekinumab, vapaliximab,
vatelizumba, vedolizumab, veltuzumab, vepalimomab, vesencumab,
visilizumab, volociximab, votumumab, zalutumumab, zanolimumab,
ziralimumab, and zolimomab aritox.
[0208] The stradobody of the present invention may be specific for
a cytokine. For example, the stradobody of the present invention
may be specific for an Interferon (such as, for example,
IFN.gamma., IFN.alpha., or IFN.beta.), IL-1, IL-2, IL-4, IL-5,
IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, or IL-23. In one
embodiment, the stradobody of the current invention is specific for
a cytokine, and is useful for treatment or prevention of one or
more inflammatory diseases or autoimmune diseases. For example, in
one embodiment, the stradobody is an anti-IL-2, anti-IL-8, or
anti-IL-17 stradobody.
[0209] The term "autoimmune disease" as used herein refers to a
varied group of more than 80 chronic illnesses. In all of these
diseases, the underlying problem is that the body's immune system
attacks the body itself. Autoimmune diseases affect all major body
systems including connective tissue, nerves, muscles, the endocrine
system, skin, blood, and the respiratory and gastrointestinal
systems.
[0210] The autoimmune disease or condition may be a
hematoimmunological process, including but not limited to
Idiopathic Thrombocytopenic Purpura, alloimmune/autoimmune
thrombocytopenia, Acquired immune thrombocytopenia, Autoimmune
neutropenia, Autoimmune hemolytic anemia, Parvovirus B19-associated
red cell aplasia, Acquired antifactor VIII autoimmunity, acquired
von Willebrand disease, Multiple Myeloma and Monoclonal Gammopathy
of Unknown Significance, Sepsis, Aplastic anemia, pure red cell
aplasia, Diamond-Blackfan anemia, hemolytic disease of the newborn,
Immune-mediated neutropenia, refractoriness to platelet
transfusion, neonatal, post-transfusion purpura, hemolytic uremic
syndrome, systemic Vasculitis, Thrombotic thrombocytopenic purpura,
or Evan's syndrome.
[0211] The autoimmune disease or condition may be a
neuroimmunological process, including but not limited to
Guillain-Barre syndrome, Chronic Inflammatory Demyelinating
Polyradiculoneuropathy, Paraproteinemic IgM demyelinating
Polyneuropathy, Lambert-Eaton myasthenic syndrome, Myasthenia
gravis, Multifocal Motor Neuropathy, Lower Motor Neuron Syndrome
associated with anti-/GM1, Demyelination, Multiple Sclerosis and
optic neuritis, Stiff Man Syndrome, Paraneoplastic cerebellar
degeneration with anti-Yo antibodies, paraneoplastic
encephalomyelitis, sensory neuropathy with anti-Hu antibodies,
epilepsy, Encephalitis, Myelitis, Myelopathy especially associated
with Human T-cell lymphotropic virus-1, Autoimmune Diabetic
Neuropathy, or Acute Idiopathic Dysautonomic Neuropathy.
[0212] The autoimmune disease or condition may be a Rheumatic
disease process, including but not limited to Kawasaki's disease,
Rheumatoid arthritis, Felty's syndrome, ANCA-positive Vasculitis,
Spontaneous Polymyositis, Dermatomyositis, Antiphospholipid
syndromes, Recurrent spontaneous abortions, Systemic Lupus
Erythematosus, Juvenile idiopathic arthritis, Raynaud's, CREST
syndrome, or Uveitis.
[0213] The autoimmune disease or condition may be a
dermatoimmunological disease process, including but not limited to
Toxic Epidermal Necrolysis, Gangrene, Granuloma, Autoimmune skin
blistering diseases including Pemphigus vulgaris, Bullous
Pemphigoid, and Pemphigus foliaceus, Vitiligo, Streptococcal toxic
shock syndrome, Scleroderma, systemic sclerosis including diffuse
and limited cutaneous systemic sclerosis, or Atopic dermatitis
(especially steroid dependent).
[0214] The autoimmune disease or condition may be a musculoskeletal
immunological disease process, including but not limited to
Inclusion Body Myositis, Necrotizing fasciitis, Inflammatory
Myopathies, Myositis, Anti-Decorin (BJ antigen) Myopathy,
Paraneoplastic Necrotic Myopathy, X-linked Vacuolated Myopathy,
Penacillamine-induced Polymyositis, Atherosclerosis, Coronary
Artery Disease, or Cardiomyopathy.
[0215] The autoimmune disease or condition may be a
gastrointestinal immunological disease process, including but not
limited to pernicious anemia, autoimmune chronic active hepatitis,
primary biliary cirrhosis, Celiac disease, dermatitis
herpetiformis, cryptogenic cirrhosis, Reactive arthritis, Crohn's
disease, Whipple's disease, ulcerative colitis, or sclerosing
cholangitis.
[0216] The autoimmune disease or condition may be Graft Versus Host
Disease, Antibody-mediated rejection of the graft, Post-bone marrow
transplant rejection, Post-infectious disease inflammation,
Lymphoma, Leukemia, Neoplasia, Asthma, Type 1 Diabetes mellitus
with anti-beta cell antibodies, Sjogren's syndrome, Mixed
Connective Tissue Disease, Addison's disease, Vogt-Koyanagi-Harada
Syndrome, Membranoproliferative glomerulonephritis, Goodpasture's
syndrome, Graves' disease, Hashimoto's thyroiditis, Wegener's
granulomatosis, micropolyarterits, Churg-Strauss syndrome,
Polyarteritis nodosa or Multisystem organ failure.
[0217] In another embodiment, the stradobodies herein described
could be utilized in a priming system wherein blood is drawn from a
patient and transiently contacted with the stradobodies for a
period of time from about one half hour to about three hours prior
to being introduced back into the patient. In this form of cell
therapy, the patient's own effector cells are exposed to
stradobodies that are fixed on a matrix ex vivo in order to
modulate the effector cells through exposure of the effector cells
to the stradobodies. The blood including the modulated effector
cells are then infused back into the patient. Such a priming system
could have numerous clinical and therapeutic applications.
[0218] The stradobodies disclosed herein may also be readily
applied to alter immune system responses in a variety of contexts
to affect specific changes in immune response profiles. Altering or
modulating an immune response in a subject refers to increasing,
decreasing or changing the ratio or components of an immune
response. For example, cytokine production or secretion levels may
be increased or decreased as desired by targeting the appropriate
combination of Fc.gamma.Rs with a stradobody designed to interact
with those receptors. Antibody production may also be increased or
decreased; the ratio of two or more cytokines or immune cell
receptors may be changed; or additional types of cytokines or
antibodies may be caused to be produced. The immune response may
also be an effector function of an immune cell expressing a
Fc.gamma.R, including increased or decreased phagocytic potential
of monocyte macrophage derived cells, increased or decreased
osteoclast function, increased or decreased antigen presentation by
antigen-presenting cells (e.g. Dendritic Cells), increased or
decreased NK cell function, increased or decreased B-cell function,
as compared to an immune response which is not modulated by an
immunologically active biomimetic disclosed herein.
[0219] In a preferred embodiment, a subject with cancer or an
autoimmune or inflammatory disease or infectious disease has their
immune response altered comprising the step of administering a
therapeutically effective amount of a stradobody described herein
to a subject, wherein the therapeutically effective amount of the
stradobody alters the immune response in the subject. Ideally this
intervention treats the disease or condition in the subject. The
altered immune response may be an increased or a decreased response
and may involve altered cytokine levels including the levels of any
of IL-6, IL-10, IL-8, IL-23, IL-7, IL-4, IL-12, IL-13, IL-17,
TNF-alpha and IFN-alpha. In a preferred embodiment, 11-6 or IL-8
are decreased in response to therapy. In an especially preferred
embodiment, IL-6 and IL-8 are decreased in a sustained response to
therapy. The invention is however not limited by any particular
mechanism of action of the described biomimetics. The altered
immune response may be an altered autoantibody level in the
subject. The altered immune response may be an altered
autoaggressive T-cell level in the subject.
[0220] For example, reducing the amount of TNF-alpha production in
autoimmune diseases can have therapeutic effects. A practical
application of this is anti-TNF-alpha antibody therapy (e.g.
Remicade.RTM.) which is clinically proven to treat Plaque
Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's
Disease, Ulcerative Colitis and Ankylosing Spondylitis. These
autoimmune diseases have distinct etiologies but share key
immunological components of the disease processes related to
inflammation and immune cell activity. A stradobody designed to
reduce TNF-alpha production will likewise be effective in these and
many other autoimmune diseases. The altered immune response profile
may also be direct or indirect modulation to effect a reduction in
antibody production, for example autoantibodies targeting a
subject's own tissues, or altered autoaggressive T-cell levels in
the subject. For example, Multiple Sclerosis is an autoimmune
disorder involving autoreactive T-cells which may be treated by
interferon beta therapy. See, e.g., Zafranskaya M, et al.,
Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in
multiple sclerosis, Immunology 2007 May; 121(1):29-39-Epub 2006
Dec. 18. A stradobody design to reduce autoreactive T-cell levels
will likewise be effective in Multiple Sclerosis and may other
autoimmune diseases involving autoreactive T-cells.
[0221] The stradobodies described herein may be used to modulate
expression of co-stimulatory molecules from an immune cell,
including a dendritic cell, a macrophage, an osteoclast, a
monocyte, or an NK cell or to inhibit in these same immune cells
differentiation, maturation, or cytokine secretion, including
interleukin-12 (IL-12), or of increasing cytokine secretion,
including interleukin-10 (IL-10), or interleukin-6 (IL-6). A
skilled artisan may also validate the efficacy of an
immunologically active biomimetic by exposing an immune cell to the
immunologically active biomimetic and measuring modulation of the
immune cell function, wherein the immune cell is a dendritic cell,
a macrophage, an osteoclast, or a monocyte. In one embodiment the
immune cell is exposed to the immunologically active biomimetic in
vitro and further comprising the step of determining an amount of a
cell surface receptor or of a cytokine production, wherein a change
in the amount of the cell surface receptor or the cytokine
production indicates a modulation of the immune cell function. In
another embodiment the immune cell is exposed to the
immunologically active biomimetic in vivo in a model animal for an
autoimmune disease further comprising a step of assessing a degree
of improvement in the autoimmune disease. The stradobodies
described herein may be used to modulate expression of
co-stimulatory molecules from a B cell.
[0222] The methods of the invention can be applied to any animal
species and the IgG molecules from which the IgG-derived portions
of Fc reagents are made can be from any animal species. Naturally,
relevant animal species are those in which IgG or IgG-like
molecules occur. Generally the species to which the methods are
applied and the species from which the IgG-derived portions of the
Fc reagents used in the methods are the same. However, they are not
necessarily the same. Relevant animal species are preferably
mammals and these include, without limitation, humans, non-human
primates (e.g., monkeys, baboons, and chimpanzees), horses, bovine
animals (e.g., bulls, cows, or oxen), pigs, goats, sheep, dogs,
cats, rabbits, gerbils, hamsters, rats, and mice. Non-mammalian
species include, for example, birds (e.g., chickens, turkeys, and
ducks) and fish.
[0223] The stradobodies disclosed herein have a number of further
applications and uses.
EXAMPLES
Example 1. Production and Purification of HER2/Neu-Specific
Stradobodies
[0224] A synthetic DNA construct encoding the trastuzumab variable
and CH1 region was obtained from Blue Heron Biotechnology (Bothell,
Wash.) and fused by PCR to a corresponding Fc region containing the
human IgG1 hinge, CH2 and CH3 regions to generate a reading frame
encoding the full trastuzumab antibody heavy chain. cDNA was cloned
into the expression vector pOptiVec (Invitrogen) for expression in
mammalian cells. Simultaneously, a similar synthetic construct was
obtained containing the trastuzumab light chain and cloned into the
vector pcDNA3.3 (Invitrogen). Stradobody heavy chain constructs
were generated by overlapping PCR using the trastuzumab heavy chain
as a template with primers encoding the multimerization domains and
linker regions. PCR products were cloned into the pOptiVec
expression vector by TA cloning to generate the stradobody
expression constructs. Following TA cloning, all constructs were
confirmed by sequencing of the complete coding frame as well as
surrounding sequences. For stradobody protein expression, large
scale DNA plasmid isolation was performed by endotoxin-free plasmid
purification kits (Macherey Nagel) and protein produced in 293-T
HEK or CHO cells by transient protein expression. Stradobody
protein was expressed by co-transfection of heavy-chain and light
chain DNA constructs. Stradobody protein was purified by FPLC on an
AKTAxpress using protein G affinity chromatography followed by
desalting on a HiPrep desalting column (GE life sciences).
Stradobody constructs are shown in FIG. 32.
[0225] To observe the formation of stradobody multimers, purified
stradobodies were analyzed by non-reducing SDS-PAGE gel. Bands of
higher molecular weight relative to the unaltered antibody GB2500
indicated multimer formation in several constructs. As shown in
FIG. 8, several C-terminal stradobodies exhibited higher molecular
weight bands relative to the unaltered protein. In particular,
several high molecular weight bands were detected upon analysis of
the construct GB2547. Serial stradobody constructs were also
tested. As shown in FIG. 9, several serial stradobody constructs,
particularly multimerizing serial stradobody GB2542, exhibited
higher molecular weight bands relative to the unaltered antibody
GB2500.
[0226] Other stradobodies directed against targets other than
HER2/neu are produced, purified, and analyzed in an analogous
manner. These other stradobodies include the GB3500 series directed
against EGFR, the GB4500 series directed against CD20, and the
GB7500 series directed against TNF.
Example 2. Cytoxicity and Binding Activity of HER2/Neu-Specific
Stradobodies
[0227] Antibody-dependent cell cytotoxicity was determined for
several stradobodies, in comparison to the unaltered antibody
GB2500. The ADCC assay was performed on freshly isolated NK cells
as effectors cells with the low HER2/neu expressing tumor cell line
MDA-MB-231 as the target cell line. MDA-MB-231 cells were
radioactively labeled with Cr-51, followed by a one hour incubation
with one of the five following solutions: media only, media
containing a non-binding human IgG1, media containing the
monoclonal antibody GB2500, and media containing the stradobody to
be tested. Cells were then plated out with freshly isolated human
NK cells at varying NK to tumor cell ratios for four hours and the
amount of killing was determined by the amount of Cr-51 released
free into the media after the cells had been pelleted.
[0228] One to four independently expressed and purified protein
batches from each of a total of 18 proteins, including GB2500, were
tested. The effector to target cell ratios tested were 50:1, 25:1,
12.5:1 and 6.5:1. Where the NK yield permitted, a ratio of 100:1
was used. FIG. 10 shows a representative example of ADCC data,
demonstrating the increased ADCC observed with GB2542 relative to
GB2500 over the range of effector to target cells. FIG. 10 also
demonstrates the variability of two different independently
purified batches of GB2500.
[0229] The compiled ADCC data on all 12 anti-HER2/neu stradobodies
and GB2500 are shown in FIG. 32. Each row in FIG. 32 represents a
purified and tested stradobody batch (e.g., four batches of GB2542
were produced and tested). Data are presented as percent killing by
NK cells isolated from the indicated donor, at the indicated ratio
of effector to target cell.
[0230] The results of the study showed that surprisingly, even
though the novel stradobodies and the trastuzumab antibody GB2500
share the identical Fab, several stradobodies were significantly
more potent in ADCC response. GB2542 was particularly potent in
ADCC assays. The rank order of the ADCC response in this particular
experiment was as follows: GB2542 (multimerizing serial stradobody
with two multimerization domains)>GB2547 (multimerizing
C-terminal stradobody with two multimerization domains)>GB2550
(multimerizing C-terminal stradobody with one multimerization
domain)>GB2500>human Isotope control and media control.
[0231] In addition to the effector to target cell ratio response
ADCC, an analysis of the stradobody concentration response ADCC was
conducted. The ADCC assay was performed with concentrations of
stradobodies and HER2/neu antibody varying from 0.4 to 4000 ng/mL
to assess the dose response of the stradobodies. The ratio of NK
cells to MDA-MB-231 target cells was kept constant at 25:1 for
these experiments. The results of the study are shown in FIG. 11.
The concentration-dependent analysis confirmed the increased ADCC
activity of stradobodies, particularly GB2542, relative to the
trastuzumab antibody (GB2500). Based on this experiment,
multimerizing serial stradobody GB2542 was estimated to be more
than 2-log more potent in the ADCC assay than GB2500, despite the
fact that the two molecules share the same Fab.
[0232] The binding strength of the stradobodies in comparison to
GB2500 was assessed as measured by plasmon resonance, using a
Biacore 3000 system. Recombinant human Fc.gamma.RIIIa was diluted
to 3 ug/ml in 10 mM Sodium Acetate pH 5.0 and manually immobilized
onto a flow cell of a CM5 chip. Stradobodies or GB2500 were diluted
to 1 .mu.M with HBS-EP (0.01 M HEPES pH 7.4, 0.15M NaCl, 1 mM EDTA,
0.005% Surfactant P20) and perfused over the immobilized human
Fc.gamma.RIIIa as follows. After activation of the flow cell, 3
ug/ml of the protein was injected in 1 .mu.l increments at a flow
rate of 5 .mu.l/min until an RU (resonance unit) of 400 was
reached. The flow cell was then blocked with 1M Ethanolamine.
Another flow cell was used as a blank control. Typically, 20 .mu.l
of the diluted samples were injected at a flow rate of 20
.mu.l/min. Regeneration of the flow cell was performed by an
extended wash with running buffer HBS-EP at 20 .mu.L/min.
[0233] Examples of binding data are shown in FIG. 12. The binding
curve for the parental antibody GB2500, the high binder/high ADCC
stradobodies GB2542 (multimerizing serial) and GB2547
(multimerizing C-terminal), and the low binders/low ADCC stradobody
GB2554 (non-multimerizing serial) are shown. As a comparison, a
binding curve for the mouse Fc based antibody MB2500 is included as
an example of a non/low binder. The rank order of binding strength
is indicated in FIG. 13. Several of the stradobodies had a higher
RU max than GB2500. In addition, GB2542 in this assay had the
highest RU max and among the slowest rates of dissociation.
[0234] Next, the correlation between the ADCC activity and the
binding measured by Biacore was evaluated. The ADCC activity was
calculated as fold difference relative to the ADCC activity of the
monoclonal antibody GB2500. When two GB2500 batches were measured
in the same experiment for the same donor, the average ADCC was
used to calculate the mean fold difference in ADCC. The binding was
measured as RU max and the data presented in FIG. 14. For several
of the stradobodies, there was an average fold increase in ADCC
higher than the parental antibody (GB2500=1). While the data set
was somewhat limited in quantity and some variance in the ADCC
activity was observed, there seemed to be an overall correlation
between binding and ADCC activity. Importantly, for several of the
high ADCC/high binding stradobodies, including GB2542
(multimerizing serial with two multimerization domains), GB2524
(multimerizing serial with one multimerization domain and one
linker), GB2547 (multimerizing C-terminal with two multimerization
domains) and GB2540 (multimerizing serial with one multimerization
domain), higher order forms were readily observable on the
non-denaturing gels indicating a correlation between multimer
formation, receptor binding, and ADCC activity.
[0235] Overall, the results of the study indicated that several of
the stradobody constructs exhibited higher ADCC and stronger
binding activity compared to the monoclonal antibody GB2500, which
shares the same Fab as all of the stradobodies tested. The
stradobody construct exhibiting the highest ADCC and strongest
binding activity was GB2542, comprising an isoleucine zipper
multimerization domain and an IgG2 hinge multimerization domain
located between the two Fc domains. In addition, there was a
significant degree of correlation between binding measured by
plasmon resonance and ADCC activity.
[0236] Other stradobodies directed against targets other than
HER2/neu are assessed for cytotoxicity and binding in an analogous
manner. These other stradobodies include the GB3500 series directed
against EGFR, the GB4500 series directed against CD20, and the
GB7500 series directed against TNF.
Example 3. Further Purification of Stradobodies
[0237] In order to determine if stradobody multimers and monomers
could be successfully separated, GB2054 was purified by ion
exchange chromatography on a Mono Q column.
[0238] The results of the study, shown in FIG. 15, demonstrated
that higher order multimers could be separated from monomers.
Multimer peaks were not easily identified in the unfractionated
peak (lane SB), but were readily detectable after ion exchange.
Without wishing to be bound by theory, it is thought that
purification of stradobody multimers will increase the potency of
the compounds.
Example 4. Enhanced Multimerization and Fc.gamma.RIIIa Binding of
Stradobodies with Multimerization Domains
[0239] In order to more stringently assess multimerization of the
serial stradobody compounds, a sensitive SDS-PAGE gel method was
used to compare multimerization of stradobody constructs to one
another and to the HER2 monoclonal antibody construct GB2500. 4-12%
gels were used for non-reduced SDS-PAGE, and 12% gels were used for
reduced SDS-PAGE. All samples were loaded at 2 .mu.g and run at
150V for approximately 2.3 hours prior to Coomassie staining.
[0240] As shown in FIG. 16, the control mAb GB2500 (lane 1) and the
non-multimerizing serial stradobody construct GB2555 (lane 7),
which has a non-multimerizing linker between the two IgG1 Fc
regions, did not multimerize. Similarly, non-multimerizing serial
stradobody construct GB2554 (lane 6), which has a G4S linker domain
between the two IgG1 Fc regions, exhibited little multimerization.
Some multimerization was evident for multimerizing serial
stradobody constructs GB2538 (lane 3) and GB2540 (lane 4), which
have an isoleucine zipper or an IgG2 hinge multimerization domain,
respectively, between the two IgG1 Fc regions. Multimerizing serial
stradobody construct GB2524 (lane 2) has a G4S linker domain and an
IgG2 hinge multimerization domain between the two IgG1 Fc regions,
but multimerized poorly. In contrast to the lesser degree of
multimerization of GB2538, GB2540, and GB2524, multimerizing serial
stradobody construct GB2542, which has an isoleucine zipper and an
IgG2 hinge between the two IgG1 Fc regions, exhibited a great deal
of multimerization (lane 5).
[0241] To analyze the binding of the GB2500 parent antibody and
each of the serial stradobody constructs to Fc.gamma.RIIIa, a
binding analysis was performed in which purified Fc.gamma.RIIIa-His
was loaded onto a ForteBio anti-penta-His sensor (Cat #18-5077) at
10 .mu.g/ml. GB2500 (produced in HEK cells), GB2524, GB2538,
GB2540, GB2542, GB2554, or GB2555 were incubated with the receptor
in 1.times. kinetics buffer (ForteBio Cat #18-5032) to measure on
rate (Kon) and the sensor tip later transferred to binding buffer
to measure off rate (Kdis). GB2500 antibodies were tested at
concentrations ranging from 3333-208 nM, and the stradobodies were
tested at concentrations ranging from 200-12.5 nM. KD was
calculated from on and off rate using ForteBio analysis software.
As shown in Table 3 and FIGS. 17A-D, multimerizing serial
stradobodies GB2542 and GB2538 exhibited the lowest KD, and
therefore the best binding capacity.
TABLE-US-00003 TABLE 3 Kinetics binding data summary KD Kon Kon+/-
Kdis Kdis+/- Rmax R2 X2 GB2500 2.75E-07 6.74E+04 3.02E+03 1.85E-02
1.28E-03 1.335 0.984 0.2903 GB2524 3.94E-09 2.38E+05 4.08E+03
9.36E-04 2.54E-05 1.1079 0.997 0.1058 GB2538 1.23E-10 2.21E+05
8.04E+03 2.71E-05 4.37E-05 1.666 0.989 0.3945 GB2540 5.11E-09
1.79E+05 4.09E+03 9.16E-04 2.73E-05 1.127 0.997 0.1335 GB2542
1.49E-10 2.28E+05 8.77E+03 3.39E-05 4.65E-05 1.362 0.987 0.3185
GB2554 4.38E-09 3.99E+05 1.34E+04 1.74E-03 6.00E-05 0.6158 0.988
0.1848 GB2555 3.14E-09 1.95E-05 2.27E+03 6.12E-04 1.82E-05 0.793
0.998 0.0296 All compounds were generated in the same CHO transient
transfection system.
[0242] Binding data from other stradobodies directed against
targets other than Her2/neu are analogous. These other stradobodies
include the GB3500 series directed against EGFR, the GB4500 series
directed against CD20, and the GB7500 series directed against
TNF.
[0243] The results of the study confirmed that GB2542 exhibited
superior multimerization compared to the control mAb and all other
serial stradobody constructs tested, as reported above. In
addition, GB2542 and GB2538 exhibited the most robust binding to
Fc.gamma.RIIIa. Together, the data showing superior multimerization
and Fc.gamma.RIIIa binding capacity of GB2542 were supportive of
the data presented above with regard to the superior ADCC observed
with GB2542.
Example 5. Multimerizing Stradobodies Reduce Serum IgM and B Cells
in the Peripheral Blood in an In Vivo Mouse Model
[0244] Severe Combined Immunodeficiency (SCID) mice were injected
intraperitoneally with 5.times.10.sup.7 human peripheral blood
mononuclear cells (PBMC) at week 0. At weeks 2 through 10, mice
were injected intraperitoneally with PBS, GB4500 (10 nM weekly),
GB4563 (1.7 nM weekly), or GB4542 (1.4 nM weekly). GB4500 was
injected three times per week, while PBS, GB4563, and GB4542 were
each injected one time per week. Therefore, stradobodies were
administered not only less frequently relative to the monoclonal
antibody, but were also given at a lower molar dose. Molarity was
based on the molecular weights estimated from non-reduced SDS-PAGE.
Blood samples were collected at weeks 1, 2, 3, 5, 7, 9, 10, 12, 16,
and 20 relative to the adoptive transfer of human PBMC, and were
evaluated for B cell numbers and serum human IgM. At the endpoint
of the study (i.e., at week 21), mice were euthanized and spleens
were harvested and evaluated for numbers of B cells. The
experimental flow chart is shown schematically in FIG. 18.
[0245] Human IgM in the serum of mice treated with PBS, GB4500,
GB4563, or GB4542 was evaluated by ELISA. The stradobodies GB4563
and GB4542 were as effective as the monoclonal antibody GB4500 in
decreasing human IgM levels (FIG. 19).
[0246] The number of human B cells per mL of peripheral blood
collected from mice treated with PBS, GB4500, GB4563, or GB4542 was
evaluated by flow cytometry. The stradobodies GB4563 and GB4542
were at least as effective as the monoclonal antibody GB4500 in
decreasing human B cells in the peripheral blood (FIG. 20).
[0247] At the end of the study, mice were euthanized and B cells in
the spleen were enumerated by flow cytometry. Stradobody GB4563 was
as effective as monoclonal antibody GB4500 in decreasing the number
of human B cells present in the spleen. Stradobody GB4542, was more
effective than the monoclonal antibody GB4500 in decreasing the
number of human B cells present in the spleen (FIG. 21).
[0248] The results of the study showed that despite the fact that
the stradobodies GB4563 and GB4542 were administered at lower doses
compared to the monoclonal antibody GB4500, the stradobodies were
at least as effective both in reducing serum human IgM levels and
in reducing human B cell numbers. In addition, the anti-CD20
stradobody GB4542 induced B cell depletion better than the
corresponding anti-CD20 monoclonal antibody GB4500.
Example 6. Multimerizing Stradobodies Inhibit Proliferation of B
Cell Lymphoma Cell Lines
[0249] B cell lymphoma cells (Daudi, Ramos, 454B, and 924B cell
lines) were cultured in the presence of various concentrations of
human IgG (negative control), monoclonal antibody GB4500, or the
stradobody GB4542 for 3 days. 0.5 .mu.ci 3H-TdR was added to the
cultures, and incorporation of 3H-TdR was measured in corrected
counts per minute (CCPM) 16 hours later. The inhibition of cell
proliferation was calculated using the formula: (1--experimental
condition CCPM/no treatment CCPM).times.100%. The results of the
study are shown in FIGS. 22 and 23, which are representative of 3
independent experiments. GB4542 was at least as effective at direct
inhibition of cell proliferation as GB4500 in all B lymphocyte cell
lines at all concentrations as measured by .mu.g/mL (FIG. 22) or in
moles (FIG. 23). GB4542 was significantly more effective at direct
inhibition of Ramos cells, 454B cells, and 924B cells at a range of
concentrations in .mu.g/mL and at a range of pmol/mL (FIGS. 22 and
23).
[0250] The results of the study showed that the anti-CD20
stradobody GB4542 mediated enhanced inhibition of proliferation of
B cell lymphoma cell lines in comparison to the corresponding
anti-CD20 monoclonal antibody GB4500.
Example 7. Multimerizing Stradobodies Mediate CDC of B Cell
Lymphoma Cell Lines
[0251] B cell lymphoma cells (Daudi, Ramos, 454B, and 924B cell
lines) were cultured in the presence of various concentrations of
human IgG (negative control), monoclonal antibody GB4500, or
stradobody GB4542 or GB4596, and in the presence or absence of
rabbit complement for 1 hour. The extent of cytoxicity was measured
by flow cytometric analysis of annexin V/7-AAD staining. The
results of the study are shown in FIGS. 24 and 25, which are
representative of 2 independent experiments. Stradobody GB4596 was
as effective as monoclonal antibody GB4500 at CDC at all
concentrations, as measured in .mu.g/mL (FIG. 24) or in moles (FIG.
25). Strikingly, stradobody GB4542 was more effective than
monoclonal antibody GB4500 at all concentrations tested, as
measured in .mu.g/mL (FIG. 24) or in moles (FIG. 25).
[0252] The results of the study indicated that B cell lymphoma cell
lines exhibit increased susceptibility to CDC in the presence of
the anti-CD20 stradobody GB4542, in comparison with its
corresponding anti-CD20 monoclonal antibody, GB4500. These effects
occur at stradobody concentrations that are at least one log order
lower than traditional monoclonal antibody concentrations.
[0253] Together, the data showed that stradobodies induce
equivalent or superior ADCC, CDC, DC, and inhibition of
proliferation of B lymphoma cell lines when compared to the
corresponding monoclonal antibody. The superior activity of
stradobodies was present even when the stradobodies were tested at
a lower concentration relative to the concentration of the
monoclonal antibody. These results indicated that the stradobodies
of the present invention offer a therapeutic benefit over
traditional monoclonal antibodies or other antigen-binding
molecules.
Example 8. Multimerizing Stradobodies Reduce Mean Tumor Volume in
an In Vivo Mouse Model
[0254] Studies were conducted to assess the extent to which a
CD20-specific stradobody exhibits tumor cell killing in vivo,
relative to an anti-CD20 monoclonal antibody sharing the identical
Fab. Severe Combined Immunodeficiency (SCID) mice were injected
subcutaneously with 5.times.10.sup.7 Raji cells at day 0. At day
10, tumor volume reached 100 mm.sup.3, and CD20-specific stradobody
(GB4542) or monoclonal antibody (GB4500) treatment was initiated.
Equimolar GB4542 (13.5 mg/kg) or GB4500 (10 mg/kg) was administered
4 times daily by intratumoral injection with CpG (100 .mu.g per
injection) or without CpG (PBS). Control mice received PBS alone or
PBS with CpG. Tumor size was measured every 1-3 day. Tumor size was
calculated as width.sup.2.times.length/2. When tumor volume reached
2000 m.sup.3, mice were euthanized.
[0255] The results of the study are shown in FIGS. 26 and 27. For
both GB4542 with CpG and GB4500 with CpG groups, the mean (FIG. 26)
and median (FIG. 27) tumor volume remained at or near baseline
levels throughout the study (i.e., through at least day 23).
Treatment with GB4500 in the absence of CpG resulted in about half
the tumor volume of the PBS group at the last timepoint prior to
euthanization that PBS groups were measured (day 18 of both FIGS.
26 and 27). Furthermore, treatment with GB4500 in the absence of
CpG resulted in equal mean (FIG. 26) and median (FIG. 27) tumor
volume compared to the PBS/CpG group at day 18, and only marginally
lower mean tumor volume (FIG. 26) or approximately half of the
median tumor volume (FIG. 27) relative to the PBS/CpG group at the
final timepoint (day 23). In contrast, treatment with GB4542 in the
absence of CpG resulted in a drastic reduction in mean as well as
median tumor volume through day 23 relative to the tumor volume in
mice treated with GB4500 alone (FIGS. 26 and 27, respectively). The
results of the study therefore demonstrate that GB4542 exhibits
superior results relative to the corresponding monoclonal antibody
with respect to mean tumor volume in vivo.
Example 9. Stradobodies Reduce Inflammation in an In Vivo Mouse
Model of Arthritis
[0256] A collagen-induced arthritis (CIA) mouse model is employed
to determine the efficacy of stradobodies in inhibiting the
inflammation, pannus formation, cartilage destruction, and bone
resorption associated with type II collagen arthritis in mice.
[0257] Male mice are anesthetized with Isoflurane and intradermally
administered 150 .mu.l of bovine Type II collagen in Freund's
complete adjuvant (with supplemental M. tuberculosis, 4 mg/mL;
Difco) on study days 0 and 21 of the study. In this model, onset of
arthritis occurs on study days 18-35. Mice are monitored for
clinical signs of disease using the following clinical scoring
scale:
[0258] 0=normal
[0259] 1=1 hind or fore paw joint affected or minimal diffuse
erythema and swelling
[0260] 2=2 hind or fore paw joints affected or mild diffuse
erythema and swelling
[0261] 3=3 hind or fore paw joints affected or moderate diffuse
erythema and swelling
[0262] 4=marked diffuse erythema and swelling, or 4 digit joints
affected
[0263] 5=severe diffuse erythema and severe swelling of entire paw,
unable to flex digits
[0264] One group of mice (n=4) is naive (i.e., is not administered
collagen). All other groups of mice are randomized after collagen
administration to receive intravenous injections of PBS, GB7500
(anti-TNF monoclonal antibody), GB7542 (anti-TNF multimerizing
stradobody), GB4500 (anti-CD20 monoclonal antibody), or GB4542
(anti-CD20 multimerizing stradobody), at the doses indicated below
in Table 4.
TABLE-US-00004 TABLE 4 Groups of mice in collagen-induced arthritis
study Volume per Endotoxin Concentration Dose dose ml/ mg/ # of
Level Cpm Mice mg/ml mg/kg .mu.l vial vial vials Route EU/mg PBS 10
400 4.8 9.6 5 IV <0.05 GB7500 10 0.75 15 400 4.8 3.6 5 IV
<0.07 GB7542 10 1.00 20 400 4.8 4.8 5 IV <0.05 GB4500 10 0.75
15 400 4.8 3.6 5 IV <0.07 GB4542 10 1.00 20 400 4.8 4.8 5 IV
<0.05
[0265] Mice are randomized into one of the five treatment groups
after swelling is obviously established in at least one paw (i.e.,
clinical score of at least 1; the first day that the animal is
graded at a clinical score of 1 is designated arthritis day 1).
[0266] Treatment with PBS, GB7500, GB7542, GB4500, or GB4542 is
initiated after randomization and continued for 10 days. Body
weight is determined on arthritis days 1, 3, 5, 7, 9, and 11; and
paw score is determined on each of arthritis days 1 through 11.
Plasma, serum, and whole blood are collected on various study days
to measure pharmacokinetics and/or anti-collagen responses, for
example using anti-collagen ELISA assays. Animals are necropsied on
arthritis day 11. Tissues, including joints, are collected and
analyzed histologically.
[0267] Clinical data for paw scores are analyzed by determining the
area under the dosing curve (AUC) for arthritis days. For
calculation of AUC, the daily mean scores for each mouse are
entered into Microsoft Excel and the area between the treatment
days after the onset of disease to the termination day is computed.
Means for each group are determined and % inhibition from arthritis
controls is calculated using the following formula:
% Inhibition=A-B/A.times.100
A=Mean Disease Control-Mean Normal
B=Mean Treated-Mean Normal
[0268] Data are analyzed using a Student's t-test or Mann-Whitney U
test (non parametric). If appropriate, data are further analyzed
across all groups, using a one-way analysis of variance (1-way
ANOVA) or Kruskal-Wallis test (non-parametric), along with the
appropriate multiple raw (untransformed) data only. Statistical
tests make certain assumptions regarding the data's normality and
homogeneity of variance, and further analysis may be required if
testing resulted in violations of these assumptions. Significance
for all tests will be set at p<0.05.
[0269] The results of the study will demonstrate that stradobodies
provide superior treatment of CIA relative to monoclonal antibodies
sharing the identical Fab as the stradobody. Specifically, the
study will show that treatment with multimerizing anti-CD20
stradobodies and multimerizing anti-TNF stradobodies results in
reduced development and/or progression of CIA relative to anti-CD20
monoclonal antibodies or anti-TNF monoclonal antibodies,
respectively. The study will show that treatment of CIA with
stradobodies is superior to the corresponding monoclonal antibody
despite the fact that the stradobody and its corresponding
monoclonal antibody share the identical Fab.
Example 10. Multimerizing Stradobodies Exhibit Superior C1q
Complement Binding Relative to the Corresponding Monoclonal
Antibody or to Non-Multimerizing Stradobodies Sharing the Same
Fab
[0270] A complement binding assay was conducted to compare C1q
binding of three multimerizing stradobodies relative to the
corresponding monoclonal antibodies having the same Fabs as the
multimerizing stradobodies.
[0271] ELISA plates were coated with 1 .mu.g/mL in PBS at 100 .mu.L
volume of complement component C1q human serum (Sigma Cat#:
C1740-0.5MG) overnight at 4.degree. C. The plates were washed 3
times with phosphate buffered saline (PBS) containing 0.05% Tween.
Non-specific binding was blocked using PBS containing 1% BSA and
0.05% Tween solution for 2 h at room temperature. Coated wells were
then incubated with experimental compounds at various
concentrations for 2 hours at room temperature. Plates were washed
3 times with PBS containing 0.05% Tween and incubated with 1:5000
biotinylated mouse anti-human IgG1 (Cat#555869, BD Biosciences) and
Strepdavidin-HRP (Cat#: 7100-05 SouthernBiotech) as detection
reagent for 1 hour at room temperature. Wells were washed 3 times
and detected with standard TMB ELISA detection method, and
absorbance was read at 450 nm.
[0272] GB4542 and the corresponding mAb sharing the same Fab
(GB4500), GB7542 and the corresponding mAb sharing the same Fab
(GB7500) and GB2542 and the corresponding mAb sharing the same Fab
(GB2500) were tested for complement C1q binding. Surprisingly, all
three of the multimerizing antibodies tested (GB4542, GB7442, and
GB2542) exhibited exponentially higher complement C1q binding
relative to their corresponding mAbs (FIG. 28). In particular,
GB4542 exhibited an extremely high level of complement C1q binding.
GB4542, GB7542, and GB2542 each share the identical multimerization
domains and Fc regions, and differ only in that each has a
different Fab. Thus, unexpectedly, the Fab on the multimerizing
stradobody affects the level of complement C1q binding.
[0273] The data were log transformed with a curve fit using
GraphPad prism 5, a commercially available software, and the EC50
(in ug/ml) was calculated for each molecule tested. EC50 is the
half-maximal effective concentration and refers to the
concentration of a molecule that gives the half-maximal response.
Strikingly, the EC50 for each stradobody was 10-20 times lower than
the EC50 for the corresponding antibody (FIG. 29). Specifically,
the EC50 for stradobody GB7542 was 8.69, whereas the EC50 for the
corresponding mAb GB7500 was 202.0; the EC50 for stradobody GB4542
was 3.25, whereas the EC50 for the corresponding mAb GB4500 was
34.5; and the EC50 for stradobody GB2542 was 11.0, whereas the EC50
for the corresponding mAb GB2500 could not be determined due to the
extremely low level of C1q binding exhibited by this molecule (FIG.
29). Thus, the concentration of stradobody required to give a
half-maximal complement binding response was at least 10-20 times
lower than that required for a monoclonal antibody having the same
Fab to achieve a half-maximal complement binding response. In
addition, the concentration of stradobody required to give a
half-maximal complement binding response was influenced by the
stradobody's Fab, and not just the multimerizing and Fc regions.
Further complement binding assays were conducted to assess the
complement C1q binding capacity of non-multimerizing stradobodies
relative to their multimerizing counterpart or to the corresponding
monoclonal antibody sharing the same Fab. In order to assess
complement C1q binding, complement assays were conducted as
described above using GB2500, GB2542, and the linear,
non-multimerizing stradobodies GB2554 and GB2555, all four of which
share the same anti Her2/neu Fab. The non-multimerizing
stradobodies GB2554 and GB2555 each exhibited superior complement
C1q binding relative to the monoclonal antibody GB2500 (FIG. 30);
however, the multimerizing stradobody GB2542 exhibited far superior
complement C1q binding compared to either of the non-multimerizing
stradobodies (FIG. 30). Furthermore, the EC50 value for the
multimerizing stradobody GB2542 was 2.5-7.0 times lower than the
EC50 values for GB2554 and GB2555. Specifically, the EC50 value for
complement C1q binding for GB2542 was 3.83, whereas the EC50 value
for complement C1q binding for GB2554 and GB2555 were 26.4 and
9.45, respectively (FIG. 31).
[0274] The results of the study indicated that, unexpectedly,
multimerizing stradobodies exhibited dramatically superior
complement binding relative to the corresponding monoclonal
antibody sharing the same Fab. The results also indicated that
while non-multimerizing stradobodies exhibit superior complement
binding relative to the corresponding monoclonal antibody sharing
the same Fab, multimerizing stradobodies exhibit far superior
complement binding relative to non-multimerizing stradobodies
sharing the same Fab. Finally, the study showed that the Fab on the
multimerizing stradobody dramatically affects the amount of C1q
binding.
[0275] All, documents, patents, patent applications, publications,
product descriptions, and protocols which are cited throughout this
application are incorporated herein by reference in their
entireties for all purposes.
[0276] The embodiments illustrated and discussed in this
specification are intended only to teach those skilled in the art
the best way known to the inventors to make and use the invention.
Modifications and variation of the above-described embodiments of
the invention are possible without departing from the invention, as
appreciated by those skilled in the art in light of the above
teachings. It is therefore understood that, within the scope of the
claims and their equivalents, the invention may be practiced
otherwise than as specifically described.
Sequence CWU 1
1
91120PRTHomo sapiens 1Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly 20 2232PRTHomo
sapiens 2Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115
120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu
Ser Leu Ser Pro Gly Lys 225 230 312PRTHomo sapiens 3Glu Arg Lys Cys
Cys Val Glu Cys Pro Pro Cys Pro 1 5 10 4264PRTHomo sapiens 4Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
Gly Ser Thr Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 20
25 30 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe 35 40 45 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val 50 55 60 Thr Cys Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe 65 70 75 80 Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro 85 90 95 Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr 100 105 110 Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125 Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 130 135 140 Lys
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 145 150
155 160 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
Gly 165 170 175 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro 180 185 190 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser 195 200 205 Phe Phe Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln 210 215 220 Gly Asn Val Phe Ser Cys Ser
Val Met His Glu Ala Leu His Asn His 225 230 235 240 Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys Glu Arg Lys Cys 245 250 255 Cys Val
Glu Cys Pro Pro Cys Pro 260 541PRTHomo sapiens 5Gly Gly Gly Ser Ile
Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu 1 5 10 15 Ser Lys Ile
Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu 20 25 30 Ile
Gly Glu Arg Gly His Gly Gly Gly 35 40 6245PRTHomo sapiens 6Asp Ala
Ala Asp Ile Gln His Ser Gly Gly Arg Ser Ser Glu Pro Lys 1 5 10 15
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 20
25 30 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
Thr 35 40 45 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
Val Asp Val 50 55 60 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val Asp Gly Val 65 70 75 80 Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu Glu Gln Tyr Asn Ser 85 90 95 Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu 100 105 110 Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 115 120 125 Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 130 135 140 Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 145 150
155 160 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala 165 170 175 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr 180 185 190 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu 195 200 205 Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser 210 215 220 Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser 225 230 235 240 Leu Ser Pro Gly
Lys 245 7260PRTHomo sapiens 7Asp Ala Ala Asp Ile Gln His Ser Gly
Gly Arg Ser Ser Glu Pro Lys 1 5 10 15 Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys Pro Ala Pro Glu Leu 20 25 30 Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 35 40 45 Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 50 55 60 Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 65 70
75 80 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
Ser 85 90 95 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp Trp Leu 100 105 110 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu Pro Ala 115 120 125 Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro 130 135 140 Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu Met Thr Lys Asn Gln 145 150 155 160 Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 165 170 175 Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 180 185 190
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 195
200 205 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser 210 215 220 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
Ser Leu Ser 225 230 235 240 Leu Ser Pro Gly Lys Ser Leu Glu Glu Arg
Lys Cys Cys Val Glu Cys 245 250 255 Pro Pro Cys Pro 260 8264PRTHomo
sapiens 8Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp
Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Arg Lys Cys Cys Val Glu Cys
Pro Pro Cys Pro 20 25 30 Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys Pro Ala 35 40 45 Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro 50 55 60 Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80 Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95 Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 100 105 110
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 115
120 125 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Ala 130 135 140 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln Pro 145 150 155 160 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu Met Thr 165 170 175 Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro Ser 180 185 190 Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 195 200 205 Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 210 215 220 Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 225 230 235
240 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
245 250 255 Ser Leu Ser Leu Ser Pro Gly Lys 260 9294PRTHomo sapiens
9Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Gly Gly Ser Ile Lys Gln Ile Glu Asp Lys Ile
Glu 20 25 30 Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile
Ala Arg Ile 35 40 45 Lys Lys Leu Ile Gly Glu Arg Gly His Gly Gly
Gly Ser Ser Glu Pro 50 55 60 Lys Ser Cys Asp Lys Thr His Thr Cys
Pro Pro Cys Pro Ala Pro Glu 65 70 75 80 Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp 85 90 95 Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 100 105 110 Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 115 120 125 Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 130 135
140 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
145 150 155 160 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro 165 170 175 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu 180 185 190 Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu Met Thr Lys Asn 195 200 205 Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile 210 215 220 Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 225 230 235 240 Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 245 250 255
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 260
265 270 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu 275 280 285 Ser Leu Ser Pro Gly Lys 290 10289PRTHomo sapiens
10Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
Pro 20 25 30 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe 35 40 45 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val 50 55 60 Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe 65 70 75 80 Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro 85 90 95 Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 100 105 110 Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125 Ser
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 130 135
140 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
145 150 155 160 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly 165 170 175 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro 180 185 190 Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser 195 200 205 Phe Phe Leu Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln 210 215 220 Gly Asn Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn His 225 230 235 240 Tyr Thr
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Ser 245 250 255
Ile Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr 260
265 270 His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
Arg 275 280 285 Gly 11266PRTMus sp. 11Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp
Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 20 25 30 Pro Cys Lys
Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe 35 40 45 Ile
Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro 50 55
60 Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val
65 70 75 80 Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
Gln Thr 85 90 95 Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
Val Val Ser Ala 100 105 110 Leu Pro Ile Gln His Gln Asp Trp Met Ser
Gly Lys Glu Phe Lys Cys 115 120 125 Lys Val Asn Asn Lys Asp Leu Pro
Ala Pro Ile Glu Arg Thr Ile Ser 130 135 140 Lys Pro Lys Gly Ser Val
Arg Ala Pro Gln Val Tyr Val Leu Pro Pro 145 150 155 160 Pro Glu Glu
Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val 165 170 175 Thr
Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly 180 185
190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp
195 200 205 Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys
Asn Trp 210 215 220 Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
Glu Gly Leu His 225 230 235 240 Asn His His Thr Thr Lys Ser Phe Ser
Arg Thr Pro Gly Lys Glu Arg 245 250 255 Lys Cys Cys Val Glu Cys Pro
Pro Cys Pro 260 265 12278PRTMus sp. 12Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp
Ala Ala Asp Ile Gln His Ser Gly Gly Arg Ser 20 25 30 Arg Glu Pro
Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys 35 40 45 Pro
Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro 50 55
60 Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
65 70 75 80 Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile
Ser Trp
85 90 95 Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr
His Arg 100 105 110 Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala
Leu Pro Ile Gln 115 120 125 His Gln Asp Trp Met Ser Gly Lys Glu Phe
Lys Cys Lys Val Asn Asn 130 135 140 Lys Asp Leu Pro Ala Pro Ile Glu
Arg Thr Ile Ser Lys Pro Lys Gly 145 150 155 160 Ser Val Arg Ala Pro
Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu 165 170 175 Met Thr Lys
Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met 180 185 190 Pro
Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu 195 200
205 Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
210 215 220 Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu
Arg Asn 225 230 235 240 Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu
His Asn His His Thr 245 250 255 Thr Lys Ser Phe Ser Arg Thr Pro Gly
Lys Glu Arg Lys Cys Cys Val 260 265 270 Glu Cys Pro Pro Cys Pro 275
13265PRTMus sp. 13Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu
Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro 20 25 30 Glu Pro Arg Gly Pro Thr Ile Lys
Pro Cys Pro Pro Cys Lys Cys Pro 35 40 45 Ala Pro Asn Leu Leu Gly
Gly Pro Ser Val Phe Ile Phe Pro Pro Lys 50 55 60 Ile Lys Asp Val
Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val 65 70 75 80 Val Val
Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe 85 90 95
Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu 100
105 110 Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
His 115 120 125 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val
Asn Asn Lys 130 135 140 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser
Lys Pro Lys Gly Ser 145 150 155 160 Val Arg Ala Pro Gln Val Tyr Val
Leu Pro Pro Pro Glu Glu Glu Met 165 170 175 Thr Lys Lys Gln Val Thr
Leu Thr Cys Met Val Thr Asp Phe Met Pro 180 185 190 Glu Asp Ile Tyr
Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 195 200 205 Tyr Lys
Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 210 215 220
Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 225
230 235 240 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His
Thr Thr 245 250 255 Lys Ser Phe Ser Arg Thr Pro Gly Lys 260 265
14287PRTMus sp. 14Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu
Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Ser Ile Lys Gln Ile Glu
Asp Lys Ile Glu Glu Ile 20 25 30 Leu Ser Lys Ile Tyr His Ile Glu
Asn Glu Ile Ala Arg Ile Lys Lys 35 40 45 Leu Ile Gly Glu Arg Gly
Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys 50 55 60 Pro Pro Cys Lys
Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val 65 70 75 80 Phe Ile
Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser 85 90 95
Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp 100
105 110 Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
Gln 115 120 125 Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
Val Val Ser 130 135 140 Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser
Gly Lys Glu Phe Lys 145 150 155 160 Cys Lys Val Asn Asn Lys Asp Leu
Pro Ala Pro Ile Glu Arg Thr Ile 165 170 175 Ser Lys Pro Lys Gly Ser
Val Arg Ala Pro Gln Val Tyr Val Leu Pro 180 185 190 Pro Pro Glu Glu
Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met 195 200 205 Val Thr
Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn 210 215 220
Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser 225
230 235 240 Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
Lys Asn 245 250 255 Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val
His Glu Gly Leu 260 265 270 His Asn His His Thr Thr Lys Ser Phe Ser
Arg Thr Pro Gly Lys 275 280 285 15291PRTMus sp. 15Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Asp Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 20 25 30
Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe 35
40 45 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
Pro 50 55 60 Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
Pro Asp Val 65 70 75 80 Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val
His Thr Ala Gln Thr 85 90 95 Gln Thr His Arg Glu Asp Tyr Asn Ser
Thr Leu Arg Val Val Ser Ala 100 105 110 Leu Pro Ile Gln His Gln Asp
Trp Met Ser Gly Lys Glu Phe Lys Cys 115 120 125 Lys Val Asn Asn Lys
Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 130 135 140 Lys Pro Lys
Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro 145 150 155 160
Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val 165
170 175 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
Gly 180 185 190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
Asp Ser Asp 195 200 205 Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val
Glu Lys Lys Asn Trp 210 215 220 Val Glu Arg Asn Ser Tyr Ser Cys Ser
Val Val His Glu Gly Leu His 225 230 235 240 Asn His His Thr Thr Lys
Ser Phe Ser Arg Thr Pro Gly Lys Gly Gly 245 250 255 Gly Ser Ile Lys
Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys 260 265 270 Ile Tyr
His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly 275 280 285
Glu Arg Gly 290 16299PRTMus sp. 16Met Glu Thr Asp Thr Leu Leu Leu
Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ala
Ala Asp Ile Gln His Ser Gly Gly Arg Ser 20 25 30 Ser Ile Lys Gln
Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile 35 40 45 Tyr His
Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu 50 55 60
Arg Gly Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys 65
70 75 80 Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile
Phe Pro 85 90 95 Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
Pro Ile Val Thr 100 105 110 Cys Val Val Val Asp Val Ser Glu Asp Asp
Pro Asp Val Gln Ile Ser 115 120 125 Trp Phe Val Asn Asn Val Glu Val
His Thr Ala Gln Thr Gln Thr His 130 135 140 Arg Glu Asp Tyr Asn Ser
Thr Leu Arg Val Val Ser Ala Leu Pro Ile 145 150 155 160 Gln His Gln
Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn 165 170 175 Asn
Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys 180 185
190 Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu
195 200 205 Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr
Asp Phe 210 215 220 Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn
Gly Lys Thr Glu 225 230 235 240 Leu Asn Tyr Lys Asn Thr Glu Pro Val
Leu Asp Ser Asp Gly Ser Tyr 245 250 255 Phe Met Tyr Ser Lys Leu Arg
Val Glu Lys Lys Asn Trp Val Glu Arg 260 265 270 Asn Ser Tyr Ser Cys
Ser Val Val His Glu Gly Leu His Asn His His 275 280 285 Thr Thr Lys
Ser Phe Ser Arg Thr Pro Gly Lys 290 295 17753DNAHomo sapiens
17atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt
60gagcgcaaat gttgtgtgga gtgcccaccg tgcccagcac ctgaactcct ggggggaccg
120tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg
gacccctgag 180gtcacatgcg tggtggtgga cgtgagccac gaagaccctg
aggtcaagtt caactggtac 240gtggacggcg tggaggtgca taatgccaag
acaaagccgc gggaggagca gtacaacagc 300acgtaccgtg tggtcagcgt
cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 360tacaagtgca
aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa
420gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg
ggaggagatg 480accaagaacc aggtcagcct gacctgcctg gtcaaaggct
tctatcccag cgacatcgcc 540gtggagtggg agagcaatgg gcagccggag
aacaactaca agaccacgcc tcccgtgctg 600gactccgacg gctccttctt
cctctatagc aagctcaccg tggacaagag caggtggcag 660caggggaacg
tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag
720aagagcctct ccctgtcccc gggtaaatga taa 75318249PRTHomo sapiens
18Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys
Pro 20 25 30 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys 35 40 45 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val 50 55 60 Val Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr 65 70 75 80 Val Asp Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu 85 90 95 Gln Tyr Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His 100 105 110 Gln Asp Trp
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 115 120 125 Ala
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 130 135
140 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
145 150 155 160 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro 165 170 175 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn 180 185 190 Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu 195 200 205 Tyr Ser Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val 210 215 220 Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 225 230 235 240 Lys Ser
Leu Ser Leu Ser Pro Gly Lys 245 19217PRTHomo sapiens 19Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25
30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu 50 55 60 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys 85 90 95 Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 115 120 125 Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155
160 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
165 170 175 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
His Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Pro Gly Lys 210
215 20264PRTHomo sapiens 20Met Glu Thr Asp Thr Leu Leu Leu Trp Val
Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro 20 25 30 Pro Cys Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 35 40 45 Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 50 55 60 Thr Cys
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 65 70 75 80
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 85
90 95 Arg Glu Glu Gln Tyr Asn Ala Thr Tyr Arg Val Val Ser Val Leu
Thr 100 105 110 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val 115 120 125 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala 130 135 140 Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg 145 150 155 160 Glu Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly 165 170 175 Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 180 185 190 Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 195 200 205
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 210
215 220 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
His 225 230 235 240 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
Glu Arg Lys Cys 245 250 255 Cys Val Glu Cys Pro Pro Cys Pro 260
21264PRTHomo sapiens 21Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro 20 25 30 Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe 35 40 45 Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 50 55 60 Thr Cys Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 65 70 75 80 Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 85 90
95 Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Ala Val Val Ser Val Leu Thr 100 105 110 Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 130
135 140 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg 145 150 155 160 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly 165 170 175 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 180 185 190 Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser 195 200 205 Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 210 215 220 Gly Asn Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His 225 230 235 240 Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Glu Arg Lys Cys 245 250
255 Cys Val Glu Cys Pro Pro Cys Pro 260 22266PRTMus sp. 22Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
Gly Ser Thr Gly Asp Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 20
25 30 Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
Phe 35 40 45 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
Leu Ser Pro 50 55 60 Ile Val Thr Cys Val Val Val Asp Val Ser Glu
Asp Asp Pro Asp Val 65 70 75 80 Gln Ile Ser Trp Phe Val Asn Asn Val
Glu Val His Thr Ala Gln Thr 85 90 95 Gln Thr His Arg Glu Asp Tyr
Asn Ala Thr Leu Arg Val Val Ser Ala 100 105 110 Leu Pro Ile Gln His
Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys 115 120 125 Lys Val Asn
Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 130 135 140 Lys
Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro 145 150
155 160 Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
Val 165 170 175 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
Asn Asn Gly 180 185 190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
Val Leu Asp Ser Asp 195 200 205 Gly Ser Tyr Phe Met Tyr Ser Lys Leu
Arg Val Glu Lys Lys Asn Trp 210 215 220 Val Glu Arg Asn Ser Tyr Ser
Cys Ser Val Val His Glu Gly Leu His 225 230 235 240 Asn His His Thr
Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys Glu Arg 245 250 255 Lys Cys
Cys Val Glu Cys Pro Pro Cys Pro 260 265 23266PRTMus sp. 23Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
Gly Ser Thr Gly Asp Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 20
25 30 Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val
Phe 35 40 45 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
Leu Ser Pro 50 55 60 Ile Val Thr Cys Val Val Val Asp Val Ser Glu
Asp Asp Pro Asp Val 65 70 75 80 Gln Ile Ser Trp Phe Val Asn Asn Val
Glu Val His Thr Ala Gln Thr 85 90 95 Gln Thr His Arg Glu Asp Tyr
Asn Ser Thr Leu Ala Val Val Ser Ala 100 105 110 Leu Pro Ile Gln His
Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys 115 120 125 Lys Val Asn
Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 130 135 140 Lys
Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro 145 150
155 160 Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met
Val 165 170 175 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
Asn Asn Gly 180 185 190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro
Val Leu Asp Ser Asp 195 200 205 Gly Ser Tyr Phe Met Tyr Ser Lys Leu
Arg Val Glu Lys Lys Asn Trp 210 215 220 Val Glu Arg Asn Ser Tyr Ser
Cys Ser Val Val His Glu Gly Leu His 225 230 235 240 Asn His His Thr
Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys Glu Arg 245 250 255 Lys Cys
Cys Val Glu Cys Pro Pro Cys Pro 260 265 24282PRTHomo sapiens 24Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
20 25 30 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe 35 40 45 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
Thr Pro Glu Val 50 55 60 Thr Cys Val Val Val Asp Val Ser His Glu
Asp Pro Glu Val Lys Phe 65 70 75 80 Asn Trp Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro 85 90 95 Arg Glu Glu Gln Tyr Asn
Ala Thr Tyr Arg Val Val Ser Val Leu Thr 100 105 110 Val Leu His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125 Ser Asn
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 130 135 140
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 145
150 155 160 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly 165 170 175 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro 180 185 190 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser 195 200 205 Phe Phe Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln 210 215 220 Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His 225 230 235 240 Tyr Thr Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Pro Pro Gly 245 250 255 Pro
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro 260 265
270 Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 275 280 25284PRTMus sp.
25Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Asp Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
Pro 20 25 30 Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
Ser Val Phe 35 40 45 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met
Ile Ser Leu Ser Pro 50 55 60 Ile Val Thr Cys Val Val Val Asp Val
Ser Glu Asp Asp Pro Asp Val 65 70 75 80 Gln Ile Ser Trp Phe Val Asn
Asn Val Glu Val His Thr Ala Gln Thr 85 90 95 Gln Thr His Arg Glu
Asp Tyr Asn Ala Thr Leu Arg Val Val Ser Ala 100 105 110 Leu Pro Ile
Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys 115 120 125 Lys
Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 130 135
140 Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro
145 150 155 160 Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
Cys Met Val 165 170 175 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu
Trp Thr Asn Asn Gly 180 185 190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr
Glu Pro Val Leu Asp Ser Asp 195 200 205 Gly Ser Tyr Phe Met Tyr Ser
Lys Leu Arg Val Glu Lys Lys Asn Trp 210 215 220 Val Glu Arg Asn Ser
Tyr Ser Cys Ser Val Val His Glu Gly Leu His 225 230 235 240 Asn His
His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys Gly Pro 245 250 255
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 260
265 270 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 275 280
2630PRTArtificial SequenceGPP multimerization domain 26Gly Pro Pro
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly 1 5 10 15 Pro
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 20 25 30
27282PRTHomo sapiens 27Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro 20 25 30 Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe 35 40 45 Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 50 55 60 Thr Cys Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 65 70 75 80 Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 85 90
95 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
100 105 110 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val 115 120 125 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala 130 135 140 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg 145 150 155 160 Glu Glu Met Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly 165 170 175 Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 180 185 190 Glu Asn Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 195 200 205 Phe
Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 210 215
220 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
225 230 235 240 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly
Pro Pro Gly 245 250 255 Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
Gly Pro Pro Gly Pro 260 265 270 Pro Gly Pro Pro Gly Pro Pro Gly Pro
Pro 275 280 28282PRTHomo sapiens 28Met Glu Thr Asp Thr Leu Leu Leu
Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gly Pro
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 20 25 30 Gly Pro Pro Gly
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly 35 40 45 Pro Pro
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 50 55 60
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 65
70 75 80 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys 85 90 95 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp 100 105 110 Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu 115 120 125 Glu Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu 130 135 140 His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 145 150 155 160 Lys Ala Leu
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 165 170 175 Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 180 185
190 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
195 200 205 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 210 215 220 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 225 230 235 240 Leu Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn 245 250 255 Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His Tyr Thr 260 265 270 Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 275 280 29284PRTMus sp. 29Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr
Gly Asp Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 20 25 30 Pro
Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe 35 40
45 Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro
50 55 60 Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
Asp Val 65 70 75 80 Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
Thr Ala Gln Thr 85 90 95 Gln Thr His Arg Glu Asp Tyr Asn Ser Thr
Leu Arg Val Val Ser Ala 100 105 110 Leu Pro Ile Gln His Gln Asp Trp
Met Ser Gly Lys Glu Phe Lys Cys 115 120 125 Lys Val Asn Asn Lys Asp
Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser 130 135 140 Lys Pro Lys Gly
Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro 145 150 155 160 Pro
Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val 165 170
175 Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly
180 185 190 Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp
Ser Asp 195 200 205 Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu
Lys Lys Asn Trp 210 215 220 Val Glu Arg Asn Ser Tyr Ser Cys Ser Val
Val His Glu Gly Leu His 225 230 235 240 Asn His His Thr Thr Lys Ser
Phe Ser Arg Thr Pro Gly Lys Gly Pro 245 250 255 Pro Gly Pro Pro Gly
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 260 265 270 Gly Pro Pro
Gly Pro Pro Gly Pro Pro Gly Pro Pro 275 280 30283PRTMus sp. 30Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
20 25 30 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
Pro Gly 35 40 45 Pro Pro Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys
Pro Pro Cys Lys 50 55 60 Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
Ser Val Phe Ile Phe Pro 65 70 75 80 Pro Lys Ile Lys Asp Val Leu Met
Ile Ser Leu Ser Pro Ile Val Thr 85 90 95 Cys Val Val Val Asp Val
Ser Glu Asp Asp Pro Asp Val Gln Ile Ser 100 105 110 Trp Phe Val Asn
Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His 115 120 125 Arg Glu
Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu
Pro Ile 130 135 140 Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
Cys Lys Val Asn 145 150 155 160 Asn Lys Asp Leu Pro Ala Pro Ile Glu
Arg Thr Ile Ser Lys Pro Lys 165 170 175 Gly Ser Val Arg Ala Pro Gln
Val Tyr Val Leu Pro Pro Pro Glu Glu 180 185 190 Glu Met Thr Lys Lys
Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe 195 200 205 Met Pro Glu
Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu 210 215 220 Leu
Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr 225 230
235 240 Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu
Arg 245 250 255 Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His
Asn His His 260 265 270 Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
275 280 31217PRTHomo sapiens 31Gln Val Gln Leu Lys Gln Ser Gly Pro
Gly Leu Val Gln Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr
Val Ser Gly Phe Ser Leu Thr Asn Tyr 20 25 30 Gly Val His Trp Val
Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile
Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60 Ser
Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 65 70
75 80 Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys
Ala 85 90 95 Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp
Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys
Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr
Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr
Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195
200 205 Ser Asn Thr Lys Val Asp Lys Arg Val 210 215 3240PRTHomo
sapiens 32Gly Gly Gly Ser Ile Lys Gln Ile Glu Asp Lys Ile Glu Glu
Ile Leu 1 5 10 15 Ser Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg
Ile Lys Lys Leu 20 25 30 Ile Gly Glu Arg Gly His Asp Ile 35 40
33764PRTHomo sapiens 33Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Lys
Gln Ser Gly Pro Gly Leu Val 20 25 30 Gln Pro Ser Gln Ser Leu Ser
Ile Thr Cys Thr Val Ser Gly Phe Ser 35 40 45 Leu Thr Asn Tyr Gly
Val His Trp Val Arg Gln Ser Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn 65 70 75 80 Thr
Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser 85 90
95 Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile
100 105 110 Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe
Ala Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala
Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205 Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215
220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340
345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445 Val Met
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460
Leu Ser Pro Gly Lys Ser Leu Glu Gly Gly Gly Ser Ile Lys Gln Ile 465
470 475 480 Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile
Glu Asn 485 490 495 Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg
Gly His Asp Ile 500 505 510 Glu Arg Lys Cys Cys Val Glu Cys Pro Pro
Cys Pro Arg Leu Glu Gly 515 520 525 Pro Arg Phe Glu Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro 530 535 540 Pro Cys Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 545 550 555 560 Pro Pro Lys
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 565 570 575 Thr
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 580 585
590 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
595 600 605 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr 610 615 620 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val 625 630 635 640 Ser Asn Lys Ala Leu Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala 645 650 655 Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg 660 665 670 Glu Glu Met Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 675 680 685 Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 690 695 700 Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 705 710
715 720 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln 725 730 735 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His 740 745 750 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 755 760 34218PRTHomo sapiens 34Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg
Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp
Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser
Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys
Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185
190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val 210 215
35765PRTHomo sapiens 35Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90
95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala
Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215
220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340
345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460
Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Gly Gly Ser Ile Lys Gln 465
470 475 480 Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His
Ile Glu 485 490 495 Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
Arg Gly His Asp 500 505 510 Ile Glu Arg Lys Cys Cys Val Glu Cys Pro
Pro Cys Pro Arg Leu Glu 515 520 525 Gly Pro Arg Phe Glu Glu Pro Lys
Ser Cys Asp Lys Thr His Thr Cys 530 535 540 Pro Pro Cys Pro Ala Pro
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 545 550 555 560 Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 565 570 575 Val
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 580 585
590 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
595 600 605 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
Val Leu 610 615 620 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Lys 625 630 635 640 Val Ser Asn Lys Ala Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys 645 650 655 Ala Lys Gly Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser 660 665 670 Arg Glu Glu Met Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 675 680 685 Gly Phe Tyr
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 690 695 700 Pro
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 705 710
715 720 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln 725 730 735 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His Asn 740 745 750 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly Lys 755 760 765 36219PRTHomo sapiens 36Gln Val Gln Leu Gln Gln
Pro Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met
His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile 35 40 45
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50
55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
Tyr Tyr Cys 85 90 95 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr
Phe Asn Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ala
Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly Gly Thr Ala 130
135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys
Val Asp Lys Lys Val 210 215 37766PRTHomo sapiens 37Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val 20 25 30
Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 35
40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg
Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp
Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr
Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys Ala Arg Ser
Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val Trp Gly Ala
Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135 140 Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165
170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290
295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410
415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu
Gly Gly Gly Ser Ile Lys 465 470 475 480 Gln Ile Glu Asp Lys Ile Glu
Glu Ile Leu Ser Lys Ile Tyr His Ile 485 490 495 Glu Asn Glu Ile Ala
Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 500 505 510 Asp Ile Glu
Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Arg Leu 515 520 525 Glu
Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys Thr His Thr 530 535
540 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
545 550 555 560 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro 565 570 575 Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val 580 585 590 Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr 595 600 605 Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val 610 615 620 Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 625 630 635 640 Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 645 650 655
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 660
665 670 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val 675 680 685 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly 690 695 700 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp 705 710 715 720 Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp 725 730 735 Gln Gln Gly Asn Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His 740 745 750 Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 755 760 765 38450PRTHomo
sapiens 38Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn
Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly
Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg
Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115
120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235
240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360
365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450
39214PRTHomo sapiens 39Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe
Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90
95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu
Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe
Asn Arg Gly Glu Cys 210 40470PRTHomo sapiens 40Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr
Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40
45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly
50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr
Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala
Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly
Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170
175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285 Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295
300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Ala Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420
425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
Cys 435 440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly Lys 465 470
41234PRTHomo sapiens 41Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser 20 25 30 Ala Ser Val Gly Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Asp 35 40 45 Val Asn Thr Ala Val
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 50 55 60 Lys Leu Leu
Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser 65 70 75 80 Arg
Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 85 90
95 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr
100 105 110 Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
Lys Arg 115 120 125 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu Gln 130 135 140 Leu Lys Ser Gly Thr Ala Ser Val Val Cys
Leu Leu Asn Asn Phe Tyr 145 150 155 160 Pro Arg Glu Ala Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175 Gly Asn Ser Gln Glu
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190 Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205 His
Lys Leu Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215
220 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 42497PRTHomo
sapiens 42Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp
Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg
Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65
70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr
Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp
Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185
190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys
Pro Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310
315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435
440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu 450 455 460 Ser Leu Ser Pro Gly Lys Glu Pro Lys Ser Cys Asp Lys
Thr His Thr 465 470 475 480 Cys Pro Pro Cys Pro Glu Arg Lys Cys Cys
Val Glu Cys Pro Pro Cys 485 490 495 Pro 43467PRTHomo sapiens 43Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
20 25 30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Asn 35 40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala
Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr
Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe
Thr Ile Ser Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys
Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145
150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys Lys Val Glu Arg 225 230 235 240 Lys Cys Cys
Val Glu Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 245 250 255 Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265
270 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
275 280 285 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val 290 295 300 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr 305 310 315 320 Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly 325 330 335 Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile 340 345 350 Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365 Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380 Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 385 390
395 400 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro 405 410 415 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val 420 425 430 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val Met 435 440 445 His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser 450 455 460 Pro Gly Lys 465
44512PRTHomo sapiens 44Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90
95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala
Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215
220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340
345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460
Ser Leu Ser Pro Gly Lys Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly 465
470 475 480 Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
Gly Pro 485 490 495 Pro Gly Pro Pro Glu Arg Lys Cys Cys Val Glu Cys
Pro Pro Cys Pro 500 505 510 45512PRTHomo sapiens 45Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn 35
40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys
Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr
Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp
Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165
170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Lys Val Gly Pro 225 230 235 240 Pro Gly Pro Pro Gly Pro
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 245 250 255 Gly Pro Pro Gly
Pro Pro Gly Pro Pro Gly Pro Pro Glu Arg Lys Cys 260 265 270 Cys Val
Glu Cys Pro Pro Cys Pro Glu Pro Lys Ser Cys Asp Lys Thr 275 280 285
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 290
295 300 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg 305 310 315 320 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu Asp Pro 325 330 335 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala 340 345 350 Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val Val 355 360 365 Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 370 375 380 Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 385 390 395 400 Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 405 410
415 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
420 425 430 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser 435 440 445 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp 450 455 460 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser 465 470 475 480 Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala 485 490 495 Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 500 505 510
46729PRTHomo sapiens 46Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90
95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala
Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215
220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340
345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn 370 375
380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 465 470 475 480 Gly Gly
Gly Gly Ser Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 485 490 495
Pro Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 500
505 510 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys 515 520 525 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val 530 535 540 Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr 545 550 555 560 Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu 565 570 575 Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His 580 585 590 Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 595 600 605 Ala Leu
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 610 615 620
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 625
630 635 640 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro 645 650 655 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn 660 665 670 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu 675 680 685 Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val 690 695 700 Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His Tyr Thr Gln 705 710 715 720 Lys Ser Leu
Ser Leu Ser Pro Gly Lys 725 47754PRTHomo sapiens 47Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn 35
40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys
Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr
Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp
Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165
170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290
295 300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn 305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400 Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410
415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly Lys Ser Val Glu Gly
Gly Gly Ser Ile Lys Gln 465 470 475 480 Ile Glu Asp Lys Ile Glu Glu
Ile Leu Ser Lys Ile Tyr His Ile Glu 485 490 495 Asn Glu Ile Ala Arg
Ile Lys Lys Leu Ile Gly Glu Arg Gly His Gly 500 505 510 Gly Gly Arg
Leu Glu Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp 515 520 525 Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 530 535
540 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
545 550 555 560 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
Ser His Glu 565 570 575 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
Gly Val Glu Val His 580 585 590 Asn Ala Lys Thr Lys Pro Arg Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg 595 600 605 Val Val Ser Val Leu Thr Val
Leu His Gln Asp Trp Leu Asn Gly Lys 610 615 620 Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 625 630 635 640 Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 645 650 655
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 660
665 670 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp 675 680 685 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val 690 695 700 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp 705 710 715 720 Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe Ser Cys Ser Val Met His 725 730 735 Glu Ala Leu His Asn His
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 740 745 750 Gly Lys
48725PRTHomo sapiens 48Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90
95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala
Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215
220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340
345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460
Ser Leu Ser Pro Gly Lys Ser Leu Glu Glu Arg Lys Cys Cys Val Glu 465
470 475 480 Cys Pro Pro Cys Pro Arg Leu Glu Gly Pro Arg Phe Glu Glu
Pro Lys 485 490 495 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu Leu 500 505 510 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr 515 520 525 Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val 530 535 540 Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val 545 550 555 560 Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 565 570 575 Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 580 585
590 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
595 600 605 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro 610 615 620 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn Gln 625 630 635 640 Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala 645 650 655 Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr 660 665 670 Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 675 680 685 Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 690 695 700 Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 705 710
715 720 Leu Ser Pro Gly Lys 725 49719PRTHomo sapiens 49Met Glu Thr
Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly
Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25
30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn
35 40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly
Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly
Tyr Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg
Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155
160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280
285 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn 305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405
410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly Lys Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser 465
470 475 480 Gly Gly Gly Gly Ser Phe Glu Glu Pro Lys Ser Cys Asp Lys
Thr His 485 490 495 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val 500 505 510 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr 515 520 525 Pro Glu Val Thr Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu 530 535 540 Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys 545 550 555 560 Thr Lys Pro
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 565 570 575 Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 580 585
590 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
595 600 605 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro 610 615 620 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu 625 630 635 640 Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn 645 650 655 Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser 660 665 670 Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 675 680 685 Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 690 695 700 His
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 705 710 715
50710PRTHomo sapiens 50Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90
95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala
Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys
Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215
220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340
345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460
Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu Glu Pro 465
470 475 480 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
Pro Glu 485 490 495 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp 500 505 510 Thr Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp 515 520 525 Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly 530 535 540 Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 545 550 555 560 Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 565 570 575 Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 580 585
590 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
595 600 605 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
Lys Asn 610 615 620 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile 625 630 635 640 Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr 645 650 655 Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys 660 665 670 Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 675 680 685 Ser Val Met
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 690 695 700 Ser
Leu Ser Pro Gly Lys 705 710 51471PRTMus sp. 51Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr
Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40
45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly
50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr
Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala
Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly
Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170
175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys Lys Val Glu Pro 225 230 235 240 Arg Gly Pro Thr Ile Lys Pro
Cys Pro Pro Cys Lys Cys Pro Ala Pro 245 250 255 Asn Leu Leu Gly Gly
Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys 260 265 270 Asp Val Leu
Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val 275 280 285 Asp
Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn 290 295
300 Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr
305 310 315 320 Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
His Gln Asp 325 330 335 Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val
Asn Asn Lys Asp Leu 340 345 350 Pro Ala Pro Ile Glu Arg Thr Ile Ser
Lys Pro Lys Gly Ser Val Arg 355 360 365 Ala Pro Gln Val Tyr Val Leu
Pro Pro Pro Glu Glu Glu Met Thr Lys 370 375 380 Lys Gln Val Thr Leu
Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp 385 390 395 400 Ile Tyr
Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys 405 410 415
Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 420
425 430 Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
Ser 435 440 445 Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
Thr Lys Ser 450 455 460 Phe Ser Arg Thr Pro Gly Lys 465 470
52467PRTMus sp. 52Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu
Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr Ile
His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val
Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala Asp
Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90 95
Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100
105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met
Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Arg 225
230 235 240 Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Asn Leu
Leu Gly 245 250 255 Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
Asp Val Leu Met 260 265 270 Ile Ser Leu Ser Pro Ile Val Thr Cys Val
Val Val Asp Val Ser Glu 275 280 285 Asp Asp Pro Asp Val Gln Ile Ser
Trp Phe Val Asn Asn Val Glu Val 290 295 300 His Thr Ala Gln Thr Gln
Thr His Arg Glu Asp Tyr Asn Ser Thr Leu 305 310 315 320 Arg Val Val
Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly 325 330 335 Lys
Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile 340 345
350 Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val
355 360 365 Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
Val Thr 370 375 380 Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp
Ile Tyr Val Glu 385 390 395 400 Trp Thr Asn Asn Gly Lys Thr Glu Leu
Asn Tyr Lys Asn Thr Glu Pro 405 410 415 Val Leu Asp Ser Asp Gly Ser
Tyr Phe Met Tyr Ser Lys Leu Arg Val 420 425 430 Glu Lys Lys Asn Trp
Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val 435 440 445 His Glu Gly
Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr 450 455 460 Pro
Gly Lys 465 53451PRTHomo sapiens 53Gln Val Gln Leu Gln Gln Pro Gly
Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met His Trp
Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile 35 40 45 Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60
Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65
70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe
Asn Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ala Ala
Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185
190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310
315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp
Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435
440 445 Pro Gly Lys 450 54213PRTHomo sapiens 54Gln Ile Val Leu Ser
Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val
Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile 20 25 30 His
Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 35 40
45 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu
Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser
Asn Pro Pro Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser
Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu
Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys
Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser
Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170
175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
Ser Phe 195 200 205 Asn Arg Gly Glu Cys 210 55471PRTHomo sapiens
55Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu
Val 20 25 30 Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser
Gly Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln
Thr Pro Gly Arg Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro
Gly Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys
Ala Thr Leu Thr Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met
Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr
Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn
Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135
140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
145 150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
Phe Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser
Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser
Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260
265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
Val 275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser
Val Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385
390 395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly
Lys 465 470 56233PRTHomo sapiens 56Met Glu Thr Asp Thr Leu Leu Leu
Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Ile
Val Leu Ser Gln Ser Pro Ala Ile Leu Ser 20 25 30 Ala Ser Pro Gly
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser 35 40 45 Val Ser
Tyr Ile His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys 50 55 60
Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg 65
70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
Ser Arg 85 90 95 Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln
Gln Trp Thr Ser 100 105 110 Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys Arg Thr 115 120 125 Val Ala Ala Pro Ser Val Phe Ile
Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140 Lys Ser Gly Thr Ala Ser
Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145 150 155 160 Arg Glu Ala
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 165 170 175 Asn
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 180 185
190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
195 200 205 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230
57468PRTHomo sapiens 57Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Gln
Gln Pro Gly Ala Glu Leu Val 20 25 30 Lys Pro Gly Ala Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn
Met His Trp Val Lys Gln Thr Pro Gly Arg Gly 50 55 60 Leu Glu Trp
Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser 85 90
95 Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110 Val Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp
Tyr Phe 115 120 125 Asn Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser
Ala Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
Glu Leu Leu 245 250 255 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys Asp Thr Leu 260 265 270 Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val Asp Val Ser 275 280 285 His Glu Asp Pro Glu Val Lys
Phe Asn Trp Tyr Val Asp Gly Val Glu 290 295 300 Val His Asn Ala Lys
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 305 310 315 320 Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 325 330 335
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 340
345 350 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
Gln 355 360 365 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
Asn Gln Val 370 375 380 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala Val 385 390 395 400 Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys Thr Thr Pro 405 410 415 Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 420 425 430 Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 435 440 445 Met His
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 450 455 460
Ser Pro Gly Lys 465 58472PRTMus sp. 58Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln
Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val 20 25 30 Lys Pro Gly
Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45 Phe
Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly 50 55
60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr
Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val Trp Gly Ala Gly Thr Thr
Val Thr Val Ser Ala Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185
190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
Lys Lys Val Glu 225 230 235 240 Pro Arg Gly Pro Thr Ile Lys Pro Cys
Pro Pro Cys Lys Cys Pro Ala 245 250 255 Pro Asn Leu Leu Gly Gly Pro
Ser Val Phe Ile Phe Pro Pro Lys Ile 260 265 270 Lys Asp Val Leu Met
Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val 275 280 285 Val Asp Val
Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val 290 295 300 Asn
Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp 305 310
315 320 Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
Gln 325 330 335 Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn
Asn Lys Asp 340 345 350 Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys
Pro Lys Gly Ser Val 355 360 365 Arg Ala Pro Gln Val Tyr Val Leu Pro
Pro Pro Glu Glu Glu Met Thr 370 375 380 Lys Lys Gln Val Thr Leu Thr
Cys Met Val Thr Asp Phe Met Pro Glu 385 390 395 400 Asp Ile Tyr Val
Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr 405 410 415 Lys Asn
Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr 420 425 430
Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr 435
440 445 Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr
Lys 450 455 460 Ser Phe Ser Arg Thr Pro Gly Lys 465 470 59468PRTMus
sp. 59Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val
Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala
Glu Leu Val 20 25 30 Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys
Ala Ser Gly Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn Met His Trp Val
Lys Gln Thr Pro Gly Arg Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile
Tyr Pro Gly Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys
Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val
Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120
125 Asn Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr
130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 225 230 235 240
Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Asn Leu Leu 245
250 255 Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
Leu 260 265 270 Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val
Asp Val Ser 275 280 285 Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
Val Asn Asn Val Glu 290 295 300 Val His Thr Ala Gln Thr Gln Thr His
Arg Glu Asp Tyr Asn Ser Thr 305 310 315 320 Leu Arg Val Val Ser Ala
Leu Pro Ile Gln His Gln Asp Trp Met Ser 325 330 335 Gly Lys Glu Phe
Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro 340 345 350 Ile Glu
Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln 355 360 365
Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val 370
375 380
Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val 385
390 395 400 Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn
Thr Glu 405 410 415 Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
Ser Lys Leu Arg 420 425 430 Val Glu Lys Lys Asn Trp Val Glu Arg Asn
Ser Tyr Ser Cys Ser Val 435 440 445 Val His Glu Gly Leu His Asn His
His Thr Thr Lys Ser Phe Ser Arg 450 455 460 Thr Pro Gly Lys 465
60449PRTHomo sapiens 60Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu
Val Gln Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser
Gly Phe Ser Leu Thr Asn Tyr 20 25 30 Gly Val His Trp Val Arg Gln
Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Ser
Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr 50 55 60 Ser Arg Leu
Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe 65 70 75 80 Lys
Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90
95 Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly
100 105 110 Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser
Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser
Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys 210 215
220 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
Met Ile Ser 245 250 255 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser His Glu Asp 260 265 270 Pro Glu Val Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val His Asn 275 280 285 Ala Lys Thr Lys Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295 300 Val Ser Val Leu Thr
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 305 310 315 320 Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 340
345 350 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
Thr 355 360 365 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
Glu Trp Glu 370 375 380 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
Thr Pro Pro Val Leu 385 390 395 400 Asp Ser Asp Gly Ser Phe Phe Leu
Tyr Ser Lys Leu Thr Val Asp Lys 405 410 415 Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met His Glu 420 425 430 Ala Leu His Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 Lys
61213PRTHomo sapiens 61Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu
Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Val Ser Phe Ser Cys Arg Ala
Ser Gln Ser Ile Gly Thr Asn 20 25 30 Ile His Trp Tyr Gln Gln Arg
Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Glu
Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser 65 70 75 80 Glu
Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr 85 90
95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu
Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe
Asn Arg Gly Ala 210 62469PRTHomo sapiens 62Met Glu Thr Asp Thr Leu
Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly
Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val 20 25 30 Gln Pro
Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser 35 40 45
Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly 50
55 60 Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr
Asn 65 70 75 80 Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn
Ser Lys Ser 85 90 95 Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser
Asn Asp Thr Ala Ile 100 105 110 Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr
Tyr Asp Tyr Glu Phe Ala Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ala Ala Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180
185 190 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
Val 195 200 205 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
Cys Asn Val 210 215 220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
Arg Val Glu Pro Lys 225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys
Pro Pro Cys Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305
310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425
430 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser 450 455 460 Leu Ser Pro Gly Lys 465 63233PRTHomo sapiens
63Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu
Ser 20 25 30 Val Ser Pro Gly Glu Arg Val Ser Phe Ser Cys Arg Ala
Ser Gln Ser 35 40 45 Ile Gly Thr Asn Ile His Trp Tyr Gln Gln Arg
Thr Asn Gly Ser Pro 50 55 60 Arg Leu Leu Ile Lys Tyr Ala Ser Glu
Ser Ile Ser Gly Ile Pro Ser 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Ser Ile Asn 85 90 95 Ser Val Glu Ser Glu
Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn 100 105 110 Asn Trp Pro
Thr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg 115 120 125 Thr
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135
140 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
145 150 155 160 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser 165 170 175 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser Thr 180 185 190 Tyr Ser Leu Ser Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu Lys 195 200 205 His Lys Val Tyr Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220 Val Thr Lys Ser Phe
Asn Arg Gly Ala 225 230 64471PRTHomo sapiens 64Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr
Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 35 40
45 Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
50 55 60 Leu Glu Trp Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile
Asp Tyr 65 70 75 80 Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys 85 90 95 Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ala Lys Val Ser
Tyr Leu Ser Thr Ala Ser Ser Leu 115 120 125 Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170
175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295
300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420
425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys 465 470
65234PRTHomo sapiens 65Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser 20 25 30 Ala Ser Val Gly Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Gly 35 40 45 Ile Arg Asn Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 50 55 60 Lys Leu Leu
Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser 65 70 75 80 Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 85 90
95 Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn
100 105 110 Arg Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
Lys Arg 115 120 125 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu Gln 130 135 140 Leu Lys Ser Gly Thr Ala Ser Val Val Cys
Leu Leu Asn Asn Phe Tyr 145 150 155 160 Pro Arg Glu Ala Lys Val Gln
Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175 Gly Asn Ser Gln Glu
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190 Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205 His
Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215
220 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 66766PRTHomo
sapiens 66Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp
Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val 20 25 30 Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr 35 40 45 Phe Asp Asp Tyr Ala Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ser Ala
Ile Thr Trp Asn Ser Gly His Ile Asp Tyr 65 70 75 80 Ala Asp Ser Val
Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 85 90 95 Asn Ser
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110
Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu 115
120 125 Asp Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180
185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305
310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425
430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Gly
Gly Ser Ile Lys 465 470 475 480 Gln Ile Glu Asp Lys Ile Glu Glu Ile
Leu Ser Lys Ile Tyr His Ile 485 490 495 Glu Asn Glu Ile Ala Arg Ile
Lys Lys Leu Ile Gly Glu Arg Gly His 500 505 510 Asp Ile Glu Arg Lys
Cys Cys Val Glu Cys Pro Pro Cys Pro Arg Leu 515 520 525 Glu Gly Pro
Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys Thr His Thr 530 535 540 Cys
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 545 550
555 560 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro 565 570 575 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val 580 585 590 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr 595 600 605 Lys Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val 610 615 620 Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys 625 630 635 640 Lys Val Ser Asn
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 645 650 655 Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 660 665 670
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 675
680 685 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly 690 695 700 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp 705 710 715 720 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp 725 730 735 Gln Gln Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His 740 745 750 Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 755 760 765 67219PRTHomo sapiens
67Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp
Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp
Tyr Ala Asp Ser Val 50 55 60 Glu Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Val Ser Tyr
Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135
140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val
Asp Lys Lys Val 210 215 68527PRTHomo sapiens 68Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40
45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 130 135 140 Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170
175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu
Glu Gly Gly Gly Ser Ile 225 230 235 240 Lys Gln Ile Glu Asp Lys Ile
Glu Glu Ile Leu Ser Lys Ile Tyr His 245 250 255 Ile Glu Asn Glu Ile
Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly 260 265 270 His Asp Ile
Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Arg 275 280 285 Leu
Glu Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys Thr His 290 295
300 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
305 310 315 320 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr 325 330 335 Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu Asp Pro Glu 340 345 350 Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys 355 360 365 Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val Val Ser 370 375 380 Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 385 390 395 400 Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 405 410 415
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 420
425 430 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu 435 440 445 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn 450 455 460 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser 465 470 475 480 Asp Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg 485 490 495 Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu 500 505 510 His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 515 520 525
69513PRTHomo sapiens 69Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90
95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Glu Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215
220 Ser Leu Ser Leu Ser Pro Gly Lys Ser Ile Lys Gln Ile Glu Asp Lys
225 230 235 240 Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn
Glu Ile Ala 245 250 255 Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His
Asp Ile Glu Arg Lys 260 265 270 Cys Cys Val Glu Cys Pro Pro Cys Pro
Glu Pro Lys Ser Cys Asp Lys 275 280 285 Thr His Thr Cys Pro Pro Cys
Pro Ala Pro Glu Leu Leu Gly Gly Pro 290 295 300 Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 305 310 315 320 Arg Thr
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 325 330 335
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 340
345 350 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
Val 355 360 365 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu 370 375 380 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys 385 390 395 400 Thr Ile Ser Lys Ala Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr 405 410 415 Leu Pro Pro Ser Arg Glu
Glu Met Thr Lys Asn Gln Val Ser Leu Thr 420 425 430 Cys Leu Val Lys
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 435 440 445 Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 450 455 460
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 465
470 475 480 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu 485 490 495 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Pro Gly 500 505 510 Lys 70524PRTHomo sapiens 70Met Glu Thr
Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly
Ser Thr Gly Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val 20 25
30 Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser
35 40 45 Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly
Lys Gly 50 55 60 Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn
Thr Asp Tyr Asn 65 70 75 80 Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn
Lys Asp Asn Ser Lys Ser 85 90 95 Gln Val Phe Phe Lys Met Asn Ser
Leu Gln Ser Asn Asp Thr Ala Ile 100 105 110 Tyr Tyr Cys Ala Arg Ala
Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr 115 120 125 Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly 130 135 140 Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 145 150 155
160 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
165 170 175 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr Phe 180 185 190 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val Val 195 200 205 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn Val 210 215 220 Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Arg Val Glu Pro Lys 225 230 235 240 Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280
285 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
290 295 300 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser 305 310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400
Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435
440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
Ser 450 455 460 Leu Ser Pro Gly Lys Ser Leu Glu Gly Gly Gly Ser Ile
Lys Gln Ile 465 470 475 480 Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys
Ile Tyr His Ile Glu Asn 485 490 495 Glu Ile Ala Arg Ile Lys Lys Leu
Ile Gly Glu Arg Gly His Asp Ile 500 505 510 Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro 515 520 71496PRTHomo sapiens 71Met Glu Thr
Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly
Ser Thr Gly Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val 20 25
30 Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser
35 40 45 Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly
Lys Gly 50 55 60 Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn
Thr Asp Tyr Asn 65 70 75 80 Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn
Lys Asp Asn Ser Lys Ser 85 90 95 Gln Val Phe Phe Lys Met Asn Ser
Leu Gln Ser Asn Asp Thr Ala Ile 100 105 110 Tyr Tyr Cys Ala Arg Ala
Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr 115 120 125 Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly 130 135 140 Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 145 150 155
160 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
165 170 175 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
Thr Phe 180 185 190 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser Val Val 195 200 205 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys Asn Val 210 215 220 Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Arg Val Glu Pro Lys 225 230 235 240 Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280
285 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
290 295 300 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser 305 310 315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405
410 415 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu 420 425 430 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser 435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser 450 455 460 Leu Ser Pro Gly Lys Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys 465 470 475 480 Pro Pro Cys Pro Glu Arg
Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 485 490 495 72511PRTHomo
sapiens 72Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp
Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Lys Gln Ser Gly
Pro Gly Leu Val 20 25 30 Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys
Thr Val Ser Gly Phe Ser 35 40 45 Leu Thr Asn Tyr Gly Val His Trp
Val Arg Gln Ser Pro Gly Lys Gly 50 55 60 Leu Glu Trp Leu Gly Val
Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn 65 70 75 80 Thr Pro Phe Thr
Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser 85 90 95 Gln Val
Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile 100 105 110
Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr 115
120 125 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys
Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp Asn Ser Gly Ala
Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala Val Leu Gln Ser
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205 Thr Val Pro Ser
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215 220 Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys 225 230 235
240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala Lys Thr Lys
Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335 Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345 350 Pro
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 355 360
365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445 Val Met His Glu Ala
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460 Leu Ser Pro
Gly Lys Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro 465 470 475 480
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro 485
490 495 Gly Pro Pro Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro
500 505 510 73728PRTHomo sapiens 73Met Glu Thr Asp Thr Leu Leu Leu
Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val
Gln Leu Lys Gln Ser Gly Pro Gly Leu Val 20 25 30 Gln Pro Ser Gln
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser 35 40 45 Leu Thr
Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly 50 55 60
Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn 65
70 75 80 Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser
Lys Ser 85 90 95 Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn
Asp Thr Ala Ile 100 105 110 Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr
Asp Tyr Glu Phe Ala Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ala Ala Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185
190 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
195 200 205 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val 210 215 220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg
Val Glu Pro Lys 225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310
315 320 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
Leu 325 330 335 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro Ala 340 345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg
Glu Glu Met Thr Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435
440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
Ser 450 455 460 Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly 465 470 475 480 Gly Gly Gly Ser Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro 485 490 495 Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala 500 505 510 Pro Glu Leu Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 515 520 525 Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 530 535 540 Val Asp
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 545 550 555
560 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
565 570 575 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln 580 585 590 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala 595 600 605 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro 610 615 620 Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr 625 630 635 640 Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 645 650 655 Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 660 665 670 Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 675 680
685 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
690 695 700 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys 705 710 715 720 Ser Leu Ser Leu Ser Pro Gly Lys 725
74753PRTHomo sapiens 74Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Lys
Gln Ser Gly Pro Gly Leu Val 20 25 30 Gln Pro Ser Gln Ser Leu Ser
Ile Thr Cys Thr Val Ser Gly Phe Ser 35 40 45 Leu Thr Asn Tyr Gly
Val His Trp Val Arg Gln Ser Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn 65 70 75 80 Thr
Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser 85 90
95 Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile
100 105 110 Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe
Ala Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala
Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205 Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215
220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340
345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
Cys Ser 435 440 445 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser 450 455 460 Leu Ser Pro Gly Lys Ser Val Glu Gly Gly
Gly Ser Ile Lys Gln Ile 465 470 475 480 Glu Asp Lys Ile Glu Glu Ile
Leu Ser Lys Ile Tyr His Ile Glu Asn 485 490 495 Glu Ile Ala Arg Ile
Lys Lys Leu Ile Gly Glu Arg Gly His Gly Gly 500 505 510 Gly Arg Leu
Glu Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys 515 520 525 Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 530 535
540 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
545 550 555 560 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu Asp 565 570 575 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn 580 585 590 Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val 595 600 605 Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu 610 615 620 Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 625 630 635 640 Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 645 650 655
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 660
665 670 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu 675 680 685 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu 690 695 700 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys 705 710 715 720 Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His Glu 725 730 735 Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 740 745 750 Lys
75713PRTHomo sapiens 75Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Lys
Gln Ser Gly Pro Gly Leu Val 20 25 30 Gln Pro Ser Gln Ser Leu Ser
Ile Thr Cys Thr Val Ser Gly Phe Ser 35 40 45 Leu Thr Asn Tyr Gly
Val His Trp Val Arg Gln Ser Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn 65 70 75 80 Thr
Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser 85 90
95 Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile
100 105 110 Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe
Ala Tyr 115 120 125 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala
Ser Thr Lys Gly 130 135 140 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly 145 150 155 160 Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175 Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190 Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205 Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215
220 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
225 230 235 240 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
Pro Glu Leu 245 250 255 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr 260 265 270 Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val 275 280 285 Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val 290 295 300 Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 305 310 315 320 Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340
345 350 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro 355 360 365 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
Lys Asn Gln 370 375 380 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala 385 390 395 400 Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr 405 410 415 Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430 Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445 Val Met
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460
Leu Ser Pro Gly Lys Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 465
470 475 480 Pro Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys Pro 485 490 495 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys 500 505 510 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val 515 520 525 Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp Tyr 530 535 540 Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu Glu 545 550 555 560 Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 565 570 575 Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 580 585
590 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
595 600 605 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
Glu Met 610 615 620 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
Gly Phe Tyr Pro 625 630 635 640 Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn 645 650 655 Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe Leu 660 665 670 Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 675 680 685 Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 690 695 700 Lys
Ser Leu Ser Leu Ser Pro Gly Lys 705 710 76526PRTHomo sapiens 76Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val
20 25 30 Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly
Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr
Pro Gly Arg Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly
Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala
Thr Leu Thr Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln
Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val
Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
Ser Leu Glu Gly Gly Gly Ser Ile Lys 465 470 475 480 Gln Ile Glu Asp
Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 485 490 495 Glu Asn
Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 500 505 510
Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 515 520 525
77498PRTHomo sapiens 77Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Gln
Gln Pro Gly Ala Glu Leu Val 20 25 30 Lys Pro Gly Ala Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn
Met His Trp Val Lys Gln Thr Pro Gly Arg Gly 50 55 60 Leu Glu Trp
Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser 85 90
95 Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110 Val Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp
Tyr Phe 115 120 125 Asn Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser
Ala Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340
345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460
Leu Ser Leu Ser Pro Gly Lys Glu Pro Lys Ser Cys Asp Lys Thr His 465
470 475 480 Thr Cys Pro Pro Cys Pro Glu Arg Lys Cys Cys Val Glu Cys
Pro Pro 485 490 495 Cys Pro 78513PRTHomo sapiens 78Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val 20 25 30
Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 35
40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg
Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp
Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr
Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys Ala Arg Ser
Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val Trp Gly Ala
Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135 140 Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165
170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro
Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325
330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450
455 460 Leu Ser Leu Ser Pro Gly Lys Gly Pro Pro Gly Pro Pro Gly Pro
Pro 465 470 475 480 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
Gly Pro Pro Gly 485 490 495 Pro Pro Gly Pro Pro Glu Arg Lys Cys Cys
Val Glu Cys Pro Pro Cys 500 505 510 Pro 79730PRTHomo sapiens 79Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val
20 25 30 Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly
Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr
Pro Gly Arg Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly
Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala
Thr Leu Thr Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln
Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys
Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val
Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
Gly Gly Gly Gly Ser Gly Gly Gly Gly 465 470 475 480 Ser Gly Gly Gly
Gly Ser Glu Arg Lys Cys Cys Val Glu Cys Pro Pro 485 490 495 Cys Pro
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 500 505 510
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 515
520 525 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys 530 535 540 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
Phe Asn Trp 545 550 555 560 Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu 565 570 575 Glu Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu 580 585 590 His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 595 600 605 Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 610 615 620 Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 625 630 635
640 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
645 650 655 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 660 665 670 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 675 680 685 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn 690 695 700 Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr Thr 705 710 715 720 Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 725 730 80755PRTHomo sapiens 80Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val 20 25 30
Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 35
40 45 Phe Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg
Gly 50 55 60 Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp
Thr Ser Tyr 65 70 75 80 Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr
Ala Asp Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys Ala Arg Ser
Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe 115 120 125 Asn Val Trp Gly Ala
Gly Thr Thr Val Thr Val Ser Ala Ala Ser Thr 130 135 140 Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165
170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290
295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410
415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys Ser Val Glu
Gly Gly Gly Ser Ile Lys 465 470 475 480 Gln Ile Glu Asp Lys Ile Glu
Glu Ile Leu Ser Lys Ile Tyr His Ile 485 490 495 Glu Asn Glu Ile Ala
Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 500 505 510 Gly Gly Gly
Arg Leu Glu Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys 515 520 525 Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 530 535
540 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
545 550 555 560 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser His 565 570 575 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val 580 585 590 His Asn Ala Lys Thr Lys Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr 595 600 605 Arg Val Val Ser Val Leu Thr
Val Leu His Gln Asp Trp Leu Asn Gly 610 615 620 Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 625 630 635 640 Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 645 650 655
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 660
665 670 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
Glu 675 680 685 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
Thr Pro Pro 690 695 700 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser Lys Leu Thr Val 705 710 715 720 Asp Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met 725 730 735 His Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 740 745 750 Pro Gly Lys 755
81715PRTHomo sapiens 81Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Gln Val Gln Leu Gln
Gln Pro Gly Ala Glu Leu Val 20 25 30 Lys Pro Gly Ala Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45 Phe Thr Ser Tyr Asn
Met His Trp Val Lys Gln Thr Pro Gly Arg Gly 50 55 60 Leu Glu Trp
Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr 65 70 75 80 Asn
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser 85 90
95 Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
100 105 110 Val Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp
Tyr Phe 115 120 125 Asn Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser
Ala Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340
345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460
Leu Ser Leu Ser Pro Gly Lys Glu Arg Lys Cys Cys Val Glu Cys Pro 465
470 475 480 Pro Cys Pro Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
Pro Pro 485 490 495 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro 500 505 510 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr 515 520 525 Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn 530 535 540 Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 545 550 555 560 Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 565 570 575
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 580
585 590 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys 595 600 605 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu 610 615 620 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe 625 630 635 640 Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu 645 650 655 Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 660 665 670 Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 675 680 685 Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 690 695 700
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 705 710 715
82498PRTHomo sapiens 82Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Arg Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr 35 40 45 Phe Asp Asp Tyr Ala
Met His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr 65 70 75 80 Ala
Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 85 90
95 Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser
Ser Leu 115 120 125 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340
345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460
Leu Ser Leu Ser Pro Gly Lys Glu Pro Lys Ser Cys Asp Lys Thr His 465
470 475 480 Thr Cys Pro Pro Cys Pro Glu Arg Lys Cys Cys Val Glu Cys
Pro Pro 485 490 495 Cys Pro 83513PRTHomo sapiens 83Met Glu Thr Asp
Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser
Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30
Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 35
40 45 Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys
Gly 50 55 60 Leu Glu Trp Val Ser Ala Ile Thr Trp Asn Ser Gly His
Ile Asp Tyr 65 70 75 80 Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys 85 90 95 Asn Ser Leu Tyr Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ala Lys Val
Ser Tyr Leu Ser Thr Ala Ser Ser Leu 115 120 125 Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165
170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290
295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410
415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys Gly Pro Pro
Gly Pro Pro Gly Pro Pro 465 470 475 480 Gly Pro Pro Gly Pro Pro Gly
Pro Pro Gly Pro Pro Gly Pro Pro Gly 485 490 495 Pro Pro Gly Pro Pro
Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 500 505 510 Pro
84730PRTHomo sapiens 84Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Arg Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr 35 40 45 Phe Asp Asp Tyr Ala
Met His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr 65 70 75 80 Ala
Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 85 90
95 Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser
Ser Leu 115 120 125 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340
345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460
Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly 465
470 475 480 Ser Gly Gly Gly Gly Ser Glu Arg Lys Cys Cys Val Glu Cys
Pro Pro 485 490 495 Cys Pro Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 500 505 510 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 515 520 525 Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys 530 535 540 Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp 545 550 555 560 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 565 570 575 Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 580 585
590 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
595 600 605 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly 610 615 620 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu 625 630 635 640 Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 645 650 655 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 660 665 670 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 675 680 685 Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 690 695 700 Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 705 710
715 720 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 725 730
85755PRTHomo sapiens 85Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu
Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Arg Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr 35 40 45 Phe Asp Asp Tyr Ala
Met His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp
Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr 65 70 75 80 Ala
Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 85 90
95 Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
100 105 110 Val Tyr Tyr Cys Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser
Ser Leu 115 120 125 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly
Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215
220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310 315 320 Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 340
345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys Leu Val Lys
Gly
Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435 440 445 Cys Ser
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460
Leu Ser Leu Ser Pro Gly Lys Ser Val Glu Gly Gly Gly Ser Ile Lys 465
470 475 480 Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr
His Ile 485 490 495 Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly
Glu Arg Gly His 500 505 510 Gly Gly Gly Arg Leu Glu Gly Pro Arg Phe
Glu Glu Pro Lys Ser Cys 515 520 525 Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro Glu Leu Leu Gly 530 535 540 Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 545 550 555 560 Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 565 570 575 Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 580 585
590 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
595 600 605 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
Asn Gly 610 615 620 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
Pro Ala Pro Ile 625 630 635 640 Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu Pro Gln Val 645 650 655 Tyr Thr Leu Pro Pro Ser Arg
Glu Glu Met Thr Lys Asn Gln Val Ser 660 665 670 Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 675 680 685 Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 690 695 700 Val
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 705 710
715 720 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
Met 725 730 735 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
Ser Leu Ser 740 745 750 Pro Gly Lys 755 86715PRTHomo sapiens 86Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
20 25 30 Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr 35 40 45 Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala
Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ser Ala Ile Thr Trp Asn
Ser Gly His Ile Asp Tyr 65 70 75 80 Ala Asp Ser Val Glu Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys 85 90 95 Asn Ser Leu Tyr Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys
Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu 115 120 125 Asp Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
Glu Arg Lys Cys Cys Val Glu Cys Pro 465 470 475 480 Pro Cys Pro Glu
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 485 490 495 Cys Pro
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 500 505 510
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 515
520 525 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn 530 535 540 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg 545 550 555 560 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val 565 570 575 Leu His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser 580 585 590 Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 595 600 605 Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 610 615 620 Glu Met
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 625 630 635
640 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
645 650 655 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
Ser Phe 660 665 670 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
Trp Gln Gln Gly 675 680 685 Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His Asn His Tyr 690 695 700 Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 705 710 715 87526PRTHomo sapiens 87Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr
Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 35 40
45 Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
50 55 60 Leu Glu Trp Val Ser Ala Ile Thr Trp Asn Ser Gly His Ile
Asp Tyr 65 70 75 80 Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys 85 90 95 Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ala Lys Val Ser
Tyr Leu Ser Thr Ala Ser Ser Leu 115 120 125 Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170
175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys Lys Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295
300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420
425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly
Gly Gly Ser Ile Lys 465 470 475 480 Gln Ile Glu Asp Lys Ile Glu Glu
Ile Leu Ser Lys Ile Tyr His Ile 485 490 495 Glu Asn Glu Ile Ala Arg
Ile Lys Lys Leu Ile Gly Glu Arg Gly His 500 505 510 Asp Ile Glu Arg
Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 515 520 525 88729PRTHomo
sapiens 88Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp
Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg
Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90 95 Asn Thr
Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110
Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp 115
120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235
240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp 275 280 285 Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335 Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350 Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360
365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly
Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg
Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val Met His Glu
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 465 470 475 480
Gly Gly Gly Gly Ser Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 485
490 495 Pro Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
Pro 500 505 510 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys 515 520 525 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val 530 535 540 Val Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr 545 550 555 560 Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu Glu 565 570 575 Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 580 585 590 Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 595 600 605
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 610
615 620 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
Met 625 630 635 640 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
Gly Phe Tyr Pro 645 650 655 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly Gln Pro Glu Asn Asn 660 665 670 Tyr Lys Thr Thr Pro Pro Val Leu
Asp Ser Asp Gly Ser Phe Phe Leu 675 680 685 Tyr Ser Lys Leu Thr Val
Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val 690 695 700 Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 705 710 715 720 Lys Ser
Leu Ser Leu Ser Pro Gly Lys 725 89714PRTHomo sapiens 89Met Glu Thr
Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly
Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 20 25
30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn
35 40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly
Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly
Tyr Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg
Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155
160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280
285 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn 305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405
410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly Lys Glu Arg Lys
Cys Cys Val Glu Cys Pro Pro 465 470 475 480 Cys Pro Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys 485 490 495 Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 500 505 510 Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 515 520 525
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 530
535 540 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu 545 550 555 560 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 565 570 575 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn 580 585 590 Lys Ala Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly 595 600 605 Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 610 615 620 Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 625 630 635 640 Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 645 650
655 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
660 665 670 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 675 680 685 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr 690 695 700 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
705 710 90754PRTHomo sapiens 90Met Glu Thr Asp Thr Leu Leu Leu Trp
Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val 20 25 30 Gln Pro Gly Gly Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn 35 40 45 Ile Lys Asp
Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 50 55 60 Leu
Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr 65 70
75 80 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser
Lys 85 90 95 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr Ala 100 105 110 Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly
Phe Tyr Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Ala Ser Thr Lys 130 135 140 Gly Pro Ser Val Phe Pro Leu
Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160 Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175 Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195
200 205 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn 210 215 220 Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
Val Glu Pro 225 230 235 240 Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu 245 250 255 Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg
Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285 Val Ser His Glu
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315
320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
Leu Pro 340 345 350 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Glu Glu Met Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440
445 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460 Ser Leu Ser Pro Gly Lys Ser Val Glu Gly Gly Gly Ser Ile
Lys Gln 465 470 475 480 Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys
Ile Tyr His Ile Glu 485 490 495 Asn Glu Ile Ala Arg Ile Lys Lys Leu
Ile Gly Glu Arg Gly His Gly 500 505 510 Gly Gly Arg Leu Glu Gly Pro
Arg Phe Glu Glu Pro Lys Ser Cys Asp 515 520 525 Lys Thr His Thr Cys
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 530 535 540 Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 545 550 555 560
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 565
570 575 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His 580 585 590 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg 595 600 605 Val Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys 610 615 620 Glu Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu 625 630 635 640 Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 645 650 655 Thr Leu Pro Pro
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 660 665 670 Thr Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 675 680 685
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 690
695 700 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
Asp 705 710 715 720 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser Val Met His 725 730 735 Glu Ala Leu His Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro 740 745 750 Gly Lys 91525PRTHomo sapiens
91Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1
5 10 15 Gly Ser Thr Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val 20 25 30 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Asn 35 40 45 Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln
Ala Pro Gly Lys Gly 50 55 60 Leu Glu Trp Val Ala Arg Ile Tyr Pro
Thr Asn Gly Tyr Thr Arg Tyr 65 70 75 80 Ala Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Ala Asp Thr Ser Lys 85 90 95 Asn Thr Ala Tyr Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 100 105 110 Val Tyr Tyr
Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp 115 120 125 Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys 130 135
140 Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160 Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu Pro 165 170 175 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His Thr 180 185 190 Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser Val 195 200 205 Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220 Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240 Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260
265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp 275 280 285 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly 290 295 300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn 305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350 Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 370 375 380
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385
390 395 400 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly Lys
Ser Leu Glu Gly Gly Gly Ser Ile Lys Gln 465 470 475 480 Ile Glu Asp
Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu 485 490 495 Asn
Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His Asp 500 505
510 Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 515 520
525
* * * * *